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Dear Sir/Madam, 
 
 
It gives us great pleasure to inform you that the First  Macedonian and Fourth Adriatic Congress 
on Pharmacoeconomics  and Outcomes Research will be held in Ohrid, Republic of Macedonia, 
from 24-27 April, 2014. Organisers of the Congress are ISPOR, Republic of Macedonia Chapter 
and Section for Pharmacoeconomics and Outcomes Research of the Croatian Society for Clinical 
Pharmacology and Therapeutics. ISPOR Chapter, Bosnia and Herzegovina and ISPOR Chapter, 
Serbia, play the role of supporting organisers. The main topics of this Congress on 
Pharmacoeconomics and Outcomes Research will enrich and fortify regional cooperation. The 
promotion and cooperation of the ISPOR CEE network at this Congress are also of particular 
importance and interest. Different topics will be covered through lectures, poster presentation 
and workshops. The programme will include health economy  and health policies, 
Pharmaceutical Parallel Trade, Cost-Effective Use of Medicines, Generic and Biosimilar Drug 
Policies, HTA and low income countries, Health Economy and Personalized Medicines and 
others. The opening day of the Congress will be marked by a specific educational course on 
pharmacoeconomic methods and studies. Sharing different experiences is one of the most 
significant aspects of the Congress, thus we invite you to take an active part at this assembly. It 
will be our pleasure to share the latest discoveries and experiences in the field of 
Pharmacoeconomics and Outcome Research. We are looking forward to spend quality time 
working and socialising with you. 
 
  
Prof. Ljubica Suturkova, PhD 
President, 
ISPOR –Republic of Macedonia 
Regional chapter 
  
Prof. Dinko Vitezic, MD, PhD 
President, Section for 
Pharmacoeconomics and Outcomes 
Research, Croatian Society for Clinical 
Pharmacology and Therapeutics, 
Croatian Medical Association 
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PROGRAM 
 
Thursday 24.04.2014 
________________________________________________ 
 
09.00 - 18.30  Registration 
14.00 - 18.00  Pre-congress course : 
  Zoltan Kalo ( Hungary) & Dinko Vitezic ( Croatia)  
  How pharmacoeconomics should be applied to support  
  decisions in lower income European countries ? 
18.30 - 19.15  Opening ceremony 
19.15 - 20.00  Plenary lecture  
  Chairpersons : Dinko Vitezic & Ljubica Suturkova  
  Zoltan Kalo ( Hungary) 
  Benefits of investment into modern medicines in  
Central-Eastern European countries 
20.30 Welcome cocktail 
 
Friday 25.04.2014 
________________________________________________ 
 
08.00 - 18.30   Registration 
08.30 - 09.15   Plenary lecture 
  Chairpersons:  Igor Francetic & Vladimir Zah 
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  Finn Kristensen ( Denmark) 
  Current trends and future prospects of  
  Pharmacoeconomics and outcomes research – with  
  special reference to health techonolgy assessment. 
09.30 - 11.30  Session 1 
  Health economics aspect of personalized medicines  
  Chairpersons :  Aleksandar Dimovski &  Aleksandar Knezevic 
  Dinko Vitezic (Croatia) 
Factors influencing pharmacoeconomic assessment 
 of new drugs in dieabetes mellitus treatment 
Czech Maricin ( Poland ) 
Health economic aspects of personalized therapy in diabetic patiens 
Hren Rok ( Slovenia) 
The importance of pharmacoeconomic modeling in  
assessing costs of asthma treatment  
Zlate Stojanovski ( Macedonia) 
Prophylactic use of ciprofloxacine in stem cell recipients 
reduce associated cost of stem cells transplantation 
Jasminka Krehic ( Bosnia and Herzegovina) 
Ethical Considerations of Personalized Medicine 
 
11.30 - 12.00  Coffee break ( Sponsored by Alkaloid) 
 
12.00 - 13.30  Session 2 
HTA implementation in lower income European countries  
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  Chairpersons :  Rubin Zareski & Carmen Kostrencic 
                        Tomek Dominik ( Slovakia) 
  Application of Pharmacoeconomics and HTA in Drug  
and Health Policies in Slovakia 
  Atanasievic Dragana ( Serbia)  
  HTA implementation in Serbia 
  Tarik Catic ( Bosnia and Herzegovina) 
  HTA in Bosnia and Herzegovina 
  Merjem Hadzi Hamza ( Macedonia)  
  Ethical principles promoting Good Governance in the 
  Public Pharmaceutical sector and their impact on 
  Health economics 
 
13.30 - 14.15   Alkaloid satellite meeting 
14.15 - 15.15    Lunch 
15.15 - 16.15   Poster session 
16.30 - 19.30    Novo Nordisk satellite meeting  
  Health economic properties of novel,  
  ultra-long lasting insulin  
 
 17.30 - 19.30  Session 3 
  Improvement of generic and biosimilar drug policies 
  Chairpersons : Ljubica Suturkova & Dinko Vitezic 
 Goznalo Calvo ( Spain) 
 Biosimilar medicinal products : from their  
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 Drug-regulation to their market-place 
 Borut Strukelj ( Slovenia)  
 Biologics and biosimilars – why the principles of  
generics do not apply? 
Vladimir Zah ( Serbia ) 
Pricing and Reimbursement related to generic and 
biosimilar products in CEE region   
Viktorija Erdeljic Turk ( Croatia)  
Generic and therapeutic drug substitution 
Aleksandra Grozdranova ( Macedonia) 
Biosimilars in Republic of Macedonia – licensing and 
market access   
      
Saturday 26.04.2014 
________________________________________________ 
 
08.00 – 18.30 Registration 
08.30 – 10.30 Session 4 
Role of health insurance of the cost – effective uste of medicines 
Chairpersons: Guenka Petrova & Robert Likic 
Maarten Postma (Netherlands) 
Pharmacoeconomic evaluation in process of introducing new vaccines in National 
Program od immunization 
Stephan Bevan (UK) 
Work Disability Related to Musculoskeletal Disorders: 
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Assesing the burden and identifying solutions in Slovenia and the wider EU 
Maja Parnargieva – Zmejkova (Macedonia) 
The role of the HIFM on the effectiveness and rational uste of medicines in 
Republic of Macedonia 
SLobodanka Bolanca (Croatia) 
Value of innovation in pharmaceutical sector in Croatia 
Rubin Zareski (Macedonia) 
Pharmaceutical pricing – a continuing crisis 
 
10.30 -11.00 Coffee break (Sponsored by Pliva – Teva) 
 
11.00 – 13.15 Session 5 
Economic impact of pharmaceutical parallel trade/External reference pricing 
Chairperson: Zoran Sterjev & Slobodanka Bolanca 
John Yfantopoulos (Greece) 
Economic impact of pharmaceutical parallel trade 
Livio Garattini (Italy) 
Risk – sharing agreements in Italy 
Slobodanka Bolanca (Croatia) 
TBC: Ensuring Patient Supply of Innovative Pharmaceutical Products in EU – is 
there any room for improvement? 
Juril Furst (Slovenia) 
The introduction of therapeutic reference pricing system in Slovenia 
Guenka Petrova (Bulgaria) 
The current pricing and reimbursement system for pharmaceuticals in Bulgaria 
Vesna Nasteska (Macedonia) 
Pharmaceutical Parallel Import in the Republic of Macedonia 
Biljana Dimitrova (Macedonia) 
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Methodology for the manner of creating prices of medicines in Republic of 
Macedonia 
 
13.15 – 14.15 FarmaBrend Nova – satellite meeting 
Including new, innovative drugs on reimbursements list of NHIF – a need of 
financial burden 
14.15 – 17.00 Lunch/Sightseeing Ohrid 
 
17.15 – 19.15 Session 6 
Applied pharmacoeconomics 
Chairpersons: Stevce Acevski & Viktorija Erdeljic 
Aleksandar Knezevic (Croatia) 
Comparison of efficacy and cost of antihypertensive therapy with fixed – dose 
combination versus free drug combination 
Robert Likic (Croatia) 
Cost effectiveness of fosfomycin use for uncomplicated urinary tract infections 
cause by microbial strains producing extended spectrum beta – lactamases 
Sonja Genadieva Stavrik (Macedonia) 
New treatment approaches in multiple myeloma patients – new drug, new price 
and new quality of life. What do we gain? 
Vjollca Qerimi (Macedonia) 
Evaluation of decision – analytic models for the treatment of multiple myeloma 
Harasani Hudhra Kleida (Albania) 
Potentially inappropriate prescribing identified by two different tools and health 
outcomes assessment 
Hana Kalinic Grgorinic (Croatia) 
Pharmacoeconomics of the short – term prophylaxis of the HAE attacks 
Igor Kikerkov (Macedonia) 
Outsourcing in pharmaceutical industry 
FIRST MACEDONIAN AND FOURTH ADRIATIC CONGRESS ON 
PHARMACOECONOMICS AND OUTCOMES RESEARCH 
 
10 
 
 
20.00 – 23.20 Congress dinner 
 
Sunday 27.04.2014 
________________________________________________ 
 
09.00 – 10.30 Session 7 
ISPOR CEE Network – regional collaboration to facilitate evidence based 
policy 
Vladimir Zah (Serbia)  
Overview of ISPOR CEE Network 
Ljubica Shuturkova 
Impotance of ISPOR CEE Network for Macedonia 
Guenka Petrova (Bulgaria) 
ISPOR CEE Network current situation for Bulgaria 
Zoran Sterjev (Macedonia) 
ISPOR CEE research committee participation from R.Macedonia 
Tarik Catic (Bosnia and Herzegovina) 
ISPOR CEE educational activity and research projects in BiH 
 
11.00 – 11.30 Closing Ceremony 
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ABSTRACTS1 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
1 The abstracts are presented as received by the corresponding authors. The Scientific Board of the 
Congress does not take any responsibility for the content of the presented papers. 
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O.P.1 
HOW PHARMACOECONOMICS SHOULD BE APPLIED TO SUPPORT DECISIONS 
IN LOWER INCOME EUROPEAN COUNTRIES?  
Zoltán Kaló1, Dinko Vitezic2 
1Professor of Health Economics (EötvösLoránd University; Syreon Research Institute) 
2Professor of Clinical Pharmacology (University of Rijeka, School of Medicine and Rijeka 
University Hospital Center) 
 
 
As health care resources are limited all over the world, reimbursement and formulary listing of 
new medicines is subject to their cost-effectiveness and affordability in more and more 
countries. The need for pharmacoeconomic evidence fundamentally changes the algorithm of 
coverage decisions, therefore medical professionals and policymakers have to be familiar with 
the principles of pharmacoeconomics, including advantages and limitations of different 
approaches to estimate the health benefit, cost-effectiveness and budget impact of medicines 
and the transferability of results among countries. 
Synthesis of scientific evidence provides better understanding of stakeholders on the real value 
of innovative medical technologies. The value proposition of health technologies are illustrated 
by different case studies in the workshop.  
In lower income European countries the major bottleneck of implementation evidence based 
health policy are the lack of trained health economists and local data for the adaptation of 
international economic models. The workshop provides practical guidance for the collection of 
local data in pharmacoeconomic analyses.  
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O.P. 2 
BENEFITS OF INVESTMENT INTO MODERN MEDICINES IN CENTRAL-
EASTERN EUROPEAN COUNTRIES 
Zoltan Kalo, Professor in Health Economics, Eötvös Loránd University, Budapest, Hungary 
 
CEO, Syreon Research Institute, Budapest, Hungary 
 
Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits--
including cost savings or productivity gain--from innovative medicines. Manufacturers try to 
fulfill this expectation by expressing the benefits of innovative technologies in monetary units 
citing approaches from the scientific literature. Unfortunately, currently available evidence has 
limited relevance and transferability in Central-Eastern European (CEE) countries. The 
presentation summarizes how innovative pharmaceuticals in CEE countries may contribute to 
WHO-defined health system objectives, including health gain, equity in health, financial 
protection, responsiveness, equity in finance and financial sustainability. References are mainly 
based on international examples; therefore, additional policy research from CEE countries is 
necessary to validate assumptions. If CEE politicians can rely on credible arguments based on 
local research evidence, they may improve long-term strategies and policy decisions related to 
healthcare innovation. 
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O.P.3 
CURRENT TRENDS AND FUTURE PROSPECTS OF PHARMACOECONOMICS AND 
OUTCOMES RESEARCH - WITH SPECIAL REFERENCE TO HEALTH 
TECHNOLOGY ASSESSMENT 
  
Finn Boerlum Kristensen, 
EUnetHTA Secretariat,Danish Health and Medicines Authority, Copenhagen,Denmark 
 
Keywords: Health technology assessment, pharmacoeconomics, clinical epidemiology, health 
policy 
  
The life-cycle approach to the assessment of technologies and the emphasis on real world data to 
substantiate the effectiveness and cost-effectiveness of technologies has a high influence on 
current development trends. This presentation will navigate between several coordinates such as 
1) trends in health policy and clinical management, 2) trends in regulatory assessment for 
marketing approval and beyond, 3) trends in HTA at scientific and policy levels, 4) trends in 
epidemiology and clinical epidemiology in the light of e-health and health informatics. 
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O.P.4 
FACTORS INFLUENCING PHARMACOECONOMIC ASSESSMENT OF NEW 
DRUGS IN DIABETES MELLITUS TREATMENT 
 
Dinko Vitezić 
 
University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia 
 
 
According to the latest WHO estimate diabetes mellitus (DM) epidemics data showed that the 
number of patients would increase to at least 300 million by 2025 (30 million in 1985; 135 
million in 1995). The global health expenditure on DM is calculated to total at least 376 billion 
USD in 2010 and 490 billion USD in 2030, i.e. 12% of the health expenditures and 1330 USD 
per person. The largest components of medical expenditures are hospital inpatient care, 
prescription medications to treat the complications of diabetes, antidiabetic agents and diabetes 
supplies, physician office visits, and nursing/residential facility stays. 
Because of limited health care funding, health care decision makers are increasingly concerned 
to understand the clinical and economic impact of interventions used to manage DM. 
Pharmacoeconomic evaluation in relation to new antidiabetic medications includes the long-
term benefits of reduced micro- and macrovascular complications, costs of side-effects and 
changes in drug utilisation patterns, in addition to the immediate drug budget impact. To help 
decision makers optimizing the allocation of healthcare resources health economic modelling 
are employed.  
Cost-effectiveness is expressed as an incremental cost-effectiveness ratio (ICER), the ratio of 
change in costs to the change in effect. Quality of life is reduced by DM-related long-term 
macrovascular complications such as coronary heart disease including angina pectoris, 
myocardial infarction, congestive heart failure, and micro-vascular complications such as 
nephropathy, retinopathy and nephropathy. Long-term clinical studies like UKPDS (T2 DM) 
and DCCT (T1 DM) demonstrated that good glycaemic control, measured by HbA1c (surrogate 
marker) level reduction, reduces the risk of DM complications. Thus, the impact on HbA1c 
reduction is widely accepted as efficacy marker in clinical and cost-effectiveness assessment of 
new antidiabetic agents. 
Efficacy of DM medications should always be assessed against the risk of hypoglycaemia. 
Even more, incidence of hypoglycaemia shall be used in evaluation of direct treatment costs 
because severe hypoglycaemia imposes a major economic burden on healthcare systems, with 
the highest proportion of direct costs resulting from the small number of patients who are 
admitted to hospital. Furthermore, because subsequent follow-up also incurs costs, 
hypoglycaemic episodes requiring professional attendance outside hospital generate greater 
costs than those treated in the community by relatives or friends. Although people with T2 DM 
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are often perceived to be at low risk of developing severe hypoglycaemia, studies have shown 
that increasing duration of insulin treatment is the important factor that determines the risk of 
experiencing severe hypoglycaemia. 
In addition to long-term complications and hypoglycaemic episodes, impact of weight 
reduction is also being considered recently in cost-effectiveness assessments of newer 
antidiabetic agents.  
Optimal glycaemic control accompanied with low frequency of hypoglycaemia is the key to 
prevent long-term diabetes complications, which are major drivers of diabetes related costs. 
Thus, cost-effectiveness of new drugs in diabetes mellitus treatment should be assessed against 
these two parameters. 
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O.P. 5 
Czech Maricin (Poland) – Health economic aspects of personalized therapy in diabetic 
patients 
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O.P.6 
THE IMPORTANCE OF PHARMACOECONOMIC MODELING IN ASSESSING 
COSTS OF ASTHMA TREATMENT 
Hren Rock1, Trkman M1, Stynes G2 
1GSK d.o.o., Ljubljana, Slovenia 
2GlaxoSmithKline, Stockley Park West, United Kingdom 
 
Background/aims: In this paper, we critically evaluated the costs of asthma treatment when 
using currently available fixed-dose combinations of long-acting beta agonists (LABAs) and 
inhaled corticosteroids (ICSs) in Slovenia.  
Methods: In order to take into account the complexity of asthma treatment and particularly 
accompanying dose titration, we applied a Markov model to the cohort of 12,300 patients based 
on the results of seminal study GOAL (Gaining Optimal Asthma Control). The comparative 
analysis included the following fixed-dose combinations of ICS/LABA: fluticasone 
propionate/salmeterol (FP/S), budesonide/formoterol (BUD/F) and beclometasone 
dipropionate/formoterol  (BD/F). In the analysis, we assumed that the clinical efficacy and 
incidence of adverse events of fixed-dose ICS/LABA combinations were identical. The time 
horizon was set at 3 years. 
Results: Model analysis showed that the three-year costs of FP/S were lower than the three-
year costs of BUD/F and BD/F by 31% (€666 per patient) and 22% (€405 per patient), 
respectively. The costs of treatment with FP/S were lower than with BUD/F and BD/F for 
patients who were previously treated both with low/medium doses of ICSs (≤500 mg 
equivalent dose of BD) and high-doses of ICSs (>500 mg and ≤1000 mg equivalent dose of 
BD). The treatment costs of FP/S were also consistently lowest irrespective of whether patients 
remained on the therapy for one, two or three years. 
Conclusions: Pharmacoeconomic models are widely used when introducing new health-care 
technologies to the market, however, the same methodology should be applied when the goal is 
to objectively and systematically assess  the costs of existing drugs. 
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O.P.7 
PROPHYLACTIC USE OF CIPROFLOXACINE IN STEM CELL RECIPIENTS 
REDUCE ASSOCIATED COST OF STEM CELLS TRANSPLANTATION 
Zlate Stojanoski, Sonja Genadieva-Stavrik, Aleksandra Pivkova, Lazar Cadievski, Borce 
Georgievski 
University clinic of Hematology, University St’s Cyril and Methodius, Skopje, R.Macedonia 
Key words:  ciprofloxacine, infections, stem cell transplantation 
Introduction: Hematopoietic stem cells transplantation (HSCT) is an important treatment 
modality and expensive lifesaving procedure for many benign and malignant hematologic and 
non-hematologic diseases. During a last 5 decades there has been a dramatic increase in the 
number of stem cells transplant procedures performed worldwide. However, an increasing use 
of transplantation has economic consequences. According to an Agency for Health Care 
Research and Quality report, HSCT generated the most rapid increase in total hospital costs 
from 2004 to 2007 with a growth rate of 84.9% and $1.3 billion spent in 2007 in the USA. It 
was estimated that 25.6% of this increase was the result of an increase in mean cost of hospital 
stays, and 59.3% was the result of an increase in the number of hospital days. According to 
study performed in Sweden in 2009, the total costs included selection and harvesting of stem 
cells, transplantation and 1-year follow-up the average costs per patient were 45,670 € for auto-
SCT and 101,919 € for sibling allo-SCT. The costs of transplantations from unrelated donors 
were much higher: 171,478 € for allo-SCT-MUD and 254,689 € for allo-SCT-UCB. Hospital 
inpatient days together with laboratory and other activities were the main cost drivers across all 
types of SCT. Common post-transplantation complications, such as infections and GVHD, 
have been shown to be significant cost drivers. Bacterial infections remain one of the main 
causes of further morbidity and mortality in patients treated with HSCT. Different strategies, 
such as barrier nursing, sterile room conditioned with HEPA filtration, hematopoietic growth 
factors, intravenous immunoglobulins, and antimicrobial agents, have been proposed in order to 
decrease infections in this patients.. Lee et al found infection, veno-occlusive disease, acute 
GVHD, and death added between $15 300 and $28 100 each to allogeneic transplantation costs 
in USA. Similar findings were reported by Esperou et al who reported an addition of 20 000 
Euros because of occurrence of GVHD and infections in Europe.  
Results and discussion: Aim: to present the use of fluoroquinolones (Ciprofloxacine 1000mg/ 
day) as antibacterial prophylaxis in stem cell recipients and the influence on the frequency of 
the febrile episodes, serious Gram-negative bacterial infections, and hospital stays after stem 
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cell transplantation.Results: during a 13 years period, from September 2000 until September 
2013 we have performed 267 stem cells transplant procedures in 253 patients with different 
hematological malignancies in our center. Autologous: 194 Allogeneic:73. Peripherall blood 
stem cells: 239 and Bone marrow: 28 transplantations. The patients were treated in sterile room 
conditioned with HEPA filtration. They received different chemotherapeutic regimen as 
conditioning therapy prior transplantation according to underlying disease. As an antibacterial 
prophylaxis we use Ciprofloxacine 1000mg./day. until neutrophile recovery. Median day of 
engraftment was: day +11 in both groups. Febrile episodes were presented in 35% of 
autologous and in 64% of allogeneic recipients, with onset on day +5 and median duration 4 
days.  Gram-negative bacteria were isolated in 27% of all isolates, Gram-negative 
bacteriaemia: 14,8% of them. Serious infections due to Gram-negative bacteria: sepsis in 2 
patients and pneumonia in 4 patients. Fatal outcomes: 2 patients (Pseudomonas aeruginosa and 
Stenotrophomonas maltophillia sepsis). Median hospital stays were median 14 days in 
autologous recipients, while 18 days in allogeneic recipients.  
Conclusion: Anti-infective prophylaxis with Ciprofloxacin was shown to be effective in 
reducing febrile episodes, bacterial infections, especially bloodstream infections caused by 
Gram-negative bacteria and the use of empirical first-line antibiotic therapy. Our results 
confirm that prevention and better management of infective complications can improve clinical 
outcomes as well as reduce the associated costs of stem cells transplantation.  
References 
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transplantation;Blood June 13, 2012, doi: 10.1182/blood-2012-05-426783 
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Katherine A. Guthrie, Mellissa Yong, Deborah Frieze, Lawrence Corey, and David N. Fredricks 
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O.P.8 
DECISION-ANALYTIC MODELING STUDIES FOR THE TREATMENT OF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
MULTIPLE MYELOMA: AN OVERVIEW 
 
Vjollca Qerimi1,3, Ursula Rochau1,2, Beate Jahn1, Christina Kurzthaler1, Martina 
Kluibenschaedl1, Ella Willenbacher 4, Guenther Gastl4,Wolfgang Willenbacher4, Uwe 
Siebert1,2,5,6 
1Institute of Public Health, Medical Decision Making and Health Technology Assessment, 
Department of Public Health and Health Technology Assessment, UMIT - University for 
Health Sciences, Medical Informatics and Technology, Hall i.T., Austria 
2Area 4 Health Technology Assessment and Bioinformatics, ONCOTYROL - Center for 
Personalized Cancer Medicine, Innsbruck, Austria 
3Faculty of Pharmacy, School of PhD Studies, Ss. Cyril and Methodius University in Skopje, 
Macedonia 
4Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Austria 
5Center for Health Decision Science, Department of Health Policy and Management, Harvard 
School of Public Health, Boston, MA, USA 
6Institute for Technology Assessment and Department of Radiology, Massachusetts General 
Hospital, Harvard Medical School, Boston, MA, USA 
 
Key words:  decision-analytic modeling, multiple myeloma, treatment, systematic literature 
search 
Introduction: Multiple myeloma (MM) is a hematological malignant plasma cell neoplasm 
presenting with a colonial proliferation of plasma cells producing monoclonal immunoglobulin. 
In recent years, the therapeutic management of MM has changed, when several new drugs were 
introduced into the clinical routine and resulted in convincing improvements in patient 
outcomes, and in new treatment combinations with different benefits, harms and costs. We 
provide an overview on published decision‐analytic models evaluating treatment strategies for 
MM focusing on the structural and methodological modeling approaches and to derive 
recommendations for future MM models evaluating different treatment regimens. We 
performed a systematic literature search in the electronic databases PubMed/Medline, NHS 
EED and the Tufts CEA Registry to identify published studies evaluating MM treatment 
strategies that used mathematical decision‐analytic models. To meet the inclusion criteria, the 
studies had to evaluate different treatment strategies and report relevant clinical health 
outcomes. We used standardized forms for data extraction, description of study design, 
methodological framework, and data sources.  
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Results and discussion: We identified eleven different decision-analytic modeling studies. All 
studies included an economic evaluation. The modeling approaches varied considerably 
(decision tree, cohort state-transition (Markov) model, discrete event simulations, partitioned 
survival analyses and area under the curve models). Analytic time horizons ranged from seven 
years to lifetime. Ten studies adopted a third-party payer perspective (e.g., governmental payer, 
health-care system); only one model was conducted from the societal perspective. Health 
outcomes included (overall, median, progression-free) survival, number needed to treat, time to 
discontinuation of treatment, life expectancy, and quality adjusted life-years. Compared 
treatment strategies included lenalidomide, dexamethasone, bortezomib, melphalan, 
prednisone, thalidomide, haemodialysis, bone marrow transplantation, zoledronic acid, and 
clodronate. Model validation was only mentioned in the discussion when comparing the results 
with other cost-effectiveness studies.  
 
Conclusion: We identified several well-designed models for MM treatment strategies 
evaluating relevant health outcomes and reporting results for cost-effectiveness/cost-utility 
analyses.  Most of the studies were not comparable due to different treatment strategies, target 
population, transferability and settings. The quality and details of reporting varied considerably 
and in some cases the models were not sufficiently described. Regarding future models, our 
findings support the recommendation for an explicit model description including all relevant 
parameters according to the ISPOR-SMDM Modeling Good Research Practices Task Force 
guidelines. 
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O.P.9 
LIMITS OF APPLICATION OF PHARMACOECONOMICS AND HEALTH 
TECHNOLOGY ASSESSMENT IN DRUG AND HEALTH POLICIES 
Tomek Dominik 
Slovak Healthcare University & Comenius University, Bratislava, Slovakia 
 
The example of Slovakia shows that the drug policy is shifted more and more towards objective 
measures with the help of pharmacoeconomics or HTA, actually without scientific evaluation 
of the results. The P&R policy in Slovakia has gone through several changes during last five 
years. The new legislation is dramatically influencing the P&R approval of new, particularly 
high priced medicines and new indications. This will challenge payers, health care providers, 
industry and patients to find new ways to maintain the availability of innovative treatment. Out 
of 12 new EU member states (accessed in May 2004 or later) HTA was applied in 10 of them; 
in 8 as a light version and in 2 as a robust NICE-like version. HTA has an impactful position in 
6 of them (Estonia, Hungary, Latvia, Poland, Slovakia and Slovenia). Threshold is officially 
published in primary legislation in 2 countries (Poland, Slovakia). There are three main pillars 
on provision of healthcare - access, quality and costs. Overall, as well as in Slovakia, this is 
challenged with focus on transparency, predictability, affordability and resource allocation. We 
are facing ongoing discussions on free market principles in healthcare, profit generation, 
redistribution, institutional and individual capabilities. The drug policy is acknowledged as one 
of the elements of effective and efficient resources allocation. In Slovakia the 
pharmacoeconomics principles have been introduced as mandatory for the pricing & 
reimbursement process since 2006, however, the full impact was reached only recently, with an 
implementation of ICER and/or cost-per-QALY thresholds into formal legislative framework. 
However, we must acknowledge that ICER is insufficient as a measure for objective evaluation 
of the value of innovation. There are fundamental differences in the potential value of threshold 
for the cost per QALY due to significant differences in utility perceptions (e.g. mild 
hypertension patient vs. final stage metastatic malignant melanoma patient), different 
healthcare provision settings (ambulatory vs. hospital, acute vs. long-term) and between 
different healthcare systems. However, the society priorities are changing. Societal values such 
as equity, preference for life-saving treatments, rare diseases issues are demanded more often. 
Patient-centered approach is to be incorporated into the assessment of innovations. Those 
requirements are pre conditions of well-performed health technology assessment, and any 
further appraisal of health technologies should have a base in HTA implementation.  
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O.P.10 
 
Atanasijevic Dragana (Serbia) – HTA implementation in Serbia 
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O.P.12 
 
Tarik Catic (Bosnia and Hercegovina) - HTA in Bosna and Hercegovina 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST MACEDONIAN AND FOURTH ADRIATIC CONGRESS ON 
PHARMACOECONOMICS AND OUTCOMES RESEARCH 
 
29 
 
O.P. 13 
BIOSIMILAR MEDICINAL PRODUCTS: FROM THEIR DRUG-REGULATION TO 
THEIR MARKET-PLACE 
Gonzalo Calvo 
The establishment of a clear regulatory framework for biosimilars has indeed been a key step to 
promote the development of these drugs. It has been estimated that the European 
biopharmaceuticals market accounts for approximately 45 per cent of the global market and 
pharmaceutical expenditure in general is constantly increasing in Europe. For many years the 
increased availability of generic medicines has had a major contribution to control the overall 
health costs in medicinal products and, therefore, it could be considered that biosimilars would 
have the same positive effect. However, the market for generics in Europe is quite split and 
their introduction and impact is highly variable among the different countries.  For instance, 
Germany and the United Kingdom have a well-developed generics market and prices for 
medicines are high in general while in Spain, Italy and France generics did not account for a 
significant proportion of the pharmaceutical market until recently. Differences in pricing 
systems, incentives, promotion and even cultural aspects may result in this fragmented 
picture. It is possible that the use of biosimilars followed the same pattern as generic medicines. 
Additionally, the marketing and launch of biosimilars needs a different strategy than generics 
(as marketing, use, patient support and post-marketing activities such as pharmacovigilance 
need more resources and experience). However it is too early to say and we probably need a 
few more years to identify the real place of biosimilars in particular therapeutic areas. 
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O.P.14 
BIOLOGICS AND BIOSIMILARS - WHY THE PRINCIPLES OF GENERICS DO 
NOT APPLY? 
Prof Borut Štrukelj, Ph.D. 
University of Ljubljana, Faculty for Pharmacy, Aškerčeva 7, 1000 Ljubljana, Slovenia 
 
Key words: medicinal,  biologicals,  biosimilars, generics, safety, comparability 
Introduction: In a field of biological medicines, last five years were dedicated to similar 
biological medicinal products, commonly referred to as biosimilars. They represent a copy 
version of an approved original biologic medicine whose data protection has expired. However, 
biosimilars cannot be assumed as completely identical to the reference product, nor can two 
different biosimilars be considered equivalent. In principle, biosimilars are the biologic drugs 
that might be regarded as biogenerics. 
Discussion: From biotechnological and clinical points of view, biologicals are derived from 
living cells or organisms and are composed of highly complex molecular entities (proteins, 
glycoproteins, lipoproteins), that may be difficult to be fully characterized. Due to the 
substantial variability of biologic expression system as well as manufacturing process, almost 
all complex biosimilars and biologicals display a certain degree of microheterogeneity, not only 
between each  biosimilar and its reference product but also between different batches of the 
same product. According to the general definition of the generic medicines that should possess 
identical molecular structure it has been through years clearly demonstrated that general 
definition of generics cannot be simply transferred into the field of biologics. Consequently, 
only physicochemical identification and demonstration of similar bioequivalence profile of 
biosimilar is not sufficient to conclude on therapeutic equivalence. Therefore, biosimilars need 
to be developed and characterized on a more extensive head-to-head comparison with the 
reference product, included clinical investigations in order to demonstrate the comparability in 
terms of quality, efficacy and safety.Since 2007, biosimilars have been approved for use in 
patients in the European Union (EU). European experience provides several base points as the 
United States (US) healthcare system prepares for biosimilar approvals. These lessons 
emphasize the need for adequate efficacy and safety studies, post-marketing surveys and a 
robust pharmacovigilance system that can accurately track and trace biologics, including 
biosimilars and their reference products, from the patient to the manufacturer. The marketing 
authorization holder’s application for the biosimilar approval must contain biosimilarity 
information based on data derived from analytical, animal, and clinical studies. Clinical studies 
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should include an assessment of immunogenicity, pharmacokinetics, pharmacodynamics, and 
address one or more indications licensed for the reference product. 
Conclusions: Based on the data presented, we demonstrate that the general principle of generic 
small chemical entities cannot apply to biosimilars. In the presented article, we will elaborated 
the basic requirements for biologicals and biosimilars in terms of structure-activity 
relationships, safety and potentially developed immunological response that might influence on 
the overall quality of the product. 
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O.P.15 
 
PRICING AND REIMBURSEMENT RELATED TO GENERIC AND BIOSIMILAR 
PRODUCTS IN CEE REGION 
Vladimir Zah  
 
Due to the differences in biological and chemical agents, biosimilars require a special approach 
for the registration of biosimilar and organization of post-marketing studies. Question is at which 
product phase ( 3 or 4) can biosimilar with certainty be released as a substitute to expired 
innovative drug?  
Author will further discuss the political and economic pressures to increase access to healthcare, 
the gradual implementation of reduced requirements for less complex biosimilars in Latin 
America.  
Impact of International Reference Pricing in CEE region is to be further examined.  
Potential end and it’s impact of CEE Protectionist market policies that are implemented will be 
discussed. 
Audience participation is anticipated.  
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O.P. 16 
GENERIC AND THERAPEUTIC DRUG SUBSTITUTION 
Viktorija Erdeljić Turk, Igor Francetić, Ksenija Makar- Aušperger, Matea Radačić- 
Aumiler, Robert Likić 
Division of Clinical Pharmacology, Department of Medicine, University Hospital Zagreb 
 
Key words: generic drug substitution; therapeutic drug supstitution; Croatia, clinical 
appropriatness; cost-minimization 
Introduction: There is considerable debate concerning the place of generic (from a brand to 
generic product) and therapeutic substitution (switching to a cheaper product usually within the 
drug class, eg. statins, proton pump inhibitors, drugs that affect the rennin-angiotensin system). 
Generic substitution is promoted by the Croatian Health Insurance Fund in Croatia in the 
primary health care setting, and recently in the secondary healthcare setting by establishment of 
centralized drug procurement system. It is estimated that generics constitute 50% of overall 
drug consumption in Croatia. Therapeutic substitution is more contentious as direct evidence to 
support equivalence is lacking. However, the price differentials makes it an attractive 
application of cost-minimization analysis for the more efficient use of health resources.  
Results and discussion: Here we explore the existing open questions taking into consideration 
the clinical appropriateness and safety of generic and therapeutic switching, from an individual 
patent perspective and health service perspective. Although substitution may affect individual 
patients, it might be a price worth paying given the opportunity cost associated with the use of 
medicines that are clinically no better than cheaper alternatives. However, tensions are created 
by the promotion of the concept of patients choice at the same time. We review clinical areas or 
drug types where brand prescribing may be considered preferable because of the possibility of 
therapeutic inequivalence or potential for confusion (eg. medicines with a narrow therapeutic 
window where there is evidence regarding the risk of adverse patient reaction or inadequate 
efficacy, vaccines, biosimilars).  
Conclusion: Generic substitution is almost universally accepted as desirable and cost reducing. 
Therapeutic substitution, although not as widely accepted, allows also considerable cost 
savings to be made. The trade-of is patient choice vs. rational fund spending. Arguably, for any 
publicly funded healthcare system, the latter has to be the priority.  
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O.P.17 
BIOSIMILARS IN REPUBLIC OF MACEDONIA – LICENSING AND MARKET 
ACCESS 
Ass. Prof. Aleksandra Grozdanova 
 
University Ss. Cyril and Methodius, Faculty of Pharmacy, Skopje, Macedonia 
 
 
Biosimilars presents significant clinical, regulatory and economical issue which is still discussed 
in Europe. Due to their complex structure and the processes of production, biosimilars are not 
identical copies of biological medicines and therefore the generic approach cannot be applied. 
The patents of a number of biologic medicines have already expired or are due to expire, which 
has led to an increased interest in the development of biosimilars. The licensing of biosimilars is 
based on abbreviated registration process and biosimilar manufacturers must submit robust data 
to demonstrate a product’s efficacy and safety profile and provide substantial data to show that 
its product is sufficiently similar to the original product. Since biosimilars are a relatively new 
and emerging market, regulatory guidelines and standards are still being developed. Within the 
European Union, Member States are generally responsible for implementing regulation adopted 
at EU level including development, authorization and manufacturing of biosimilars. The first 
biosimilar guidelines was created in EMA in 2005, followed by the first approved biosimilar 
products in 2006 and at the end of 2013 the number of biosimilar products approved by the EMA 
was seventeen. Regulation has evolved rapidly with many countries establishing national 
guidelines based on the WHO and EMA framework. Although many things including regulations 
for licensing of biosimilars are harmonized within the EU, the attitude towards biosimilars and 
their substitution in different countries of the EU varies widely. The regulatory aspects of 
licensing of biosimilars in countries like Macedonia where the presence of biosimilars is still 
limited, are in development, but there is lack of official guidelines for substitution or 
interchangeability between biosimilars and biological reference products. 
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O.P. 18 
ETHICAL PRACTICES  PROMOTING GOOD GOVERNANCE IN THE PUBLIC 
PHARMACEUTICAL SECTOR AND THEIR INFLUENCE IN HEALTH 
ECONOMICS 
Merjem Hadjihamza1,  Mihail Minov2, Eleonora Pandova1 Renata Raicki3,  
1Ministry of Health, Skopje, Republic of Macedonia    
2Europharm , Skopje, Renata Raicki 
3University “Ss. Cyril and Methodius” Faculty of Pharmacy,Skopje 
Key words: pharmaceutical procedures, drug chain, economic impact, unethical practices, 
Ethical practices promoting Good Governance are an important factor affecting economic 
growth and sustainable development at every level and within all sectors of society. 
Pharmaceutical sector is one of the key elements of the health system with a great influence on 
public health. As acknowledge, the pharmaceutical sector is very complex and highly regulated 
in most economies. The complex nature of the pharmaceutical sector comprises broad spectrum 
of functions. Thus, the ‘drug lifecycle’ includes many different steps beginning with the 
research and development of new drugs through their manufacturing, clinical trials, marketing 
authorization, procurement, selection, distribution, inspection, promotion, pricing, 
reimbursement  and ending with rational drug use and  pharmacovigilance. In principle, each 
step in the drug chain involves variety of procedures, applied standards, policy instruments, 
competent regulatory authority and professional expertise. Considering the value of the global 
pharmaceutical market it is estimated to reach over 600 billion US dollars while health 
expenditures each year exceed the figure of 3 trillion US dollars. However, it is disappointing 
to note that imposing tangible assets related to the pharmaceutical market have often been 
targeted for abuse and from this perspective the pharmaceutical sector is becoming highly 
vulnerable to unethical practices. These unethical practices may have significant economic and 
health impact by cousing ireverisble lost of health funds and  affecting the quality of  public 
health, as well. This has become an important issue since in most developing countries 
pharmaceutical expenditure and drug procurement account for 20-50% of total public health 
budget. Improper management of public funds reduces the government capacity to provide 
good - quality essential drugs and leads to irrational use of drugs too. Therefore it is of crucial 
importance to meet ethical criterions during implementation of different procedures related to 
pharmaceutical sector. In addition, each specialized professional activity in this domain 
requires a combination of knowledge, expertise, skills, experience and the availability of 
timely, non-discriminatory, transparent and predictable processes. 
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The reasons worldwide considered responsible for the appearance of unethical 
practices are:  (1) Imprecisely defined and documented procedures (2) Lack of control 
mechanisms (3) Lack of transparent procedures. Imprecisely defined and poorly 
documented procedures, lack of control mechanisms as well as lack of transparency 
always causes a delay and bureaucratization of procedure implementation and play an 
significant role in shaping economic lost. This can further increase the vulnerability to 
unethical practices. Therefore it is particularly important equal sharing of information’s 
between all participants in the drug chain so they can make decisions based on relevant 
information and evidence.   
Many models are globally recommended in order to prevent unethical practices 
worldwide in pharmaceutical sector.  
 
(UNESCAP)-Figure 1. 
 
 
Figure 1: Elements of Good governance 
 From the perspective of good governance, at first it is fundamental need to have 
policy framework, stringent regulations, and procedures that improve the governance of 
drugs chain and promote access to drugs with proven high quality. In order to improve 
the good governance in pharmaceutical sector Ministry of Health of Republic of 
Macedonia with WHO support has published the, Ethical framework for Good 
Governance in public pharmaceutical sector”. ,,Good governance” refers to the 
implementation of appropriate policies and procedures that ensure the effective and 
ethical management of pharmaceutical systems and drug supply systems in a manner 
that is transparent, accountable, follows the rule of law and minimize unethical 
practices. The World Health Organization (WHO) has developed a technical package 
which helps Countries to establish Good Governance for Medicines (GGM) program at 
national level. The establishment of GGM program is an essential tool which can be 
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helpful to all health systems to improve all functions within the health sector and have positive 
impact on health economics.  
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O.P. 19 
PHARMACOECONOMIC EVALUATION IN PROCESS OF INTRODUCING NEW 
VACCINES IN NATIONAL PROGRAM OF IMMUNIZATION 
 
Maarten J. Postma 
 
University of Groningen, Netherlands 
 
 
Health economics is becoming increasingly important in the evaluation of vaccination strategies, 
for example, in the context of formal health-technology assessments of new vaccines. Notably, 
guidelines for health economics are omnipresent and often developed for therapeutic 
pharmaceuticals (pharmacoeconomics). It is debated in how far these guidelines can 
straightforwardly be applied to vaccines as well. It is well known they generally impact quite 
differently on vaccines than they do concerning therapeutics pharmaceuticals. Issues of such 
debate concern discounting, the perspective chosen, the desired time horizon and type of clinical 
endpoints warranted. The debate will be illustrated using examples from newly available 
vaccines, such as the rota and HPV-vaccines, but also apply to already longer existing 
vaccination programs for various respiratory infections. The aim is to identify the issues of 
relevance and suggest ways for better precision in the guidelines to optimally accommodate 
economic evaluations of vaccines as well, as in the current situation these guidelines seem to fail 
in that respect.  
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O.P. 20 
 
WORK DISABILITY RELATED TO MUSCULOSKELETAL DISORDERS: 
ASSESSING THE BURDEN AND IDENTIFYING SOLUTIONS IN SLOVENIA AND 
THE WIDER EU 
 
Stephen Bevan 
 
Fit for Work Europe Coalition, The Work Foundation, Lancaster University 
21 Palmer Street, London SW1H0AD 
 
 
Keywords: Musculoskeletal; Work Ability; Slovenia; Productivity; Early Intervention 
 
Introduction: The global burden of disease data show that musculoskeletal disorders (MSDs) 
are the largest contributors to the burden of years lived with disability (YLDs). The impact on 
lost productivity in the EU is also substantial as MSDs affect over 40m workers (at an annual 
cost of €240 bn) and cause 49% of all lost working days. As the EU workforce ages and as the 
burden of chronic illness grows it will become an economic necessity to devise and implement 
cost-effective and timely interventions to reduce work disability and sustain productivity levels. 
This paper will examine the prevalence and impact of MSDs in the EU and, using research 
conducted into the Slovenian labour market as a case study, will highlight how healthcare 
decision-making, clinical practice and welfare policy might better coordinate to improve 
outcomes for people living with MSDs.  
 
Results: A multi-method study has been conducted into the burden of MSDs in the Slovenian 
workforce as part of a pan-European study called ‘Fit for Work Europe’. In Slovenia, almost 
50% of the workforce report having conditions such as back pain, that 2.47m working days are 
lost to MSDs in Slovenia each year and that MSDs overall contribute significantly to the disease 
burden among Slovenian citizens – affecting both labour market participation and social 
inclusion. The study found challenges in the measurement of MSDs in the working age 
population of Slovenia. It also found that improved diagnosis and early clinical interventions 
could significantly improve both job retention and return to work. The study calculated that a 
25% reduction in temporary work disability among Slovenian workers with MSDs would allow 
an additional 2,800 to attend work each day. 
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It also found that labour productivity among Slovenian workers with MSDs could be improved if 
healthcare professionals routinely considered work as a clinical outcome of care and if early 
clinical interventions which improved work ability were prioritised by healthcare decision-
makers. Cost effectiveness data from a number of EU examples of early intervention show that 
returns of 9:1 are feasible. 
 
Conclusion: The study concludes that in Slovenia – and in the wider EU – the productivity gains 
of early clinical interventions for people with MSDs are considerable and that the return on 
investment from such interventions should incentivise better coordinated responses from policy-
makers, clinicians and employers. 
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O.P. 21 
THE ROLE OF THE HIFM ON EFFECTIVENESS AND RATIONAL USE OF 
MEDICINES IN REPUBLIC   OF MACEDONIA 
Maja Parnargieva-Zmejkova 
Health Insurance Fund of Macedonia 
Key words: health insurance, HIFM, health expenditures, drug expenditures     
Introduction: Macedonia has a solidarity based compulsory health insurance system, that 
collects the funds from health insurance contributions in form of earmarked social payroll tax, 
which is the main source of financing the health system.The Health Insurance Fund of 
Macedonia (HIFM) is a purchaser of health care services for the insured. HIFM contracts with 
around 3.500 health providers that provide health services and pharmaceuticals. The health 
insurance system covers 85% of the population, but the system enables every citizen to be 
insured, of actually every person living in the country is insured.Currently the HIFM Budget is 
4,6% of GDP, or 22 billion MKD (357 million EUR), with pharmaceuticals accounting more 
than 10% (drugs used in hospitals are not included). 
Pharmaceutical expenditures and consumption: Worldwide expenditure on pharmaceuticals 
has been increasing at a faster rate than total health spending: per capita spending on 
pharmaceuticals rose by more than 50% between 1995 and 2005. The system is based on a 
positive list of drugs that defines which drugs are eligible for reimbursement from the HIFM. 
The process of revision of the list has been reestablished and there will be 14 bodies responsible 
for introducing new drugs in the list. 
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Figure 1. Number of prescribed drugs and total expenditure for drugs 
Having in mind the constant increase of the consumption and the expenditures for drugs and how 
serious concern is to the financial sustainability of the health system, the cost control policies are 
inevitable. In the Macedonian system some mechanisms for efficiency have been introduced in 
the past years and some are in the process of implementation in the moment. 
The most important measure that significantly stopped the increase of these expenditures in 2009 
and 2010 or in the beginning of the economic crises was the introduction of the new 
methodology for reference pricing. As a result of that in 2010 in comparison to the previous year 
the expenditures for pharmaceuticals decreased for 2,8%, while the number of prescribed drugs 
continued to increase.  
The other mechanisms are structured in two groups 
1. Measures focused on the doctors 
- Generic prescribing has been introduced in Macedonia for several years, and as a part 
of that process the doctors can’t suggest pharmaceutical brands and pharmacists are 
obliged to inform the insured about the different brand names and the difference in 
the price 
- Level of prescribing. For part of the drugs on the positive list is required to be 
prescribed by a doctor from higher level of health care (specialist, subspecialist) 
- Guidelines for standard treatment have been implemented by the Ministry of Health 
a few years ago and the role of the HIFM is to make sure there are followed by the 
hospitals  
2. Measures focused on the consumers 
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- National campaign for rational use of drugs especially antibiotics. Macedonia is one 
of the countries with highest use of antibiotics. One part of the campaign is education 
for the final consumers but also monitoring and education for the doctors, especially 
the ones that over prescribe antibiotics. 
Conclusion:  Macedonia is a country with limited funds for health care in total, as % of GDP 
and also as the part of the public funds allocated to health. Despite that, in the past few years a 
lot has been done by the health authorities and by the Government towards containing the 
expenditures for pharmaceuticals without decreasing their availability. With all the measures 
introduced significant efficiency in the use of pharmaceuticals has been achieved. Some of the 
measures that are implemented in Macedonia, like the generic prescribing, even the developed 
countries have difficulty introducing in their systems. But there are a lot of steps that have to be 
completed in the future. The process of defining the medical guidelines is in halfway, but the 
HIFM has started the control of their enforcement in hospitals. At its beginning is a big national 
campaign for rational use of antibiotics accompanied with additional education focused on 
medical workers and the consumers that is expected to remove Macedonia from the top of the 
list of the biggest consumers of antibiotics.  As in all health systems, the biggest challenge to 
come is how to finance the constant growth of health expenditures.  But even within the limited 
resources, with a lot of work from the authorities and health institutions and cooperation with the 
pharmaceutical industry, positive effects for the health status of the population can be achieved.    
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Slobodanka Bolanča (Croatia): Value of innovation in pharmaceutical sector in Croatia 
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O.P. 23 
PHARMACAUTICAL PRICING- A CONTINUING CRISIS 
Rubin Zareski 
Pharmaceutical faculty, Skopje 
 
Key words: pharmacoeconomics, drug costs, new common model, HTA  
Introduction: In the last 10 years we are experiencing hidden debate where decision makers do 
not want to opt for the “unpopular” decisions, which need to be taken if we need a sustainable 
health systems. In the crisis that is being driven by external global forces that are beyond our 
control, spending more money will not solve the problem. Making the system sustainable 
requires that the Governments implement changes to the way care is funded and delivered, which 
limits the services provided by the state – creating new losers as well as winners. In this new 
environment, pharmaceutical companies will have to make major shift in the policy 
implementation by trading price for access to markets. Although Governments are pleased by 
this changed position, on the long run they will face with more problems than ever. Finding a 
right balance by introducing a pharmacoeconomic studies will address the problem on a long 
run. 
New Common model: Healthcare consumes 12% of global GDP, and is a $5.2 trillion industry. 
Spend is growing at average of 4% per annum, which will double expenditure in less than 20 
years. By 2080, estimated 50% of world GDP will be spend on health costs (OECD analysis). 
Question is whether this growth is sustainable? Health players inevitably are changing the 
behaviour patterns, influencing the fundamental global forces that will change the way systems 
work. The shape of global health systems in the next 20 years will continue to undergo dramatic 
change. Reduction on the reliance on market forces (Obamacare), growth in importance of 
emerging markets,need for control of costs and increase of performance levels must lead towards 
new agreement of delivering the services and products and covering the costs by third party 
payers. It is therefore important to find a right balance between global trends, funding and 
expenditure. By default this requires establishment of a common Model that will implicate the 
Government and Pharma industry policies. 
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Source: WHO 
 
The core elements of changes: Universal access to the healthcare as a human right is no longer 
affordable. The options are limitedto the need to implement changes that will improve efficiency, 
control demand and finally shift the focus from the decisions that are partly rational, but also 
driven by societal preferences, political expediency and partisan pressure. One of potential exit 
solutions is to limit the scope of “Core Services” paid through taxation and to drive Government 
policies to focus on investments that have the biggest impact on the health of the nation. Core 
element for these revised policies is to focus on what really drives value in the 
Markets.Considering the fact that about 15% to 20% of clinical spend is wasted on efforts that 
are not valued by key stakeholders, urgent changes in policies are needed. To address this 
negative coralations,pharmacoeconomists need to focus on what really drives treatment decisions 
and what new data would be viewed as clinically meaningful for prescribers and value-creating 
for economic stakeholders. This requires: 
1. continuinganalysis, including assessment of the critical drivers of behavior for each 
stakeholder (prescriber, payor, and patient).  
2. detailed comparison of competitor labels and clinical data- to further  inform which efficacy 
and safety endpoints matter most, and maps each of the brands against them stakeholder 
perception mapping-  
3. understanding of how competitors are perceived by each stakeholder against the most critical 
factors, which can help identify unmet needs, and a  
4. profound understanding of real-world data on treatment decisions and  outcomes. 
Major challenge that we will face is the size and content of “core provision”. We need to 
understand that this choice is arbitrary. Eventually all health systems will converge largely onto 
the same system structure – the Common Model. As attempts of establishing of the common 
model expand, it will challenge the very basis of innovation funding. This will by default 
considerably provoke change in the policies the drugs companies strategically operate.The drugs 
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companies will no longer be able to develop and price drugs assuming model of universal 
reimbursement, unaffordable drugs will see price regulation, or exclusion and Companies will 
need to decide which segment to target. They will have to consider and weight several options:  
 Low cost per unit/high volume/mass market/core service 
 High cost/out of pocket funded 
as consequence drug pricing will need to become far more flexible and pricing policies will be 
affordable against other health priorities 
 Novel pricing mechanisms to meet local system needs e.g. risk based, licence based, volume 
based  
 Pricing based on a global model to maximise overall revenue, not based on what markets can 
bear 
 The model of innovation funding will need to be adjusted to the new reality. 
Conclusion: In recent years, the pharma industry has shifted towards areas that may be excluded 
from core services. Partially this is reflection of the different methods countries use to manage 
price, make it difficult to have a consistent global pricing approach.Pricing needs to evolve to 
take into account the realities of the 21st Century where ‘pricing corridors’ no longer work. This 
will change value expectations, affordability, utility assessments, commitment to access, de-
linking from health and industrial agenda. By default this will lead towards greater cross-border 
transparency, it will define new global pricing referencing and consequently it will change nature 
of innovation in a way it will shift towards small volume therapies, interclass referencing, 
lifestyle diagnostics etc. 
 
 
 
Establishment of a common denominator with a clear ‘value proposition’ needs to be at 
the core of pricing and re-imbursement submissions. To optimise pricing across markets, 
development plans need to move from clinical claim vs. placebo and incorporate economic 
outcomes. Finally, incremental costs need to consider potential incremental revenues from 
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priority markets (price, positive formulary place, time-to-market) and the potential downside risk 
of unfavourable comparisons with alternative treatments. A long way to go but shorter if it starts 
today.  
 
References 
Rubin Zareski, Basics of Pharmacoeconomics, Akademika,2012 
McKenzey&Company, Invention reinvented 2010 
OECD, WHO,Growth rate average growth in spending in OECD countries 1995-2015 
WTO, Annual reports 2013 
UK Pharmaceutical Industry Competitiveness Task Force, 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST MACEDONIAN AND FOURTH ADRIATIC CONGRESS ON 
PHARMACOECONOMICS AND OUTCOMES RESEARCH 
 
50 
 
O.P. 24 
 
John Yfantopoulos (Greece) - Economic impact of pharmaceutical parallel trade 
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Livio Garattini (Italy) - Value Based Pricing 
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Slobodanka Bolanča (Croatia) - TBC: Ensuring Patient Supply of 
Innovative Pharmaceutical Products in EU – is there any room for improvement? 
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O.P. 27 
THE INTRODUCTION OF THERAPEUTIC REFERENCE PRICING SYSTEM IN 
SLOVENIA 
Jurij Fürst, Rozeta Hafner 
Zavod za zdravstveno zavarovanje Slovenije, Miklošičeva c. 24, SI-1507 Ljubljana 
 
In 2003, the Health Insurance Institute of Slovenia (ZZZS) introduced a reference pricing system 
(NPV) for interchangeable drugs. This is one of the most important systemic mechanisms to 
control expenditure on medicines. The others are control of maximum prices by the Agency for 
Medicines and ZZZS’ agreements with pharmaceutical companies. In 2013, the therapeutic 
reference pricing system (TSZ) was introduced. It determines the same reference level for a 
therapeutic group of drugs with the same indication. Sub-groups based on dosage levels may be 
formed. In each group the reference active ingredient can be defined; if not defined, the reference 
level is always on the cheapest product. The reference active ingredient has to have a certain 
volume market share, defined by the formula: 100/ (n+1) (where n = the number of active 
ingredients). In case of four active ingredients, for example, the minimum share would be 100/5 
or 20 %. Furthermore, in order for a product (presentation) to be used as a reference product, it 
would need to account for at least 0,5 % share by volume (DDD) of its group or sub-group. For 
products with certain pharmaceutical or therapeutic properties, an added value may be defined 
and the reference level can be lifted. In the same group, a limited range of prices may be created. 
Price ranges in many groups are large; they may be well over 100%. 
In October 2013, first group with proton pump inhibitors was published. In 2014, lipid-lowering 
drugs (statins and ezetimibe) ACE inhibitors, acetylsalicylic acid and imatinib followed. New 
group will be regularly added and the existing ones periodically checked. Savings in each group 
are between 15 and 40 %. Most of the prices of medicines adjusted in the first month following 
introduction of each group. There are co-payments for less than 10 % of products in the groups. 
In case when replacement of medicines for medical reasons (i.e. side-effects) is not possible, a 
doctor may write on prescription: "do not substitute!" and a patient is exempted from the co-
payment.  
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THE CURRENT PRICING AND REIMBURSEMENT SYSTEM FOR 
PHARMACEUTICALS IN BULGARIA 
Guenka Petrova¹, Tatyana. Benisheva²,³, Alexandra Savova¹,³, Assena Stoimenova¹,³ 
¹Faculty of pharmacy, Medical university-Sofia, Dunav 2, Sofia 1000, ²Faculty of Public Health, 
Medical University-Sofia 1431, 15 Ivan Geshov bvd., ³National Council on Pricing & 
Reimbursement of Medicinal Products 
Key words:  reimbursement, medicinal products, pharmaceuticals, regulation, Bulgaria 
Introduction: The pricing and reimbursement framework is an essential part of a 
pharmaceutical system. In the European Union (EU), Member States are free to develop their 
national pharmaceutical policies in the field of pricing and reimbursement as long as they 
comply with the general EU provisions – the Transparency Directive 89/105/EEC. The first 
positive reimbursement list (PDL) for pharmaceuticals was published in Bulgaria in 2003. The 
relevant regulation at that time required pharmacoeconomic analysis of the anticipated benefits 
of the treatment submitted for reimbursement but no detailed information regarding the template 
and the requirements of such analysis in the current legislation or in guidelines was given at that 
time. The regulation endorsed in 2008 unlike the previous one, focused on cost-effectiveness of 
pharmaceutical products submitted for reimbursement, and its budget impact. A new pricing and 
reimbursement regulation came into force in end of April last year 2014 in Bulgaria. It continues 
the line of amendments which started at the end of 2012 as a result of the heavy pressure to 
lower the prices of the medicinal products. In May 2012 the Bulgarian Parliament appointed the 
Bulgarian National Audit Office (BNAO) to audit the performance of the price regulation system 
for reimbursed medicinal products in the period January 2008 – December 2011. The report was 
published in November 2012 and one of the key conclusions was that the pricing and 
reimbursement administration process was extended and prevented the adequate market access 
of mainly new medicinal products and it was ineffective to systematically update the approved 
prices in case of referent prices decrease. As a result of these (BNAO) findings a new institution 
responsible for pricing and reimbursement of medicines was established in March 2013 – namely 
National Council of Pricing and Reimbursement of Medicinal Products (NCPRMP). The current 
publication analyses the effect on the pricing and reimbursement  of the new legislation. 
 
Results and discussion: Currently Bulgaria applies both medicinal product-specific eligibility 
and disease-specific eligibility schemes. There are reimbursement rates of 100%, 75%, 50% and 
25%. Inclusion in positive drug list is based on the efficacy of the medicinal products, their cost-
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effectiveness, existence of therapeutic alternative and their budget impact. De-listing is executed 
in case of lower therapeutic efficacy, excessive prices and switch to over-the-counter regimen.  
The NCPRMP had 276 (accounting for 6% from all procedures in 2013) procedures transferred 
from the previous Commission on Pricing and Reimbursement which led to overload of the 
Council from the very beginning of its formation. For the observed period number of the 
assessed applications were 5287 where the majority of the submitted procedures (68%) 
concerned reference price comparison in 17 MSs in the EU based on  official price reviews 
(performed every 6 months for each authorized MP).  
The procedures for inclusion in PDL accounted for 24,9% from the submitted to the 
National Council procedures, while exclusion of MPs  from reimbursement procedures were 
5,3%. All inclusion procedures requested pharmacoeconomic analysis submitted by the 
companies, which was reviewed by the experts in the NCPRM. For the observed period 205 
medicinal products were approved for reimbursement which includes 22 new INN which is 
serious scientific and administrative work. Еxclusion of 140 MPs from reimbursement system 
were observed for different  market and manufacture reasons. As a result in 2013 the prices of 
842 medicinal products were reduced and the reduction of the prices per pack varies from 0.1% 
to 57.26% which led to substantial reduction of treatment costs.   
Conclusion: The creation of National Council on Pricing & Reimbursement was a step forward 
as the single pricing and reimbursement administrative procedure cut down the overall 
procedural timeline. However, the reimbursement system in Bulgaria is facing several substantial 
challenges amongst which are lack of overall financial analysis of healthcare system and 
pharmaceutical policy; lack of legal environment for generic substitution of medicinal products 
and incentives for physicians to constrain the costs (or pharmaceutical budgets for doctors); lack 
of registries for patients with chronic diseases, etc.  
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PHARMACEUTICAL PARALLEL IMPORT IN THE REPUBLIC OF MACEDONIA 
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1Ministry of Health – Bureau for Medicinal Products of the Republic of Macedonia, Skopje, 
2Faculty of Pharmacy, University “Ss Cyril and Methodius”, Skopje, Republic of Macedonia 
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Introduction: The term “parallel” describes that the medicinal products (MPs) are imported via 
pathways that are parallel to the authorized ones (designated by manufacturer or its original 
supplier), as a rival channels that are active in the same time. Parallel imported MPs are not 
counterfeit medicines, but lawfully authorized MPs that generate a lot of benefits for patients and 
health insurance funds i.e. access to lower-prices versions of the same authorized MPs (1). 
“Parallel import (PI)” as a legal category was introduced in the pharmaceutical legislation in the 
Republic of Macedonia (RoM) in January 2012 and it showed its real economic, legal and 
marketing effects after October 2013, when the last amendments of the national Law on 
Medicinal Products and Medical Devices (2) were adopted. The purpose of this article is to 
present the concept of pharmaceutical parallel import in the RoM and to discuss the economic 
impact raised by it. 
Materials and Methods: Primary, the legal basis and provisions of the actual national 
legislation that regulates PI was reviewed. For the analysis of the economic impact of parallel 
imported medicines, the data-base (Central Register of MPs) of the Ministry of Health was 
searched. Cost comparison was made, as a basic model, to explore the economic impact of PI. 
Results and Discussion: With the actual pharmaceutical legislation, the RoM has adopted own 
PI policies and rules with respect to exhaustion of rights recognized in WTO TRIPS Agreement. 
Parallel importers have to hold a valid wholesaler and distribution license, manufacturing 
authorization for insertion a stick-label and a user leaflet (written in the official language), 
qualified person for pharmacovigilance and in a case of a product recall, a written agreement 
with licensed wholesaler from the exporting country. In addition, they should not be in 
commercial relation with the marketing authorization (MA) holder. National requirements do not 
allow any additional operations to be performed on the original packaging (e.g. repackaging into 
new contact container and/or external box). Such provisions are an adequate safeguard against 
counterfeiting, preventing from any infringement of the product reputation and damage of its 
origin. Within an approval process, the parallel importer must obtain a PI authorization, issued 
by the Bureau for MPs of the RoM. PI authorization can be granted if the imported medicine 
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meets the safety and quality standards and it is significantly similar to the authorized medicine in 
the RoM, thus being covered by the same authorization. Both products do not have to be 
identical in all aspects; at least, they should have same dosage form, same active ingredient in 
the same quantitative composition, same therapeutic effects, primary packaging with similar 
graphic package design and a common origin. Very important criterion is that both medicines 
should be produced by the same manufacturer/manufacturers that belong to the same group or 
should be produced under the license of the same licensed partner. Differences are possible, in 
composition of the non-active ingredients, production site and/or producer name, shelf-
life/period of stability, and recommended indications; if they don’t affect the quality, safety 
and/or efficacy. National provisions ensure and maintain safety of parallel imported medicines 
by permitting PI only for the MPs registered in the reference countries, with similar regulatory 
standards for MA. The procedure for obtaining PI authorization, quality control, responsibility of 
parallel importer in the process of vigilance and product recall in the supply chain are regulated 
by provisions that protect the public health. The implementation of PI policy in the RoM has 
started 6 months ago. Four domestic stakeholders showed interest for PI, primarily focused on 
branded MPs for hospital use. Several MPs obtained PI authorization and the number of 
applications increases. The first benefit from the PI was availability of the lower-price branded 
MPs, competition between wholesalers and price reduction of locally sourced products (Table 1). 
With multiple PI entrants in the last 6 months, the unique prices of the branded MPs have been 
reduced by 6,5 %. The effect of the marketplace and competition between branded and generic 
MPs was evident in a case of Imatinib, tabl. 400 mg. Namely, the PI of Glivec, tabl. 400 mg, 
decreased the unique price of the locally sourced branded MP by 4%, while the reduction in 
costs of hospital supply of this MP was 37%. However, the costs for hospital supply of the same 
generic drug, with market competition, have been reduced by 90%, suggesting that the generic / 
biosimilar penetration on the market might have additional impact on prices. 
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Table 1. Economic impact of PI on four parallel imported MPs in the RoM (source: Central 
Register of the Bureau for MPs, Ministry of health of the RoM) 
MP Cost-savings 
with parallel 
imported MP 
(%) in public  
hospitals 
Decrease in the 
unique price of 
the branded 
MPs with local 
MA (%) 
Eprex, amp. 
4000 IU/0,4 
ml 
33 8 
Sandostatin 
Lar, amp. 20 
mg 
13 4 
Herceptin, 
amp.    150 
mg 
17 0 
Glivec, tabl. 
400 mg 
37 4 
 
Conclusion: Pharmaceutical legislation in the RoM promotes the PI of MPs and with such a 
policy the both important goals are achieved, drug availability and moderation of the MPs prices. 
With this, a climate for foster competition between wholesalers is created, price reduction of 
locally sourced products, savings to patients/consumers and financial benefits for the health 
budget. The long-term impact of PI on MPs prices in all pharmacy settings (hospital as well as 
community pharmacies) still has to be determined. 
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Key words:  reference countries, comparable wholesale price, average comparable wholesale 
price, and maximum wholesale price 
Introduction: According to the Law of medicines and medical devices (Official Gazette of R.M 
106/07), for the first time the new system of pricing of all prescribed medicines was introduced 
by the Ministry of health. As a result of breakdown of state pharmaceutical chain of pharmacies, 
establishment of unique retail prices of all medicines under prescription was necessary in order 
to keep the balance and to support the system of 760 licensed private pharmacies that were 
economically threatened from the existing large chains of pharmacies. In parallel this was 
needed to further protect the patients from variation of prices for same medicines. It was 
unavoidable that these changes had provoked a reaction by the number of suppliers and traders.  
Bureau of medicines regulated the prices of all 2.700 registered medicines placed on the market 
in Republic of Macedonia on three levels: unique wholesale price, unique retail price and defined 
wholesale and retail mark ups for all pharmacies and health institutions. Till 30.11.2011 
wholesale and retail prices of all medicines under prescription were form only according to 
Article 108 of the Law of medicines and medical devices as a sum from the following elements; 
Manufacturer’s price; Wholesale mark-up and; Retail mark-up.In November 2011 Government 
of the Republic of Macedonia adopted the new Methodology for forming the prices of 
medicines. This methodology, although is not fully cost based methodology, provides a unique 
and general approach to the manner of establishment of medication prices. 
Results and discussion: The wholesale and retail sale prices of medicines are established on the 
basis of a comparative wholesale price of the specific medicine in the countries of reference. 
Reference countries are the countries whose wholesale prices of drugs are being used for 
comparison with the wholesale prices of the drugs in the Republic of Macedonia as follows: 
Slovenia, Bulgaria, Netherlands, Poland, United Kingdom, France, Croatia, Serbia, Greece, 
Germany, Turkey and the Russian Federation. They have been chosen as reference, according to 
the large number of registered medicines placed on their markets. 
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For each pharmaceutical formulation both from generic category or originator and innovative 
category, twice a year Bureau of medicines creates and publish maximum wholesale price. The 
maximum wholesale price is an average comparable wholesale price of those medicines 
according to analyzes of the comparable wholesale prices of that formulation in reference 
countries. The comparable wholesale price in the reference countries according to Article 4, 
paragraph 2 of the Methodology is the wholesale price of the identical medicine (it has the same 
international nonproprietary name (INN), same pharmaceutical formulation, strength and 
packaging) in the reference countries. The comparable wholesale price is established for each 
pharmaceutical formulation, strength and packaging, respectively. If there is no drug of the same 
pharmaceutical formulation in the reference countries, a drug may be compared to a kindred 
formulation (for example: tablet – coated tablet – capsule or suspension – syrup – solution), 
whereas the formulations of drugs with extended or modified effects can not be recognized as the 
ones that do not have the same effect. In the event of a different number of packaged dosage 
units of the drug, the package that contains a comparable number of units i.e. the package that is 
the closest to the required one shall be used. In this case the comparable wholesale price is 
calculated as a comparable wholesale price per unit, calculated per number of units of the 
product. The comparable wholesale price for originator and innovative drugs is the average value 
of the two lowest comparable wholesale prices of the originator or innovative medicine of the 
same producer in the reference countries, and that shall be the maximum wholesale price of that 
originator or innovative medicine in the Republic of Macedonia. Mark-ups of the retail sales 
price of medicines is strictly defined according to this Methodology, and depends of the amount 
of the wholesale price. First revision of prices according to this methodology in February 2012 
produced significant results with decrease of prices of 1025 generic medicines from 2178 
medicines placed on the market in R.M, and 570 medicines originators and innovative from 766 
placed on the market. The average decrement was 28, 13% at generic medicines and 34, 72% at 
originators and innovative medicines. The total saving for the HIF is estimated at 17,000, 000 
Euros. The most common decreased generic medicines during these four revisions of prices in 
2012 and 2013 are anti cancer medicines  (up to 85,65%), antivirus medicines (up to 70,42%), 
cardiovascular medicines ( up to 70,02%), CNS medicines (up to 68,90%), immunosuppressive 
medicines  (up to 65,82%), anti lipoid  medicines (up to 61,05%), anti inflammatory  medicines 
(up to 55,37%). It is expected that this “release” of funds as results from the price reduction, will 
be shifted towards better generic and innovative drugs that will find a place by 
pharmacoeconomic analysis in the new positive list of drugs.  
Conclusion: Pricing methodology gives a wide view of wholesale and retail prices of medicines 
in the region and in Europe. More than 1500 generic medicines and almost all originators were 
drastically decreased according to this Methodology during these three years which brought 
savings both to Health Insurance Fund, Public hospitals, and patients as well. However, it is 
noticeable that the process for price optimization will continue, but it will be focused on 
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implementation of pharmacoeconomic studies and evaluation methodology. Ultimate 
beneficiaries of this new approach will be the patients.  
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O.P. 31 
COMPARISON OF EFFICACY AND COST OF ANTIHYPERTENSIVE THERAPY 
WITH FIXED-DOSE COMBINATION VERSUS FREE-DRUG COMBINATION 
Aleksandar Knežević1, Antonija Banić2, Sanja Sarić-Kužina3 
 
1General Hospital Zadar, Zadar, Croatia, 
 2Pharmacy of Split – Dalmatian County, Split, Croatia 
3Bayer d.o.o., Zagreb, Croatia 
Key words:  fixed-dose combination, free-drug combination, anthypertensive therapy, 
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Introduction: Patients’ adherence and persistence with pharmacotherapy is crucial for the 
successful treatment of hypertension. The majority of hypertensive patients are likely to require 
multiple-drug therapy in order to reach blood pressure targets, so fixed-dose combination of 
different drugs may help to increase patients' compliance and persistence in these cases. Multiple 
analyses have clearly demonstrated that a lack of adherence and/or persistence significantly 
increases the risk of cardiovascular events, emergency department visits, and hospitalization.Our 
goal was to compare the effectiveness and cost of the therapy with fixed-dose combination 
versus free-drug combination. Our analysis included 202 patients from pharmacy in Kaštel 
Sućurac (104 patients on therapy with fixed-dose combination and 98 on therapy with free-drug 
combination). In spite of the fact that the most used  fixed-combination was 
ramipril/hydrochlorothiazide (in 31% of patients), in our analysis we compared fixed-dose 
combination of perindopril and indapamide  5/1.25 mg with free-drug combination of same 
drugs because hydrochlorothiazide as a single component is not available in Croatia. The cost of 
fixed-dose combination was 0.90 HRK per tablet and the cost of free-drug combination 1.30 
HRK per tablet. 
Results and discussion: The results of our analysis showed that average blood pressure level 
with fixed-dose combination was 149.2±17.9/86.2±8.5 mmHg and with free-drug combination 
156.7±18.9/88.4±11.8 mmHg. The target blood pressure level 140/90 mmHg was achieved in 
37.2% patients treated with fixed-dose combination compared with 16.3% patients on free-drug 
combination.  The cost of monthly therapy with fixed-dose combination was 27 HRK and with 
free-drug combination 39 HRK. 
 
Conclusion: Patients who receive fixed-dose combinations have been shown to be more likely to 
achieve BP goal compared with patients who receive free-drug combination therapy. Our results 
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show that fixed-dose combination is more effective in lowering blood pressure than free-drug 
combination and at the same time less costly. In these patients, use of fixed-dose preparations 
simplifies the therapeutic regimen and has been shown to improve adherence and persistence. 
Consequently, use of fixed-dose combinations rather than free-drug combinations in patients 
with hypertension may be both clinically and economically beneficial. It could be concluded that 
fixed-dose combination should be preferred option in the pharmacotherapy of hypertension. 
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O.P.32 
COST EFFECTIVENESS OF FOSFOMYCIN USE FOR UNCOMPLICATED URINARY 
TRACT INFECTIONS CAUSED BY MICROBIAL STRAINS PRODUCING 
EXTENDED SPECTRUM BETA-LACTAMASES 
Likic Robert1,3, Bielen Luka3, Firis Natasa2, Erdeljic Viktorija1, Radacic-Aumiler Matea1, 
Makar-Ausperger Ksenija1, Francetic Igor1,3 
1Division of Clinical Pharmacology and Therapeutics, Department of Internal Medicine, 
University Hospital Centre Zagreb, Kispaticeva 12, Zagreb 10000, Croatia,  
2Division of Clinical Microbiology, University Hospital Centre Zagreb, Kispaticeva 12, Zagreb 
10000, Croatia, 
 3University of Zagreb Medical School, Salata 3b, Zagreb 10000, Croatia 
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Introduction: Antimicrobial Availability Task Force (AATF) in 2006 identified 6 most 
important multiresistant microbial pathogens: Acinetobacter baumannii, Aspergillus spp., 
Enterobacteriaceae producing extended spectrum betalactamases (ESBL), vancomycine resistant 
Enterococcus, MRSA and P. aeruginosa. Fosfomycin is an antibiotic that inactivates enolpyruvyl 
transferase, thus blocking condensation of uridine diphosphate- N-acetylglucosamine with 
phosphoenopyruvate and inhibiting bacterial cell wall synthesis. Standard therapy of urinary 
tract infections (UTI) caused by ESBL producing pathogens (38% of Kl. pneumoniae and 7% of 
E. coli hospital urinary isolates in Clinical Hospital Centre Zagreb in 2013.) relies on i.v. 
administration of carbapenem antibiotics (ertapenem, meropenem, imipenem + cilastatin, 
doripenem). In contrast, fosfomycin is given orally, in a single dose for uncomplicated urinary 
tract infections. It is well tolerated, in vitro resistance of common urinary pathogens as well as of 
ESBL producing strains is low and there is no cross resistance. 
Results and discussion: Cost of 3 day course of carbapenem therapy of ESBL strain caused UTI 
can be projected as follows: ertapenem (140 €), meropenem (157€), imipenem+cilastatin (157€). 
If fosfomycin would be used, the projected cost for 1 day of therapy would be 10€ and 28€ for 3 
day therapy (given as one dose every other day for 6 days), where longer administration is 
expected to increase effectiveness in comparison with single day fosfomycin regimen. 
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Conclusion: With reported therapy success rates between 80% and 95%, which is comparable to 
carbapenems, fosfomycin represents an extremely cost effective therapeutic option for 
uncomplicated UTI caused by ESBL producing strains.  
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O.P. 33 
 NEW TREATMENT APPROACHES IN MULTIPLE MYELOMA PATIENTS - NEW 
DRUG, NEW PRICE, AND NEW QUALITY OF LIFE. WHAT DO WE GAIN? 
S. Genadieva Stavrik1, A. Stojanovik1,  Z. Stojanoski1, B.Georgievski1, A.Pivkova 
Veljanovska1, O.Karanfilski1,  T. Sotirova1, L. Cadievski1, Zoran Steriev2 
1University Hematology Department, Medical Faculty - Skopje, Macedonia, 
2Faculty of Pharmacy, Skopje, Macedonia 
Multiple myeloma is still an incurable disease with pattern of regression and remission followed 
by multiple relapses raising from the residual myeloma cells surviving even in the patients who 
achieve complete clinical response to treatment. New anti-myeloma drugs change treatment 
paradigm providing both tumor reduction and tumor suppression. Today, multiple myeloma 
reminds of a bride with a story of something old, something new, something borrowed; 
something blue…..There is so much progress, but still many unsolved questions. In the mode of 
sequencing treatment for patients with multiple myeloma we are still using old drug such is the 
alkylatng agent melpahalan, which plays the role in an autologous transplantation as the only 
drug which attack myeloma stem cell. There are a lot of new drugs rising on the treatment scene 
like the monoclonal antibodies, histone deacetylases, new oral proteasome inhibitor, carfilzumib. 
We treated the patients with a borrowed concept, previously created for other hematological 
malignancies, consisting of induction, transplantation, maintenance. Allogeneic transplantation 
still reminds us of something blue. 
The efficacy of treatment is mainly related to the achievement of a durable response.  The goal 
of induction therapy is to achieve a maximum degree of tumor reduction before stem cell 
harvestration and transplantation. The achievement of a complete response (CR) is associated 
with prolongation of progression, free survival and overall survival. There are several 
randomized studies that enable physicians to choose the best regimen for initial therapy on the 
grounds of evidence based medicine. There are at least five classes of medications for the 
treatment of multiple myeloma: alkylators, corticosteroids, proteasome inhibitors, 
immunemodulatory drugs, and antracyclines. All these drugs posses significant activity against 
multiple myeloma when used alone, but having in mind that they’re mechanisms of action are 
complementary, their activity is increased further when they are combined accordingly between 
each-other. So, today we are facing numerous doublet, triplet and quadruplet combinations 
which have been tested through the use of these drugs.  
Today, physicians are able to offer wider variety of treatment options for both young and elderly 
patients with multiple myeloma. Therapeutic options should be tailored and personalized 
according to patient’s characteristics by balancing efficacy and toxicity of each drug. Effective 
treatment should be concentrated at the early phase of disease, when clones are more drug 
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sensitive, long – lasting remission are more frequent, and serious adverse events are less 
prominent. This approach significantly improves quality of life and may ultimately prolong 
overall survival. 
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POTENTIALLY INAPPROPRIATE PRESCRIBING IDENTIFIED BY TWO 
DIFFERENT TOOLS AND HEALTH OUTCOMES ASSESSMENT 
Klejda Harasani (Hudhra)1,2, Natalia Casares Gómez1, Marta Garcia Caballos1, Aurora 
Bueno1 
1Faculty of Medicine, University of Granada, Av de Madrid, 11, 18012 Granada, Spain, 
 2Faculty of Pharmacy, University of Medicine Tirane, Rr. Kongresi i Manastirit, 133, 1005, 
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Key words:  potentially inappropriate prescribing, Beers criteria, STOPP-START, health 
outcomes  
 
Introduction: Elderly patients are at increased risk of adverse clinical outcomes such as 
hospitalization, falls, disability and mortality, directly involving increased consumption of health 
and social resources, being responsible for 70% of the pharmaceutical expenditure. The use of 
inappropriate medications is a major contributor to the risk of adverse events, especially in 
polymedicated patients aged 65 years old or more. Therefore, optimization of prescribing for this 
group of patients has become a major public health problem worldwide; the implementation and 
evaluation of screening tools is still needed to optimize the appropriate use of medicines. 
There is growing interest in finding mechanisms to define the adequacy of 
pharmacological treatments and develop protocols for screening of potentially inappropriate 
prescriptions (PIP) in the past two decades. Two types of methods are being used - implicit and 
explicit. Among the most used, there are Beers criteria and STOPP-START. Beers criteria have 
dominated the international geriatric literature since they were first described in 1991. They have 
subsequently been modified to facilitate their use in people living in the community and were 
revised in 1997, 2003 and 2012. STOPP-START criteria were first created in Ireland and their 
clinical development has been undertaken by the Society of Geriatric Medicine of the European 
Union. These criteria, organized by physiological systems, list the most common treatment errors 
and omissions in prescribing and are easy to relate to active diagnostics and the list of drugs that 
appear in computerized medical records of patients.  
The objective of our study was to evaluate the association between potentially 
inappropriate prescribing and health outcomes (specifically mortality, number of 
hospitalizations, domiciliary visits and emergency care) in an older people population at hospital 
discharge using two different tools for PIP detection (Beers and STOPP-START).  
The study population was patients hospitalized in the University Specialty Hospital of 
San Cecilio, Granada, Spain during 2011-2012 and the average follow up period was 415 days. 
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Results and discussion 
624 patients were included in the study, 55% women, with a mean age of 77.7 years (+ / -6.86 
years). The patients had a Charlson Index average of 3.22. The average number of drugs 
prescribed at discharge was 8.55, with 47.92% of patients receiving more than 8 prescription 
drugs. The most frequently prescribed drugs at hospital discharge were Proton Pump Inhibitors 
in 72% of patients, followed by loop diuretics (44%), aspirin (33%), and beta-blockers (30%). A 
high frequency of prescribing was also observed for NSAIDs, warfarin, thiazide diuretics, oral 
and inhaled corticosteroids. The drugs most frequently listed as inappropriate using Beers criteria 
were alpha blockers, NSAIDs, and calcium antagonists; using STOPP criteria, aspirin and 
NSAIDs predominated.  
Among the events detected during monitoring stands out the frequency of hospital readmissions 
within 30 days after discharge, which is higher for patients without PIP (p = 0.053) and an 
increase in the mean of domiciliary visits (43.7 versus 29.7) in patients with PIP, almost 
significantly. 
Table 1. Effect of PIP on mortality after hospital discharge 
 cOR CI aOR CI 
Gender (ref. 
men) 
1.10 
0.73-
1.67 
1.04 
0.66-
1.62 
Age (per year 
increase) 
1.04 
1.01-
1.07 
1.04 
1.00-
1.07 
Charlson index 
1.42 
1.24-
1.63 
1.42 
1.23-
1.64 
No. of drugs 
0.99 
0.94-
1.05 
0.96 
0.90-
1.02 
Aspirin 
1.72 
1.04-
2.85 
1.74 
1.02-
2.97 
 
In Table 1, the effect of collected variables on mortality is analyzed. Association was found with 
age, representing 4% increase of the annual risk and with Charlson Index, with an increased 
mortality risk of 42% for each point increase. The possible effect of therapeutic drug groups 
classified as inappropriate by each set of criteria was assessed. We did not find any significant 
association for Beers criteria. Using STOPP-START criteria for PIP detection, a significant and 
independent increase in mortality was observed when aspirin was improperly prescribed, which 
was not verified when all aspirin prescriptions were analyzed. 
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Conclusion 
Our results do not confirm the existence of a relationship between PIP measured by Beers or 
STOPP-START criteria and the use of health services in the medium term, although a 
significantly higher number of domiciliary visits is recorded. The inappropriate prescription of 
aspirin according to STOPP-START criteria behaved as an independent risk factor for mortality. 
If we accept, as noted repeatedly in literature that the prescription of potentially inappropriate 
drugs is associated with increased healthcare costs and adverse events, and that this effect is 
preventable, it is truly essential to further identify and evaluate specific tools that can detect 
inappropriate prescribing. Acting on it might improve the safety of drug treatments, particularly 
among elderly patients with multiple pathologies. 
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O.P. 35 
PHARMACOECONOMICS OF THE SHORT- TERM 
PROPHYLAXIS OF THE HAE ATTACKS 
 
                                 Hana Kalinić Grgorinić 1 ,Ksenija Makar Aušperger 2 ,  
1General Hospital Pula, Pula, Croatia,2Clinical Hospital Center Zagreb, Zagreb, Croatia 
    
Key words: Hereditary angioedema, short- term prophylaxis, C1 inhibitor, attenuated 
androgens, price 
Introduction: Hereditary angioedema ( HAE) is a rar disease with autosomal dominante 
inheritance, characterized by deficiency or dysfunction of C1 inhibitor (C1-INH).  Typical 
clinical presentation includes recurrent angioedema, without urticaria and pruritus, that primarily 
affects the skin or the mucosal tissues of the upper respiratory and gastrointestinal tracts. 
Swelling maybe self- limited,  but laryngeal involvement can lead to airway obstruction and even 
death. The prevalence in general population is 1: 50 000.  
There are 3 types of HAE. Type I HAE is characterized by low plasma levels ofl C1-INH 
protein. Type II HAE is characterized by normal to elevated C1- INH protein, but function is 
low. Type III HAE occurrs mainly in women with normal functional and quantitative levels of 
C1-INH 
Treatment approach consists of acute attacks therapy and prophylactic therapy. 
Prophylactic therapy can be short- term and long- term.  Shor- term prophylaxis is indicated in 
situations that are recognized as triggers for attack, such as dental, oral and general surgery.  
Attenuated androgens are currently the initial mode of prophylactic treatment. Therapy should be 
minimized, balancing disease severity with minimizing adverse effects. The drug most 
commonly used is danazol, but all attenuated androgens are useful in treatment. The nano-
filtered C1-INH concentrate is also labeled for short- term prophylaxis. The other opitions are 
antifibrinolytics and plasma products. 
 
Discussion:  There are few medications recognized as short- term prophylaxis of HAE attacks, 
with different mechanism of action, different adverse effects and different contraindications. 
Assuming effectivness and safety profile among approved short- term prophylaxis reasonable 
options would be attenuated androgens and C1- inhibitor. 
There are no head- to- head randomized clinical trials comparing these medications. 
On the other hand, no one of thise medications provides 100 % protection of HAE attacks. 
The price of therapy is also very important factor in making decisions, and big differences are 
presented in the table 1. 
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Table 1.        
Danazol 600 mg/ day Approx. 5 € 5 days before and 5 
days after surgery 
C1 inhibitor  
( Berinert )* 
1500 IU Approx.  4730 € preferably within the 
hour before the 
procedure 
Nanofiltered C1 
inhibitor 
( Cinryze) 
1000 IU Approx. 2000 € preferably within the 
hour before the 
procedure 
*off- label use 
In making decision process which short-term prophylaxis medication to chose, it is important to 
know what kind of surgery ( minor or major) will patient undergo, is she/he already taking a 
long- term prophylaxis and what medications approved for prophylaxis are currently available at 
the hospital pharmacy. 
Conclusion: Decision making while prescribing short- term prophylaxis should be pointed on 
the patient benefit considering all the facts about patient, procedure that patient will undergo and 
of course his prior expirience with similar situations and prophylaxis if that one has already been 
taken. 
On the other hand, the question is also the price of these medications. That fact largly influence  
their affordability.  
 Besides that, if the medicine is expensive and not the standard therapy for numerous patients, 
should it be allways available at the hospital pharmacy.  Or, maybe we can simply prescribe 
cheap, effective medicine as attenuated androgen is, whenever there are no contraindications. 
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  OUTSOURCING IN PHARMACEUTICAL INDUSTRY 
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Management 
 
The pharmaceutical industry is facing countinuose rapid changes of its business practice and 
implemented strategy necessary for survival in terms of severe competition on the global market. 
The need of decrement of growing costs in this scientific and highly specialized area forces the 
engaged parties to rationalize their business activities without compromising the already 
achieved level of quality of their products. In the field of pharmacy and biotechnology the 
outsourcing or the cooperation with contract research organizations has been evidenced as the 
most attractive method in favor of cost rationalization and optimal usage of recourses available. 
The practice of engaging contract research organizations (CROs) has not been a novelty for the 
above mentioned industries, however it has been tremendously intensified during the last two 
decades. Using the services of the scientific and research, as well as of medical centers from the 
new market economies, the pharmaceutical companies managed to rationalize the usage of their 
own recourses, to eliminate time-gaps and to provide maximal rationalization of the duration of 
certain phases, by which they provided significant cuts of their costs and expenses. On the 
market as contract research organizations can act contract scientific and research organizations, 
academic medical centers and university hospitals, analytical laboratory centers, associated 
management organizations and institutions specialized for a particular market segment.  
Outsourcing has especially great importance for the pharmaceutical companies in the field of 
generic drug development. In the strategy of the pharmaceutical companies from the developed 
economies dominates the orientation of intensifying scientific research activities in the field of 
development of additional large number of new generics. These activities have been effectuated 
by implementing project management as practice performed by the contemporary business elite 
for decades. The project management applied in pharmacy is effectuated in five key steps: 
project definition, strategy creation, detailed planning, implementation and control and revision 
and learning. Including Central and Eastern European countries as full members of the EU, a part 
of the Balkan states, among which belongs our country as well, became attractive for conducting 
projects sponsored by pharmaceutical companies that originate from the EU. Being included in 
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this type of projects our institutions are able to achieve not only gains in terms of additional 
financial inflow, but also of knowledge transfer on standardization and management of the 
terminal phase of generic drugs development up to the adopted western standards and practices. 
Up-to-date experience confirmed that also institutions of higher education in the western 
economies are able to comply with the role of single-window providers for different services for 
the needs of the pharmaceutical industry. Also, the Faculty of Medicine at the “Ss. Cyril and 
Methodius University” in Skopje has established a six-decade tradition of well developed system 
of cooperation with the domestic pharmaceutical industry. Lately it started to develop 
cooperation with foreign pharmaceutical companies, as well. 
For the successful accomplishment of this kind of research it is necessary to fulfill the following 
preconditions: presence of highly qualified and professional personnel; thorough knowledge of 
the national and international legislation and regulation on generic drugs; established standard 
operation procedures as required for conducting project activities; excellent reputation on 
following dead lines up to the contract; quality project management and consulting role 
fulfillment; well-established infrastructure, capacity and technology under controlled working 
conditions; experience in performing different laboratory practices; quality data-management on 
contracted projects; reputation confirmed by cooperating clients’ satisfaction; etc. The 
preparation and the conduct of the research is a multitasking process where activities should be 
performed by a precisely defined schedule and established criteria. 
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Vlad Zah (Serbia) – Overview of ISPOR CEE Network 
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IMPORTANCE OF ISPOR CEE NETWORK FOR MACEDONIA 
 
Ljubica Shuturkova 
 
            President of  ISPOR –Skopje, regional ISPOR chapter from Republic of Macedonia 
 
ISPOR Regional Network was established in November 2012, within the organizational 
structure of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 
which consists of ISPOR Regional Chapters from different countries, who share a common 
language or geographic location. 
 
The Network represents Regional Chapter members interested in the science of 
pharmacoeconomics (health economics) and outcomes research which is used in health care 
policies and decisions. Namely, this Network serves as a resource at the regional level for 
researchers who specialize in pharmacoeconomics, patient health outcomes, as well as those 
interested in ways how science is used in health care decisions.  
 
An ISPOR Network is composed of the Executive Committee and three Working Committees: 
Education Committee, Publication Committee and Research Committee. The Executive 
Committee is the governing body.  
 
The main goals of the Network include the following: 
- initiating and promoting quality educational opportunities on pharmaeconomics and 
outcome research (clinical, economic and patient reported outcomes); 
- organizing regional conferences, training activities and translation activities; 
- collaborating on research proposals; 
 
ISPOR CEE Network  gives opportunities to all CEE members for collaboration in the field  of 
pharmacoeconomy and outcomes.  The importance of such activities for R. Macedonia as a low-
income country is of immense significance. Being a member, we Regional Chapter can 
contribute in all activities of the Network and at the same time improve the  effectiveness and 
efficiency of our health care system.  
 
 
 
 
 
 
 
 
 
FIRST MACEDONIAN AND FOURTH ADRIATIC CONGRESS ON 
PHARMACOECONOMICS AND OUTCOMES RESEARCH 
 
79 
 
O.P. 39 
 
Guanka Petrova (Bulgaria) – ISPOR CEE Network current situation for Bulgaria 
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ISPOR CEE RESEARCH COMMITTEE PARTICIPATION FROM R.MACEDONIA 
 
Ass.Prof. Zoran Sterjev 
 
             ISPOR –Skopje, regional ISPOR chapter from Republic of Macedonia 
 
ISPOR CEE Network Research Committee is developed under the umbrella of ISPOR CEE 
Network. The Network Research Committee is formed to design and/or engage in projects that 
enhance the science of the pharmacoeconomics (health economics) and outcomes research 
(clinical, economic, and patient-reported outcomes) and lead to improvements in the health care 
system in the region. The Committee facilitates the development of ISPOR Global Health Care 
Systems Roadmap and provides updates to ISPOR PE Guidelines (if applicable). The Regional 
ISPOR Chapter from Republic of Macedonia, ISPOR - Skopje participated in this network from 
2013. In the previous period we have been included in some activity of the Research Committee 
like: Development of ISPOR Global Health Care Systems  Roadmap and International Price 
Referencing Survey in Central-Easten European Middle – Income Countries. As the members of 
ISPOR CEE Network Research Committee, we also received a list of preliminary research topics 
proposed by the Research Committee which will be developed into the Research Committee 
projects. This list covered 18 preliminary research topics. In accordance with our interest in the 
offered topics, we decided to join  eight of these research topics. Each one of the registered 
experts for the individual proposed research topics was contacted by the ISPOR CEE research 
committee  in order to express his/her opinion about the proposed issue, the expectations about 
the results from these projects and the timeline for implementation of the project. Another 
benefit for all of us professionals from CEE countries, is Value in Health Regional Issues 
(ViHRI) a new scientific journal of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR). Formation of CEE research network is a very important benefit for 
a small and low-income country such as Macedonia, which finds it difficult to share the same 
problems with highly developed European countries and therefore, requires different kinds of 
solutions. The CEE research network will allow researchers access to a vast domain of research, 
and thus will enable their inclusion and recognition in the wider international teams. 
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O.P. 41 
 
Tarik Catic (Bosnia and Hercegovina) –  ISPOR CEE educational activity and research 
projects in BiH  
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ECONOMIC EVALUATION OF THE ESTRADIOL VALERATE/ DIENOGEST 
THERAPY FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING IN R. 
MACEDONIA 
 
A. Kapedanovska Nestorovska, Z. Naumovska, Z. Sterjev, Lj. Suturkova  
 
Faculty of Pharmacy, Skopje, R. Macedonia 
 
 
Introduction: Combined oral contraceptives (COCs) are generally used as off-label therapy in 
the treatment of heavy menstrual bleeding (HMB). Estradiol valerate/ dienogest (E2V/DNG) is a 
new COC approved for treatment of HMB in women who have no organic pathology, and who 
want to receive oral contraception.  
 
Objective: The aim of this study was to compare the costs and effectiveness of the E2V/DNG 
versus LNG-IUS in the first line treatment of HMB and to evaluate the economic viability of 
their use in R. Macedonia. 
  
Method: A cost-effectiveness and cost-utility analysis was carried out.  A decision tree model of 
first line E2V/DNG compared to first line LNG-IUS was constructed for patients diagnosed with 
idiopathic menorrhagia. Clinical data from the Lete et al. 2011, trial were used to replicate the 
effectiveness of LNG-IUS and COCs in a time horizon of 5 years. Only direct costs relating to 
the HMB drug therapy are included in the analysis.  The utility estimates of the medical 
treatments, measured as quality-adjusted life months (QALMs) were extracted from randomized 
clinical studies data. The analysis was performed from the National Health Care System 
perspective. The price per dose was then estimated, and cost per QALM with a 3% annual 
discount was calculated.  
 
Results: A total accumulated cost per patient, for E2V/DNG vs. LNG-IUS, after one year of 
treatment, was 169.57 EUR versus 43.15 EUR, respectively. The incremental cost per QALM 
gained for LNG-IUS compared to E2V/DNG was 78.03 - 224.54 EUR, after 12 months-5 years. 
 
Conclusion: Although, the costs associated with both therapies of choice justify their therapeutic 
outcome, E2V/DNG cannot be considered as the dominant option (less costly and more 
effective) in comparison with first-line use of LNG-IUS for the treatment of HMB in R. 
Macedonia. 
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ANTIBACTERIALS CONSUMPTION IN THE AMBULATORY CARE REIMBURSED 
BY HIF IN ALBANIA DURING 2013 
 
Admir Malaj, Iris Hoxha, Ledjan Malaj 
 
Faculty of Pharmacy, University of Medicine, Tirana 
 
Key words: Antibacterial consumption, drug utilization, ambulatory care, Albania 
 
Background: Emphasis on the misuse of antibacterials in Albania and an increased sensibility 
on the antibacterial resistance have been reported in the grey literature lately.The objective of 
this study is to assess the antibacterial utilization reimbursed by the  Health Insurance Fond 
(HIF) (1) in the ambulatory care in Albania during 2013. Data  from the HIF database for all the 
reimbursed and dispensed antibacterial in the ambulatory care were taken and the methodology 
of ATC/DDD (version 2014) (2) for the study of antibacterial utilization was 
applied.Antibacterial grouped in ATC class were measured in defines daily doses (DDDs) and 
DDD/1000 inhabitant/day (DIDs) (3,4) and then compared with the data of the European 
Surveillance of Antimicrobial Consumption Network (ESAC-Net), latest report of 2011(5). Also 
the reimbursement data were compared with the reimbursement data of penicillin’s and 
cephalosporin’s during 2011-2012 (6,7) and also with the latest reimbursement list of 2014 in 
order to track the possible changes in the reimbursement scheme for antibacterials for systemic 
use (J01) in Albania. 
 
Results and disccusion: Results of the total consumption of antibacterials reimbursed by the HII 
measured during 2013 are (2.98 DID).The penicillin’s (J01C) total consumption in 2013 is (1.69 
DID) which is the mostly used subgroup and its use slightly increased compared with the 
reimbursement data of 2012 (1.6 DID) The consumption shifts to the cephalosporin’s subgroup 
with (0.45 DID), this subgroup increased significantly compared with 2012 reimbursement data 
(0.37 DID). Also, an enhancement of the use of second generation of cephalosporin’s (J01DC) 
was distinguished within the class of cephalosporin’s in 2013, (0.27 DID). Quinolones, 
macrolides and tetracycline’s are the frequently subgroups used in 2013. Compared with the 
reimbursement drug list approved in 2014, only nitrofurantoine (J01XE01) was added to the 
reimbursement drug list 2014and the rest of the J01C list contains the same subclasses with some 
alternatives removed or added in the subclasses. The quantities of antibacterial reimbursed for 
HIF covered population during 2013 are more lower than the average consumption of EU/EAA 
countries part of ESAC-Net as referred in the latest report (EU median 19.5DID)(5). The  low  
consumption  of  reimbursed  antibacterials  may  depend  from  several  factors  like  the  low  
use  of  insurance  services  or  low  access  to  these  services  from  the covered population in 
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the ambulatory care. This could suggest that patients tend to consume out of pocket prescribed 
antibacterials and also bypass the treatment protocols, and also the insurance scheme.   
 
Conclusions: Further studies on antibacterial regulation and protocols should be made in order 
to better assess these issues, because as we are sure that the treatment protocols used to prescribe 
reimbursed antibacterials referee to the standards approved by Ministry of Health, we are not 
surethat the out of pocket antibacterial prescription is in coherence with the treatment protocols, 
as suggested by a little survey made in Tirana(8).Studies on accessibility of reimbursed 
healthcare services, specifically ambulatorial one should be made. Also studies for the overall 
consumption have to be finalized by the working group. 
 
 
Graph 1. Antibacterial consumption reimbursed by HIF during 2013. 
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FINANCIAL ANALYSIS OF THE COST OF RARE DISEASES PHARMACOTHERAPY 
IN BULGARIA 
 
Albena Zlatareva, Georgi Momekov, Guenka Petrova 
 
Medical University of Sofia, Faculty of Pharmacy 
2 Dunav Str., Sofia 1000, Bulgaria 
 
Key words:  rare diseases, pharmacotherapy cost, financial analysis 
 
Introduction: This study presents the results of the analysis of financial performance of 
pharmacotherapy for rare diseases from the perspective of the payer (NHIF) in Bulgaria. Key 
points of this study are the proportion of funds allocated for rare diseases as part of the cost of 
drugs and GNP of the country; type of resource-intensive diseases and medicines; trends in 
financing the treatment of rare diseases and orphan drugs in our country. 
 
Materials and methods: It is a macro costing, retrospective incidence cost study for the period 
2010 to 2013. From the National health insurance fund on central and regional level was 
collected and analyzed the reimbursement of medicinal products, medical devices and dietary 
foods for special purposes, number of diagnoses of rare diseases financed by the Fund (ICD), 
and number of patients. The medicines are grouped by INN and therapeutic class. Regressive 
correlation models were built to forecast the future medicines expenses till 2016. 
 
Results and discussion: The number of patients, as the budget allocated to orphan drugs, 
increased over time, as critical is the transfer of cancer drugs to the NHIF. Expenses for rare 
diseases account for no more than 10% of that cost due to regulatory restrictions. Regional 
budget data also show that pharmacotherapy of rare diseases require significant financial 
resources, with great variations in small regions (Figure 1).  
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Figure 1. Regional cost differences for patients with thalassemia 
 
So care is needed to provide the necessary resources to enable more patients to be treated with 
advanced therapy without straining the limited public funds. In 2013 the expenditures for 
pharmaceuticals for RD were included into the total health care budget and were not reported 
separately. The expenditures for oncology medicines were added, due to the fact that their 
financial responsibility was transferred to the NHIF from the Ministry of health (Table 1).  
 
Table 1. The structure of the NHIF medicines expenditures during 2010-2013 (mill €) 
 
2010 2011 2012 2013 
Expenditures for 
medicines, 
medical devices, 
and special 
foods. 
197 242 265 274 
Expenditures for 
medicines 
187 231 255 263 
Expenditures for 
orphan medicines 
for rare disease 
therapy 
 
20 20 27 
 
It is evident that there is a substantial growth in the health care expenditures for pharmaceuticals, 
including the RD therapy and all the changes in expenditures are statistically significant 
(p<0.05). The increase in the expenditures is a consequence of not only the changes in budget 
policy, but also of the changes in the number of the reimbursed diagnoses and medicines which 
are constantly increasing. The reimbursed sum for medicines for rare diseases follows a linear 
regression curve. The mathematical model is based on a linear regression model, built from 
existing date regarding the reimbursed sums by the NHIF for rare disease, with a base year 1 = 
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2011 and subsequent 2 = 2012 и 3 = 2013, all shown on the x-axis. The regression equation, 
which describes the model, is as follows: 
Reimbursed sum = 15 430 000 + 13 520 000 x year 
Correlation coefficient R = 0.999; Coefficient of determination R2 = 0.998] F = 613.099, p = 
0.026 – This coefficient shows the extremely high adequacy of the model. If the current 
tendencies continue, the expected value for the sums reimbursed by the NHIF will be in the 
vicinity of 96,5 million BGN for the next three years (Table 2). 
 
Table 2. Prognosis for the reimbursed sum for pharmacotherapy of rare diseases 
Year 
sequence 
number Year 
Reimbursed 
sum ( mill 
BGN) 
Expected 
sum ( mill 
BGN) 
1 - base 2011г. 28,629  28,950  
2 2012г. 43, 092  42, 470  
3 2013г. 55, 665  55, 990  
4 2014г.   69, 510  
5 2015г.   83, 030  
6 2016г.   96, 550  
 
Conclusion: Within the framework of the very dynamic regulatory environment and extensive 
scientific work in the field of rare diseases therapy the financial resources remain extremely 
limited to ensure appropriate therapy and scientifically based treatment. There is a need of 
collaboration on a European level and the creation of a global fund to be able to satisfy 
therapeutic needs.  
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COST MINIMIZATION ANALYSIS OF TRASTUZUMAB SC VS. TRASTUZUMAB IV 
FORMULATION IN PATIENTS WITH EARLY BREAST CANCER IN REPUBLIC OF 
MACEDONIA 
 
Aleksandra Manchovska, Darko Stoleski 
 
Roche Macedonia DOOEL, 8mi Septemvri 18, Skopje, Macedonia 
 
Key words:  Trastuzumab, cost-minimizaton, breast cancer 
 
Introduction: Breast cancer places a substantial economic burden on the whole society, patients 
and caregivers. According to last published data form 2012, for female cancer-related mortality 
in R.Macedonia, breast cancer is the leading cause, with mortality rate of 27.7 % per 100.000.1 
This puts R. Macedonia among the countries with the highest breast cancer mortality rate.2 
Trastuzumab is a humanized monoclonal antibody which selectively targets the human 
epidermal growth factor receptor (HER2).4 One-year adjuvant trastuzumab therapy increases 
disease-free and overall survival in the adjuvant treatment of early HER2-positive breast cancer.3 
A cost-minimisation analysis has been developed to compare the direct drug and non-drug costs 
associated with trastuzumab SC and trastuzumab IV.  The analysis does not consider 
chemotherapy drug costs since these do not differ between the two formulations.4 This analysis 
comprehends non-drug related direct cost (IV lines, needles, infusion bags, cannules). 
Trastuzumab SC is provided in a ready-to-use, fixed dose vial, and is administered 
subcutaneously. Therefore, no reconstitution or weight-related dose adjustments are required, 
thus providing benefits in terms of equipment, resources and time required. Trastuzumab IV 
formulation requires an initial loading dose, as well as dose adjustment for individual patient 
body weights.  Such dose adjustment may be associated with drug wastage, increased resource 
time and potential dosing errors. HannaH (BO22227) is a pivotal phase III, randomized, open-
label, international, multicentre study in patients with operable or locally advanced EBC. The 
study was designed to assess non-inferiority between trastuzumab SC and trastuzumab IV in 
terms of two co-primary endpoints: pharmacokinetics (PK) and efficacy (pathological complete 
response rate). Results from HannaH show that trastuzumab SC provides comparable PK and 
efficacy to trastuzumab IV with non-inferiority demonstrated for both co-primary endpoints. 
Results also demonstrated comparable safety profiles which were consistent with the known 
safety profile of trastuzumab.5 
 
Results and discussion: The cost-minimization analysis is a study in which two or more 
therapeutic alternatives with the same effectiveness or efficacy are compared in terms of net 
costs in order to establish the cheapest alternative. Since SC formulation of trastuzumab is 
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comparable to the IV formulation in terms of clinical efficacy and safety, a cost-minimization 
analysis was performed. The evaluation was considered from the perspective of Macedonia’s 
Health Insurance Fund and includes only direct medical cost (drug and non-drug related). One 
year time frame was considered based on the treatment of early breast cancer; consequently a 
discount rate was not necessary. To conduct this evaluation the following parameters were 
considered: maximal price of both formulations on the basis of the Law on Medicines and 
Medical Devices and the Methodology on the Manner of Establishment of medication prices, 
which is also the referral (reimbursement) of the Health Insurance fund of Macedonia according 
last published prices from 28.01.2014.7 Consumption resources prices for trastuzumab IV 
application (IV lines, needles, infusion bags, and cannulas) are based on the last tender on 
medical devices and contracts published on Public Procurement Buraeu.6 Since trastuzumab IV 
dosing is weight dependent mean weight of 70 kg was considered in the calculation. The 
calculations showed that total drug cost for the treatment per cycle per patient is lower for the SC 
formulation than for IV (101.928 MKD vs. 103.816 MKD). For all 18 cycles (1 year treatment) 
per patient also the SC drug cost is lower than the IV (1.834.704 MKD vs.1.868.687 MKD). 
Considering non-drug related costs, i.e administration cost per cycle of the IV formulation of 
4.140 MKD, the overall cost of trastuzumab IV per patient for all cycles is 1.872.827 MKD. 
Prices are excluding VAT. No discounting rate was applied since the time frame considered was 
1 year. Results from the analysis showed that for a full course of treatment and assuming no drug 
wastage for trastuzumab IV, as it is the current practice, the use of trastuzumab SC results in a 
drug cost saving of 1.8% of the trastuzumab IV cost, if patients are treated with trastuzumab SC 
instead of trastuzumab IV. One-way sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. The following variables were assessed: cost of the 
drug, both formulations and the mean weight of the patients.  
 
Conclusion: The results of this study suggest that routine use of trastuzumab SC instead of 
trastuzumab IV has the potential to reduce the cost of treatment of 38.123 MKD per patient. Also 
if adding the saved time when using the SC formulation (e.g. staff time for infusion, preparation 
in pharmacy, preparation of patient for infusion, administration, chair time, and total time 
required for the patient in the hospital) the benefits are immense. 
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UTILIZATION OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARINS AT 
THE ORTHOPEDIC DEPARTMENT AT THE CLINICAL HOSPITAL IN STIP 
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1Clinical hospital, Stip, Republic of Macedonia 
2University “Ss. Cyril and Methodius”, Faculty of Pharmacy - Skopje, Republic of Macedonia 
 
 
Background: A number of cost drivers that contribute to the rising specialty drug spend have 
been identified within the managed care infrastructure. Among these cost drivers are drug mix, 
the degree of provider reimbursement, member benefit design, distribution channel, the extent of 
utilization management, and the degree of operational effectiveness in paying claims correctly.  
 
Objectives: The main goal of our study was the comparison of the utilization of heparin and low 
molecular weight heparins at the orthopedic department at the Clinical Hospital in Stip, along 
with the required quantities of the drugs for the Orthopedic Department needs, in the 2013 year. 
Through this comparison, we wanted to see whether the established way of requisition 
correspond with the actual utilization, or it generates unrealistic charges imposing the need of 
introducing system for internal requisition of the medicines in our hospital. 
 
Methods: In order to realize this goal, the review of the medical records of a total of 1087 
registered patients from the orthopedic department at the Clinical Hospital – Stip was made, 
during 2013 year. Data for utilization of analyzed drugs are compared with the official data for 
the required heparin and low molecular weight heparins, from the Orthopedic Department at the 
Clinical Hospital in Stip.  
 
Results: During their treatment, 423 patients from the total number of registered patients 
received heparin or its low molecular derivatives. 223 patients of these were treated with 
heparin, 164 patients were on low molecular weight heparin preparations, and 36 patients were 
on combined therapy of heparin and low molecular weight heparins. Administered dose and 
duration of therapy of these two classes of drugs were different, depending on individual 
characteristics and diagnosis of patients. The average daily dose of administered heparin was 10 
000 IU, while the average daily dose of low molecular weight heparin was 4000 IU which is 
consistent with the therapeutic guidelines for the treatment of patients with these diseases. The 
requisition of the total amount of the required heparin for the needs of the Orthopedic 
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Department at the Clinical Hospital in Stip in 2013 was 23 725 000 IU/ 198810.55 MKD which 
according to the achieved prices for this period it amounted 65 000 IU / 544,69 MKD per day. 
The requisition of the total amount of the low molecular weight heparins for the purposes of the 
Orthopedic Department at the Clinical Hospital in Stip in 2013 was 7 108 850 IU/ 243599,56 
MKD which according to the achieved prices for this period it amounted 19 476 IU/ 667,4 MKD 
per day. According to the evaluated data from the hospital patient records, the total consumption 
of heparin at the Orthopedic Department was 23 330 000 IU/ 195 500,53 MKD, while the total 
amount of low molecular weight heparin was 6434 150 IU/ 229 099,48 MKD . Expressed in 
monetary units, the difference between the requisition quantity and real consumed quantity of 
heparin amounted 3310,02 MKD, while for the low molecular weight heparin it is 14500,08 
MKD.  
 
Conclusion: The recorded results suggest that the current method of requisition of drugs, based 
on the daily needs of patients is irrational and it generates the costs in the operation of the 
Clinical Hospital. To overcome this problem, it is necessary of introduction the new health 
technologies, such as bar coding of distribution of medicines, as an investment that has been 
shown to be cost-effective in a number of healthcare centers in the world. Anyway, before taking 
such a step, it is necessary to make all investigations into the cost-effectiveness of the 
introduction of the new technology.   
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Introduction: The competition between innovative and generic pharmaceutical companies 
intensified in the last decades. The models created by innovative pharmaceutical industries rest 
on market exclusivity, higher medicines prices and patent protection system. Republic of 
Macedonia has a limited medicines budget, and its healthcare policies aim to save on medicines 
supplies. The legislation in the Republic of Macedonia is constantly modified due to the 
harmonisation with the European regulation. The country intends to allow the entry and use of 
innovative medicines, especially for first- and second-line therapy. In this study, we aim to 
analyze the current legislation (legal acts, bylaws, price methodology) and describe the 
circumstances that lead to innovative medicines’ market entry. 
 
Results and discussion: National regulations were put in place to accelerate the access to 
innovative medicines, but their frequent adjustments according to all interested parties have 
delayed the process of efficient implementation. The legal changes and drug pricing policies 
were designed to support the generic market rather than innovations, and control drug budget. 
This illustrates the national dilemma of how to improve access to innovative medicines 
beneficial for patient health with restrictive budget. The generic prescribing and reference 
pricing have a negative impact on brand medicines and limit the choice of prescribers and 
patients, but save the budget resources that can be used to include innovative medicines on the 
market and the reimbursement list. The parallel importation is benefiacial to the market offer, 
competition and medicines prices, but hampers the financial sustainability of the innovative 
companies.. The discontinued legal procedures and the complicated procedures delay its 
completion and the inclusion of innovative medicines on the positive list. The reduction of 
medicines prices using the methodology of unique prices and reference prices for reimbursed 
medicines can free resources to be used to include new medicines in health care, but lower prices 
decrease the innovative companies’ interest to enter the Macedonian market. Table 1 illustrates 
requests to include innovative medicines on the positive list. Only Imatinib was put on the 
positive list i 2011, including 3 more medicines with the same generic name later on. Other listed 
medicines have been rejected on the justification for limited national financial means and the 
existence of therapeutic alternatives. All these medicines have all been registered in the country, 
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but their presence on the Macedonian market depends largely on their inclusion on the 
reimbursement list. Since 2012, the 14 expert committees have not been appointed yet, so there 
have been no new applications for inclusion on the list.    
 
Conclusions: Given the limited and insufficient drug budget, savings can be made by 
rationalising the positive list, use of medicines in hospital and introduction of 
pharmacoeconomic aspects in practice, which can be used to include new medicines for patient 
care. The inclusion of expensive innovative medicines should be based on scientific evidence on 
drug efficiency, pharmacotherapeutic and pharmacoeconomic indicators and HIF financial 
possibilities. The presence of innovative medicines on the Macedonian market and their 
inclusion on the positive list shall be done according to the experience in the EU and countries in 
the region with comparative economic systems.  
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Introduction: Many drugs administered to children are not available in formulations for 
pediatric use. Most marketed oral medicines are intended for adults and are solid dosage forms. 
Solid dosage forms present problems as children have difficulty swallowing whole tablets 
(TBL). Sometimes TBL are cut into smaller parts to obtain appropriate units for children The 
purpose of this study was to evaluate accuracy of splitting ranitidine hydrochloride 150 mg TBL, 
in dosage for children. Ranitidine oral is used for the treatment of gastric/duodenal ulcer and 
GERD for both neonates and children, in respective dosage 1.5-2mg/kg/24h, q12h and 1-
5mg/kg/24h, q6-8h (Bebeçi, 2006). The study was made with ranitidine hydrochloride 150 mg 
TBL, from 3 different manufacturers present in Albanian market. Products have been chosen 
based on the presence or not of the score line: scored on one side (S), scored on both sides (BS) 
and not scored (NS). Of each product, 100 TBL were taken at random and weighed, and mean 
weight (MW) was calculated. Then the TBL were divided into halves and quarters by using a 
pill-splitter. From each TBL one half and one quarter was weighed and mean weight was 
calculated. The range of 85% to 115% and 75% to 125% confidence intervals (CI) was 
determined based on the mean weight. For the whole TBL, halves and quarters, the weight 
deviation from the average weight was compared to the above interval.  
 
Results and discussion: From the study were found that all the whole TBL were conform to the 
Eur.Pharm mass uniformity requirements. And only halves from S and BS tablets complied with 
the Eur.Pharm. 37% of halves from NS tablets deviated more the 15% from the mean (Table 1). 
 
Table 1: Percentage of halves, that weight falls in the CI. 
Deviation from 
MW 
% of halves fall in CI  
 
S BS NS 
X < 15% 100 100 63 
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15%  ≤ X < 
25% 
 
0 0 29 
25 % ≤  X 0 0 8 
 
The results were worse with quarters. None of the quarters from evaluated products complied 
with Eur. Pharm requirements. Only 73% of quarters from S and BS tablets and 62% of quarter 
from NS tablets were within the CI of 15% (Table 2).   
 
Table 2: Percentage of quarters, that weight falls in the CI. 
Deviation from 
MW 
% of quarters fall in CI   
 
S BS NS 
X < 15% 
 
73 73 62 
15%  ≤ X < 
25% 
 
20 23 25 
25 % ≤  X 7 4 13 
 
 
Conclusion: By breaking Ranitidine TBL into halves and quarters were observed large 
deviations. These deviations were related to the presence or not of the score line. Such 
inadequate breaking of TBL may result in dose variability and complicate therapeutic outcome. 
In small markets where introduction of lower doses may not have commercial interest, 
appropriate scored TBL (scored both sides) can ensure more flexible dosage. There is a need for 
pediatric formulations and dose adaptation based to child body weight. 
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Introduction: “Pharmacoeconomics” is a new word; but economic interest in drug and other 
treatments of health problems is much older. Decisions about what treatments should be 
available within a health-care system have always been influenced by the resources available to 
pay for them. Pharmacoeconomic analysis should be the preferred tool for guiding antibacterial 
formulary decisions and evaluating the economic impact of antibacterial use because it is usually 
based on clinical outcomes and does not merely evaluate drug acquisition costs. Knowledge of 
pharmacoeconomics is therefore vital for doctors to promote rational prescribing. Cost 
Minimization Analysis (CMA) involves measuring only costs, and is applicable only when the 
health benefits obtained from two alternative therapies are identical and therefore need not be 
considered separately. For example, comparing the costs of two different brands of the same 
drug or comparing the cost of a branded drug with its generic form. The objective of the study 
was to perform a cost minimization analysis of antibiotic prescriptions in pediatric cases. This 
was a retrospective study performed in 3151 pediatric out-patients prescribed with antibiotics. 
The commonly prescribed antibiotics in this study were chosen as examples to illustrate the cost 
difference between the most expensive and the least expensive brand versions of the same 
antibiotic, expressed in denars. In evaluating them, the same dosage form, equal strength and the 
same frequency of dosing were considered. If only one brand was available for a drug without 
any competitor’s brand that particular drug was excluded. The prices were obtained from the 
official price list, put up by the Ministry of Health of Republic of Macedonia. The percentage 
variation in price was calculated and presented in the results section.  
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Results and discussion: Results for cost minimization analysis are given in Table 1. This table 
shows a summary of prescribed antibiotics, their frequency of prescription, costs and the 
percentage of price difference. Results indicated that the use of branded drugs which were more 
expensive was noticeable even when the cheaper options were available. The costliest brand of 
amoxicillin syrup prescribed in 277 (65.6%) patients, having a maximum retail price of 89.6 
denars, was 33.7% costlier than the least expensive version (34.4%). 
 
Table 1. Cost comparison between the most expensive and the least expensive brand versions of 
antibiotics 
 
Among cephalosporins, cefalexin syrup was the most commonly prescribed. Its most expensive 
brand version was 47.1% costlier than the least expensive brand version. The most expensive 
brand was prescribed 347 times (88.3%) compared with the least expensive version prescribed 
only 46 times (11.7%). In case of cefaclor syrup 125 mg, the cost differences between the most 
and least expensive brands were 6.8%. The most expensive branded cefaclor was prescribed 338 
(96.3%) compared with the least expensive version prescribed 13 times (3.7%). The cost 
difference between the most expensive brand of cefaclor syrup 250 prescribed 32 times (76.2%) 
Antibiotic No. of 
prescrip
tions 
Cost of 
most 
expensive 
brand in 
denars 
Frequency of 
prescriptions 
Cost of least 
expensive 
brand in 
denars 
Frequency of 
prescriptions 
% Of cost 
difference 
Amoxicill
in Syrup 
250 mg 
422 89.6 277 (65.6%) 67 145 (34.4%) 33.7 
Cefalexin      
Syrup 250 
mg 
393 162.2 347 (88.3%) 110.3 46 (11.7%) 47.1 
Cefaclor      
Syrup 125 
mg 
351 152.8 338 (96.3%) 143.1 13 (3.7%) 6.8 
Cefaclor      
Syrup 250 
mg 
42 241 32 (76.2%) 201.8 10 (23.8%) 19.4 
Cefadroxi
l   Syrup 
250 mg 
287 307.1 111 (38.7%) 282.2 176 (61.3) 8.8 
Cefadroxi
l Capsules 
250 mg 
15 433.3 7 (46.7%) 329.2 8 (53.3%) 31.6 
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and least expensive brand prescribed 10 times (23.8%) was 19.4%. Cefadroxil syrup brand 
versions showed 8.8% cost difference, with higher percentage of prescribing toward the least 
expensive brand in 61.3% compared to the most expensive brand prescribed in 38.7% patients. 
The cost difference was higher when cefadroxil capsules 250 mg were prescribed (31.6%). 
 
Conclusion: Antibiotics account for the highest proportion of the drug budget in many countries 
and constitute the largest group of drugs purchased. This cost minimization study has shown a 
presence of cost difference between the most expensive and least expensive brand versions of the 
same antibiotic. The cost of most expensive branded drugs prescribed was 6.8% to 47.1% more 
than the least expensive versions. This means that parents are spending much more on the 
treatment of their children than what is necessary. It is concluded that economic evaluation, such 
as cost minimization analysis is of paramount importance in policy and decision making to 
facilitate more rational choices and to reduce the financial burden on the patients. 
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An evidence-based practitioner must be able to understand the patient's circumstances, to 
identify knowledge gaps, and frame questions to fill those gaps; to conduct an efficient literature 
search; to critically appraise the research evidence, and to apply that evidence to patient care.1 
Delivering evidence-based medical care requires providing care that is high-quality and safe, and 
at the same time cost-effective. However, while the knowledge and technology regarding 
effective medical therapy continuously improves, the practice of medicine is not on the same 
level, because the risk of iatrogenic errors becomes higher.2 Regarding the gaps between 
evidence and practice, Lomas et al.3 evaluated a series of published guidelines and found that it 
took an average of approximately five years for these guidelines to be adopted into routine 
practice. Pharmacoeconomics involves processes similar to EBM, but it deals with decisions on 
the population rather than the patient level. Pharmacoeconomics is the scientific discipline that 
evaluates the clinical, economic and humanistic aspects of pharmaceutical products, services, 
and programs, as well as other health care interventions to provide health care decision makers, 
providers and patients with valuable information for optimal outcomes and the allocation of 
health care resources.The overall goal of it is to provide the most efficient use of resources, 
taking into account both the cost and the value derived from a given technology. These 
evaluations assist health care decision making because both cost and effectiveness are 
considered. New therapies are increasingly complex in terms of administration, effects, and cost. 
At present, there is no standard threshold for what constitutes cost-effective therapy, so each 
health care system is likely to have its own criterion for acceptance. Taking into consideration 
the accelerated process of developing/edopting and adapting Clinical Guidelines based on high 
level of evidence, the aim of this paper was to evaluate the role of Evidence Based Medical Care 
in the context of pharmacoeconomic (PE) decision making by health care providers. Clinical 
Guidelines may be considered a measure for providing evidence-based care, increasing the 
patient safety and reducing the unnecessary costs, thus improving the cost/benefit ratio. The 
method of evaluation consisted of the following steps: deep review process of the two most 
frequent clinical disturbances (neonatal non-haemolytic jaundice and early onset infection) in 
term newborns born at the University Clinic for Gynecology and Obstetrics in Skopje, detailed 
analysis of the nationally accepted Clinical evidence based guidelines covering the same 
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diseases, and performing comparative analysis of the number and type of investigations in two 
time-periods-before and after implementation of the Guidelines.  
 
Results: throughout the evaluation, many of the previously explored investigations and therapy 
introduced, were found unnecessary. Within the first clinical disease-non-haemolytic jaundice, 
using evidcence-based Clinical guidelines enables the clinician to reduce the number of 
venepunctures (by introducing the transcutaneous bilirubinometer and clinical application of the 
Kramer’s rule), reduces the necessity for phototherapy (PT) by using the threshold levels of the 
serum bilirubin for PT for separate gestational age and for exchange transfusion as well. 
Regarding the secong Clinical guideline, early onset of neonatal infection, as cost reduction were 
considered: number of venepunctures for full blood count and C-reactive protein using the 
empirical therapy for all term newborns having prenatal maternal risks for infection, 
recommendation to cease the therapy following normal levels of white blood cells and 
neutrophils, etc.  
Unfortunatelly, the exact cost-reduction can not be calculated due to the type of reduction 
(mainly qualitative reduction, meaning time consuming, health benefit for the baby etc). The 
credibility of pharmacoeconomics lies in developing studies in accordance with generally 
applicable standards of analysis and interpretation. Then users can translate pharmacoeconomic 
research findings into practices to ensure that decision makers allocate scarce health care 
resources wisely, fairly, and efficiently.4  
Moving toward more evidence-based practice has the potential to improve quality and safety 
while simultaneously reducing costs, thus improving the outcomes of the Pharmacoeconomics. 
This field of the pharmacotherapy becomes increasingly important in terms of patient safety and 
national cost saving, thus enabling the relevant authorities to reallocate the resources.  
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Introduction: Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint 
pain and damage with collateral effects on other organ systems. RA can progress steadily if 
untreated and can lead to impairment of physical function affecting basic activities of daily 
living such walking, eating, standing, and gripping. After 10 years, 50% of patients can continue 
to work or function normally on a day to day basis. It may also cause anemia, fatigue and shorten 
life expectancy. The prevalence of RA in Europe is 870 per 100 000 inhabitants. Country 
specific prevalence is varying at around 1%, as is in France (0.8%), Germany (1.1%), Italy 
(0.9%), Spain (0.7%) and UK (1.1%).  The main goal in this analysis is to estimate the direct 
medical and indirect costs of RA treatment in Macedonia. Direct medical costs are the medical 
costs that result directly from the treatment of the disease.  
Direct medical costs include: 
1. Hospitalization costs  
2. Ambulatory costs  
3. Costs for treatment of articular manifestations of RA 
4. Costs for treatment of extra-articular manifesracions of RA 
Data for hospitalization costs has been taken from the register book for hospitalized patients at 
Rheumatology Clinic – Skopje, Macedonia (this clinic is the only specialized center for treating 
and hospitalizing patients with RA in Macedonia). All data for patients, hospitalized with RA at 
the Rheumatology Clinic, have been processed in order to determine the average cost for 
hospitalization per patient. This has been calculated by multiplying the average number of yearly 
hospitalizations per patient and the prevalence of DRG codes for their hospitalizations. 
According to DRG standards the average yearly cost for hospitalization at Rheumatology Clinic 
per patient is 29,101.00 MKD. The average ambulatory cost per patient has been taken from 
Informatics Center at Rheumatology Clinic. Average ambulatory cost per patient per year is 
11,918.04 MKD. In order to calculate the costs for treating articular and extra-articular 
manifestations of RA prevalence, data has been taken from official publications. The average 
cost for treatment of articular manifestations of RA per patient is 293,363.83 MKD. The average 
cost of extra-articular manifestations of RA per patient is 66.453,12 MKD. The total direct 
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medical costs in patients with RA in Macedonia will be 400.697,44 MKD, this is shown on 
Table 1. 
 
Table 1. Total direct medical costs 
Direct medical costs 
Yearly costs 
per patient in 
MKD 
Hospitalization costs at Rheumatology 
Clinic 29.101,27 
Ambulatory costs at Rheumatology 
Clinic 11.918,03 
Costs for treatment of articular 
manifestations of RA 293.363,83 
Costs for treatment of extra-articular 
manifestations of RA 66.453,12 
Total direct medical cost 
        
400.697,44  
 
Indirect costs involve the costs that result from the loss of productivity because of illness. 
Indirect costs include: 
1. Costs for invalid pension 
2. Loss of productivity (GDP/No. of employed) 
3. Loss of Health Insurance Aid (9.2% of average gross salary) 
4. Family nursing costs 
Data for indirect costs have been taken directly from Macedonian Government official web sites. 
Total indirect costs per patients with RA is 836.217,32 MKD, these are shown on Table 2. 
 
Table 2. Total indirect costs 
Indirect costs  Yearly costs per patient in MKD 
Costs for invalid pension                   102.720,00  
Loss of productivity                   654.320,50  
Loss of Health Insurance Aid                     28.956,82  
Costs  for homecare of other person                     50.220,00  
Total indirect costs 836.217,32 
 
Results and discussion: Based on this analysis we can calculate the total direct medical and 
indirect costs of RA in Macedonia per patient. Total direct medical and indirect costs of RA in 
Macedonia per patient is 1.236.914,76 MKD, these are shown on Table 3. 
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Table 3. Total direct medical and indirect costs of RA 
Direct and indirect costs МKD 
Direct medical costs 400.697,44 
Indirect costs 836.217,32 
Total direct medical costs and indirect 1.236.914,76 
 
Conclusion: This analysis estimates the RA costs per patients in Macedonia in terms of direct 
medical cost (Hospitalization costs, Ambulatory costs, Costs for treatment of articular 
manifestations of RA and Costs for treatment of extra-articular manifesracions of RA) and 
indirect cost (Costs for invalid pension, Loss of productivity, Loss of Health Insurance Aid and 
Family nursing costs). According to this analysis total direct medical costs and indirect costs per 
patient is estimated to be 1.235.914,32 MKD showing that RA exerts a big economic impact 
from socioeconomic perspective. 
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Introduction: Studies show that antibacterial consumption is associated with the development 
of antibacterial resistance. (1) There are little studies on antibacterial consumption and less on its 
resistance in Albania. An important step in this direction is measuring the antibacterial 
consumption/utilization. (2) We choose to make further studies on the cephalosporin’s subclass 
consumption as it is an important and commonly used subclass in Europe. (3, 4) Data on the 
cephalosporin’s class were collected for the year 2011 and 2012 from the National Center of 
Drug Control (NCDC) (5) and the ATC/DDD methodology was used in order to measure the 
drug consumption. (6) Data on antibacterial for systemic use were collected and then 
cephalosporin’s class were selected from the national drug register to enter to pharmaceutical 
market in Albania (hospital and outpatient use). Cephalosporins’s were divided by ATC code, 
specifically J01DB, J01DC, J01DD and J01DE and then DDD per each class were assigned 
referring to the ATC/DDD guidelines of  WHO online index, version 2014. (7,8) The refereed 
population taken into study was from the latest report of CENSUS 2011. (9) The consumption 
was calculated as Defined Daily Dose (DDD) and DDD/1000inhabitant/day (DID). (10) 
 
Results and discussion: The total consumption of cephalosporin’s subclass was (3.51 DID) in 
2011 and (3.18 DID) in 2012. The first generation of cephalosporin’s (J01DB), specifically 
cefazolin and cefalexin was the mostly used from the J01D in 2011 (1.66 DID) and a slightly 
decrease was observed in 2012 (0.95 DID). The second generation of cephalosporin’s (J01DC), 
mostly cefuroxime and cefaclor was higher in 2012 (1.50 DID), where in 2011 the consumption 
was1.28 DID. The third generation of cephalosporin’s consumption (J01DD) mostly cefriaxone 
and cefixime, increased during 2012 (0.73), where in 2011 it was 0.55 DID. In the Albanian 
pharmaceutical market, during 2011 the fourth generation of cephalosporin’s (J01DE), 
specifically cefipime was present and it’s consumption was (0.02 DID), whereas in 2012 it was 
out of the market.  
 
Table 1. Cephalosporin’s consumption during 2011 – 2012 expressed in DID. 
Antibacterial ATC DDDs per 1000 inhabitants per day 
2012 2011 
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Cephalosporins J01D 3.18 3.51 
First-generation cephalosporin’s J01DB 0.95 1.66 
Second-generation cephalosporin’s J01DC 1.50 1.28 
Third-generation cephalosporin’s J01DD 0.73 0.55 
Fourth-generation cephalosporin's J01DE   0.02 
 
The overall consumption of cephalosporin’s in 2011 and 2012 in terms of DIDs results higher 
that the consumption of  J01D in the ambulatory care reimbursed by the Healthcare Assurance 
Fund during the same period (11), which refers only to the covered population. Although the 
overall consumption include even the hospital consumption of antibiotics, the difference with is 
too big (more than 9.5 times than the reimbursed cephalosporin’s consumption (0.375DID)). 
There is a doubt that the out of pocket consumption is out of protocol referred to previous survey 
(12), and also the antibacterial prescription may be inappropriate. The average consumption in 
Albania results (3.345 DID) higher than the median consumption of the ESAC-Net, which in the 
last report was 1.6 DIDs (0.04-7.6 DID) (3).  
 
Conclusion: Further studies have to be made in order to investigate the low level of antibacterial 
reimbursement consumption in confront of the high level of overall J01D class of antibacterial 
consumption. Also, it would be suitable that health institution take this data in consideration in 
order to improve the regulation and strategies regarding the antibacterial prescription, dispense 
and utilization even of those paid out of pocket. As we are sure that the treatment protocols used 
to prescribe reimbursed antibacterials referee to the standards approved by Ministry of Health, 
we are not sure that the out of pocket antibacterial prescription is in coherence with the treatment 
protocols, as suggested by a little survey made in Tirana (12). In order to make further 
conclusions, the research group is currently analyzing the overall consumption of antibacterial 
class and the results will be finalized soon. 
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Introduction: Antibacterial consumption, its misuse and resistance nowadays are global public 
health concerns, but until now there is little evidence on the antibacterial consumption or 
resistance in Albania. There is a lack of monitoring on the antibacterial dispense in out-patient 
sector, in hospital care, and also on respecting the treatment protocols in general. As overuse and 
misuse of antibiotics are main drivers for antibiotic resistance(1), this leads us to necessary 
investigation for antibacterial consumption/utilization data. We primarily choose to study the 
penicillin’s (J01C) consumption as it was reported by ESAC-Net (2) as the mostly consumed in 
the community in Europe. Data were taken from the National Center of Drug Control 
(NCDC)(3) for all drugs registered in 2011 and 2012 entering the pharmaceutical market in the 
country, for hospital and outpatient use and also data from the reimbursement scheme from the 
Health Insurance Fund (HIF) (4). The population taken into study was the residential population 
of Albania referring to latest Census report of 2011.(5) Antibacterial drug class was selected and 
divided by ATC code and class. We referred to the guidelines(6) for ATC code and DDD 
assignment for each drug of the penicillin’s subgroup. The consumption was calculated as 
Defined Daily Dose (DDD) and DDDs/1000inhabitants/day (DID).(7,8) 
 
Results and discussion: The total consumption referring to national reports shows a total 
penicillin’s (J01C) consumption of 10.70 DID in 2011 and 10.48 DID in 2012. Where the 
penicillin’s with extended spectrum (J01CA) were consumed 6.05 DID in 2011 and 6.93 DID in 
2012. J01Ca is followed by combinations of penicillin’s, including β-lactamase inhibitor 
(J01CR) with 4.62 DID 2011 and 3.48 DID in 2012. Beta-lactamase resistant penicillin’s 
(J01CF) consumption was 0.04 DID in 2011 and 0.06 DID in 2012. Beta-lactamase sensitive 
penicillin’s (J01CE) was not present in Albanian drug market in 2011 and by 2012 its 
consumption resulted of 0.002 DID. 
 
Table 1. 
Antibacterial ATC DIDs 
2012 2011 
Penicilins J01C 10.48 10.70 
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Penicillin’s with extended spectrum J01CA 6.93 6.05 
Beta-lactamase sensitive penicillins J01CE 0.00 none 
Beta-lactamase resistant penicillins J01CF 0.06 0.04 
Combinations of penicillin’s, incl. β-lactamase inhib. J01CR 3.48 4.62 
 
Overall consumption of penicillin’s in 2011 and 2012 in terms of DIDs results higher that the 
consumption of penicillin’s in the ambulatory use and reimbursed by the HIF during the same 
period (9), which refers only to the covered population. Although the overall consumption 
include the hospital consumption of antibiotics, the difference with HIF is too big (more than 6 
times than the reimbursed penicillin’s consumption (1.6 DID) to be explained only by this factor. 
So there may be two scenarios: First the uncovered population consume far more penicillin’s in 
the ambulatory use than the covered population, and second may be that even the covered 
population consume penicillin’s out of the reimbursement scheme. However the two scenarios, 
there is a doubt that the out of pocket use is inappropriate and treatment protocols are bypassed 
(10). The overall consumption in Albania compared with the ESAC-Net report (11) is 
approximately the same with the EU median consumption, 9.7 DIDs, where the consumption 
ranged from 3.9-16.5 DIDs in 2011.  
 
Conclusion: Due to our results and discussions, further investigation is needed in order to 
determine the reasons which lead to the different values of reimbursed and not reimbursed 
antibacterial consumption in the country. Two main elements have to be investigated a- the level 
of reimbursed health services access; b- as we are sure that the treatment protocols used to 
prescribe reimbursed antibacterials referee to the standards approved by Ministry of Health, we 
are not sure that the out of pocket antibacterial prescription is in coherence with the treatment 
protocols, as suggested by a little survey made in Tirana (12). In order to make further 
conclusions, the research group is currently analyzing the overall consumption of antibacterial 
class and the results will be finalized soon.  
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Introduction: In order to rationalize the application of perioperative antimicrobial prophylaxis 
and therapy, taking into account the ISKRA guidelines [1] and the guidelines of the European 
Society of Urology [2], own system of perioperative antimicrobial prophylaxis and therapy is 
introduced  in the Department of Urology, University Hospital . 
 
Objective: To investigate the possible influence of the new guidelines implementation on 
reducing expenditure on antimicrobials and present the results of a retrospective analysis of the 
perioperative antimicrobial prophylaxis and therapy use in the department with regard to the 
pharmacoeconomic analysis. 
 
Materials and Methods: The medical records of 44 randomised patients treated in the period 
from January 1 to June 30 2012th and 44 randomised patients treated during the same period 
2013th were included. The number and proportion of patients according to the mode of 
administration of antimicrobial prophylaxis and therapy, the average duration of the application 
as well as the average daily cost of antimicrobial drug per patient (calculated according to the 
List of reimbursement from the 2013th [3]) were retrospectively analyzed. 
 
Results: Prior to the implementation of own guidelines all patients received parenteral 
antibiotics, according to the findings of urine culture or attitudes according to some of the 
clinical guidelines. During this period all patients received perioperative antimicrobial 
prophylaxis, but none of the patients received only a single dose of antibiotic prophylaxis nor 
antimicrobial prophylaxis orally. The average duration of antimicrobial therapy was 5.48 days 
with an average daily cost from 109.50 Kn per patient. In the same period 2013th 45,4 % patients 
were receiving parenteral antibiotics, 11,4 % patients had no  perioperative antibiotic treatment, 
9,1 % patients received one-time antibiotic and 34.1 % patients received antibiotics only orally. 
The antibiotic was administered according to the findings of urine culture or on newly 
implemented clinical guidelines. The average duration of therapy was 5,09 days  with an average 
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daily cost from 39,17 Kn per patient, which represents a saving of 64 % compared to the same 
period of the 2012th. 
 
Conclusion: The application of the new guidelines contributed to a more rational use of 
antibiotics with significant cost-savings. 
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Introduction: A definition by European Alliance Personalized Medicine (EAPM) states that 
personalized medicine most frequently refers to a medical model using molecular profiling for 
tailoring the right therapeutic strategy for the right person at the right time, and/or to determine 
the predisposition to disease and/or to deliver timely and stratified prevention. It may also 
involve imaging and other technologies. Further, it is stated by EAPM that in practice, rather 
than having a unique treatment for each individual person, patients are sub-divided into groups 
based on their “molecular make up”, i.e. using biomarkers. This definition does not mention any 
of genetic or genomic profiling, primarily referring to pharmacogenetic and pharmacogenomic 
technologies. If we take into account that adverse drug reactions (ADRs) rank as fourth leading 
cause of death in United States (Lazarou, J. et al., 1998) and that ADRs are significant cause of 
morbidity (World Health Organization - WHO, 2006) with the fact that many diseases have a 
genetic component with tests already available, the role of pharmacogenetic, pharmacogenomic 
and other genetic and genomic research is priceless. But, at the same time all advantages and 
benefits of personalized medicine rises new ethical considerations, especially questions on 
patient’s privacy, confidentiality, data protection as well as patient’s right on equity. 
 
Results and discussion: Genetics is the study of heredity (WHO, 2002) and genomics is defined 
as the study of genes and their functions, and related techniques (WHO, 2002; WHA, 2004). 
Thus, pharmacogenetics refers to genetic differences/genetic variations in metabolic pathways 
which can affect individual responses to drugs while pharmacogenomics is more complex and it 
analyzes entire genome – the complete set of DNA within a single cell of an organism. Genome 
contains deeply personal information and with fact that basic principle in bioethics is the moral 
right to self-determination – principle of autonomy , there are many questions that need to be 
answered as: 1. protection and safeguarding of private information; 2. obtaining of informed 
consent and of which kind; 3. which are the priorities for testing – common diseases, rare 
diseases, hereditary diseases, carcinomas etc.; 4. ownership on individual’s genetic information; 
5. sharing information for population benefit; 6. “right to know” and “right not to know” genetic 
information; 7. communicating genetic information to relatives; 8. decisions “to treat” and “not 
to treat” and its legal implications; 9. what are implications for the future of patient; 10. should 
FIRST MACEDONIAN AND FOURTH ADRIATIC CONGRESS ON 
PHARMACOECONOMICS AND OUTCOMES RESEARCH 
 
117 
 
children be tested for adult-onset diseases; 11. how to manage the right on equitable access to 
medicines; 12. how and at what extent information should be given to the patient; 13. are we 
developing techniques and personalized medicine only for those who can pay for it … and 
finally - is it ethical to do  these tests when majority of world’s population lack basic health care, 
common medications and insurance? WMA Declaration of Geneva (May 2006) states: “... The 
health of my patient will be my first consideration; I will respect the secrets that are confided in 
me, even after the patient has died;… Modern version of Hippocrates oath written by Louis 
Lasagna (1964) states:…I will respect the privacy of my patients, for their problems are not 
disclosed to me that the world may know..... The main dedication of physicians was always to 
provide the best possible care for their patients. The ethical argument supporting techniques used 
for personalized medicine at the beginning was the need to reduce the incidence of mortality and 
morbidity caused by ADRs with later improvement of efficacy and finally, with diagnosis of 
different diseases and tumor subtypes. Hidden are the concerns about possible racial and ethnic 
discrimination, stigmatization of particular subpopulations, employment discrimination, and of 
special concern – patient’s different emotional reactions. There are substantial concerns about 
commercially available direct-to-consumer DNA tests (i.e. 23andMe, decode genetics, Pathway 
Genomics, Interleukin Genetics, DNA Direct and others) with prices ranging from $ 2000 to $ 
149 - who and how will interpret these results, will they be misused? The ethical issues that arise 
with the use and reuse of personal data from any kind of genetic or genomic tests, especially 
when biobanks are in question, needs collaboration and communication between legal, ethics, 
scientific, patient’s as well as industry organizations, based on mutual recognition and trust to 
break existing barriers for the benefit of mankind.  
 
Conclusion: Already, there are numerous examples for benefit from different genetic and 
genomic research so that need for implementation of policies that will ensure ethically sounded 
testing used for personalized  medicine and ethical drug development, is clear.  Large-scale 
international trials and research collaboration are preferred for pharmacogenomics and related 
biomarker technologies can be introduced in patient care. Informed consent (IC) for genetic 
testing should not be the paravane but fair and transparent consent for both sides that sign it 
(patient and physician) with all options listed so that patient can make a free and voluntary 
choice. Informed consent should be obtained after full genetic counseling and high level of 
privacy protection. IC for drug metabolism genotyping may only require standard IC with 
information which test will be performed and for what reason, and does not need a full genetic 
counseling. As ethics nowadays requires flexibility and if GCP harmonization was possible 
between the continents, why ethical considerations of personalized medicine could not be? 
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Introduction: Elderly patients are at increased risk of adverse clinical outcomes such as 
hospitalization, falls, disability and mortality, directly involving increased consumption of health 
and social resources, being responsible for 70% of the pharmaceutical expenditure. The use of 
inappropriate medications is a major contributor to the risk of adverse events, especially in 
polymedicated patients aged 65 years old or more. Therefore, optimization of prescribing for this 
group of patients has become a major public health problem worldwide; the implementation and 
evaluation of screening tools is still needed to optimize the appropriate use of medicines. There 
is growing interest in finding mechanisms to define the adequacy of pharmacological treatments 
and develop protocols for screening of potentially inappropriate prescriptions (PIP) in the past 
two decades. Two types of methods are being used - implicit and explicit. Among the most used, 
there are Beers criteria and STOPP-START. Beers criteria have dominated the international 
geriatric literature since they were first described in 1991. They have subsequently been 
modified to facilitate their use in people living in the community and were revised in 1997, 2003 
and 2012. STOPP-START criteria were first created in Ireland and their clinical development 
has been undertaken by the Society of Geriatric Medicine of the European Union. These criteria, 
organized by physiological systems, list the most common treatment errors and omissions in 
prescribing and are easy to relate to active diagnostics and the list of drugs that appear in 
computerized medical records of patients. The objective of our study was to evaluate the 
association between potentially inappropriate prescribing and health outcomes (specifically 
mortality, number of hospitalizations, domiciliary visits and emergency care) in an older people 
population at hospital discharge using two different tools for PIP detection (Beers and STOPP-
START). The study population was patients hospitalized in the University Specialty Hospital of 
San Cecilio, Granada, Spain during 2011-2012 and the average follow up period was 415 days. 
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Results and discussion: 624 patients were included in the study, 55% women, with a mean age 
of 77.7 years (+ / -6.86 years). The patients had a Charlson Index average of 3.22. The average 
number of drugs prescribed at discharge was 8.55, with 47.92% of patients receiving more than 8 
prescription drugs. The most frequently prescribed drugs at hospital discharge were Proton Pump 
Inhibitors in 72% of patients, followed by loop diuretics (44%), aspirin (33%), and beta-blockers 
(30%). A high frequency of prescribing was also observed for NSAIDs, warfarin, thiazide 
diuretics, oral and inhaled corticosteroids. The drugs most frequently listed as inappropriate 
using Beers criteria were alpha blockers, NSAIDs, and calcium antagonists; using STOPP 
criteria, aspirin and NSAIDs predominated. Among the events detected during monitoring stands 
out the frequency of hospital readmissions within 30 days after discharge, which is higher for 
patients without PIP (p = 0.053) and an increase in the mean of domiciliary visits (43.7 versus 
29.7) in patients with PIP, almost significantly. 
 
Table 1. Effect of PIP on mortality after hospital discharge 
 cOR CI aOR CI 
Gender (ref. 
men) 
1.10 
0.73-
1.67 
1.04 
0.66-
1.62 
Age (per year 
increase) 
1.04 
1.01-
1.07 
1.04 
1.00-
1.07 
Charlson index 
1.42 
1.24-
1.63 
1.42 
1.23-
1.64 
No. of drugs  
0.99 
0.94-
1.05 
0.96 
0.90-
1.02 
Aspirin  
1.72 
1.04-
2.85 
1.74 
1.02-
2.97 
 
In Table 1, the effect of collected variables on mortality is analyzed. Association was found with 
age, representing 4% increase of the annual risk and with Charlson Index, with an increased 
mortality risk of 42% for each point increase. The possible effect of therapeutic drug groups 
classified as inappropriate by each set of criteria was assessed. We did not find any significant 
association for Beers criteria. Using STOPP-START criteria for PIP detection, a significant and 
independent increase in mortality was observed when aspirin was improperly prescribed, which 
was not verified when all aspirin prescriptions were analyzed. 
 
Conclusion: Our results do not confirm the existence of a relationship between PIP measured by 
Beers or STOPP-START criteria and the use of health services in the medium term, although a 
significantly higher number of domiciliary visits is recorded. The inappropriate prescription of 
aspirin according to STOPP-START criteria behaved as an independent risk factor for mortality. 
If we accept, as noted repeatedly in literature that the prescription of potentially inappropriate 
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drugs is associated with increased healthcare costs and adverse events, and that this effect is 
preventable, it is truly essential to further identify and evaluate specific tools that can detect 
inappropriate prescribing. Acting on it might improve the safety of drug treatments, particularly 
among elderly patients with multiple pathologies. 
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Introduction: Prematurity is still a major problem not only in the field of obstetrics and 
perinatal medicine but also for the society as a whole, not to mention the burdens for the 
concerned infants and their families.(1) The financial burden of preterm birth (PB) is 
exceptionally high. The cost of care of premature in Germany is around €730 million per year. 
When this amount is added to the cost of clinical management of mothers with threatened PB 
which amounted to about €360 million, the total cost is more than €1 billion. These calculations 
do not include the cost of long-term care of children and adults with disabilities due to 
prematurity. (2) The annual cost for care of premature in Sweden is estimated at around €65 
million (3), and the USA including caring for the mother, infant, and long-term care, estimates 
range around $26 billion. (4) From everything stated above, it is clear that prevention of PB is an 
important task for perinatologists. The association between infections and prematurity has been 
proved in many studies and much research has focused on finding infectious risk factors suitable 
for screening. If early diagnosed, infections can often be treated effectively.  The most of the 
avoidable causes are to be found among patients with ascending genital infections, urinary tract 
infections and sometimes with systemic infection, even parodontitis, thus suggesting to have the 
main emphasis on prevention of infections, not neglecting other causes (e.g. psycho-social stress) 
if possible. In cases of other causes the possibility of intervention and successful therapy is 
clearly not so good. (5) The human vagina possesses a bio-system which under normal 
conditions provides a balance between physiologic lactobacilli and pathogenic flora, and so 
ensures a good protection against the spreading of pathogens, including their ascension to the 
uterine cavity. Lactobacilli are the main regulating factor of the vaginal milieu, keeping the pH 
value at the vaginal introitus under 4,5. A simple way of measuring the vaginal pH is to use 
indicator strips which are introduced into the area of the vaginal introitus before vaginal 
examination and compare the color of the indicator with the corresponding color chart. 
Disturbance of the vaginal milieu means threatened infection. It can be detected by pH-
measurement at regular intervals, before bacterial vaginosis or infection develops (6). The main 
reason for the good results is not the early detection of existing infections, but the early detection 
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of precursors, namely disturbance of the milieu. The German “Self-care” program promoted by 
Erich Saling, in which vaginal pH was measured by pregnant women twice a week, from the first 
trimester, showed that participation of only 50% of pregnant women may significantly reduce 
prematurity, thus leading to significant annual save of expenses. (7) 
 
Results and discussion: The study conducted at the University Clinic of Obstetrics and 
Gynecology, Skopje, included 120 pregnant women <37 gw, divided in two groups - the first 
group – with vaginal pH measurement from the first trimester of pregnancy, and the second 
group - with preterm labor. In cases of elevated vaginal pH we started therapy with Lactobacillus 
or lactic acid locally and in cases of positive cultures we suggested treatment according to 
antibiogram. The results showed significantly lower percent of PB among women controlled 
from the first trimester (11% vs. 86%). These 11% were all near term (34-36gw), opposite to 
86% from the other group, of which 17,4% were between 32-34gw, and 26,7% were <32gw. The 
risk for PB was eight times higher among women with elevated vaginal pH. The results from the 
study are in accordance with the statement of Saling and Caillouette that the routine vaginal pH 
testing by every pregnant woman is simple, inexpensive (certainly relative to the cost of a 
damaged child), can lead to better informed sex habits and better vaginal health. “How much 
more simple and inexpensive does the solution need to be?’’ (7) 
 
Conclusion: Regular vaginal pH measurement from the first trimester of pregnancy is almost an 
ideal method for a reliable, rapid ‘bed-side’ risk assessment. It is easy, clinically simple strategy 
to identify the patient at risk and may achieve reduction in the rate as well as the cost of 
prematurity. Efficient screening should start early, before 16 gw and should be applied often 
enough.  
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PHARMACOECONOMICS OF THE SHORT- TERM 
PROPHYLAXIS OF THE HAE ATTACKS 
 
Ksenija Makar Aušperger1 , Hana Kalinić Grgorinić2 
 
1Clinical Hospital Center Zagreb, Zagreb, Croatia 
2General Hospital Pula, Pula, Croatia 
 
Key words: Hereditary angioedema, short- term prophylaxis, C1 inhibitor, attenuated 
androgens, price 
 
Introduction: Hereditary angioedema ( HAE) is a rare disease with autosomal dominante 
inheritance, characterized by deficiency or dysfunction of C1 inhibitor (C1-INH).  Typical 
clinical presentation includes recurrent angioedema, without urticaria and pruritus, that primarily 
affects the skin or the mucosal tissues of the upper respiratory and gastrointestinal tracts. 
Swelling maybe self- limited,  but laryngeal involvement can lead to airway obstruction and even 
death. The prevalence in general population is 1: 50 000. There are 3 types of HAE. Type I HAE 
is characterized by low plasma levels ofl C1-INH protein. Type II HAE is characterized by 
normal to elevated C1- INH protein, but function is low. Type III HAE occurrs mainly in women 
with normal functional and quantitative levels of C1-INH. Treatment approach consists of acute 
attacks therapy and prophylactic therapy. Prophylactic therapy can be short- term and long- term.  
Shor- term prophylaxis is indicated in situations that are recognized as triggers for attack, such as 
dental, oral and general surgery. Attenuated androgens are currently the initial mode of 
prophylactic treatment. Therapy should be minimized, balancing disease severity with 
minimizing adverse effects. The drug most commonly used is danazol, but all attenuated 
androgens are useful in treatment. The nano-filtered C1-INH concentrate is also labeled for 
short- term prophylaxis. The other opitions are antifibrinolytics and plasma products. 
 
Discussion: There are few medications recognized as short- term prophylaxis of HAE attacks, 
with different mechanism of action, different adverse effects and different contraindications. 
Assuming effectivness and safety profile among approved short- term prophylaxis reasonable 
options would be attenuated androgens and C1- inhibitor. There are no head- to- head 
randomized clinical trials comparing these medications. On the other hand, no one of thise 
medications provides 100 % protection of HAE attacks. The price of therapy is also very 
important factor in making decisions, and big differences are presented in the table 1. 
 
Table 1. 
Danazol 600 mg/ day Approx. 5 € 5 days before and 5 
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days after surgery 
C1 inhibitor  
( Berinert )* 
1500 IU Approx.  4730 € 
preferably within the 
hour before the 
procedure 
Nanofiltered C1 
inhibitor 
( Cinryze) 
1000 IU Approx. 2000 € 
preferably within the 
hour before the 
procedure 
*off- label use 
 
In making decision process which short-term prophylaxis medication to chose, it is important to 
know what kind of surgery ( minor or major) will patient undergo, is she/he already taking a 
long- term prophylaxis and what medications approved for prophylaxis are currently available at 
the hospital pharmacy. 
 
Conclusion: Decision making while prescribing short- term prophylaxis should be pointed on 
the patient benefit considering all the facts about patient, procedure that patient will undergo and 
of course his prior experience with similar situations and prophylaxis if that one has already been 
taken. On the other hand, the question is also the price of these medications. That fact largely 
influence their affordability. Besides that, if the medicine is expensive and not the standard 
therapy for numerous patients, should it be always available at the hospital pharmacy. Or, maybe 
we can simply prescribe cheap, effective medicine as attenuated androgen is, whenever there are 
no contraindications. 
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MANAGING PROCUREMENT AND SUPPLIES OF DRUGS AND MEDICAL 
DISPOSABLES WITH ABC ANALYSIS IN CLINICAL HOSPITAL STIP 
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Introduction: Pareto, an Italian economist of the eighteenth century argued that the wealth of a 
country is in the hands of a small part of the total population, about 20%, while the remaining 80 
% belonged to 10-20 % of the wealth. During time this theory proved to be true and is also called 
Pareto rule and the curve is called Lawrence curve. In fact, analogous imbalance in the 
distribution of wealth, but primarily inversely proportional between number and wealth (value) 
also exists in pharmacy (drugs and medical supplies ). According to the theory of Pareto, but by 
empirical data as well, it can be seen that about 80 % of the value of all products held in stock 
belongs to 20 % of the products, while the remaining 80 % contributed only 20 % of the total 
value of stocks. The existence of this imbalance requires implementation of specific controls for 
specific types of products that will be reviewed based on their relative importance. ABC analysis 
gives us a criterion for selection of products that allows us to control inventory by dividing all 
products in three groups A, B, C:   
• A group or products that are few in number , but cost much and that is why are vital from an 
economic point of view ; 
• Group B or products that are more numerous, but still important ; 
• Group C or many and cheap products . 
Obviously it is more important to focus attention on the fewer number of major products, 
controlling the others occasionally. To implement this approach, ABC analysis is performed in 
the warehouse of the pharmacy which gives the hierarchy of products according to their 
importance. The importance of a product depends on the contribution of that product in the value 
of inventories. This means that the importance can be calculated by multiplying the amount of 
product delivered to the business units and its value, i.e. the purchase price. If the pharmacy has 
a computer program for managing inventory, usually an option of displaying the products in 
tables is available, ranging from most important to least important. We can choose the 
percentage that is of our interest. For example if you choose 60 % the program will give us those 
products whose value (supplied units are multiplied with purchasing price) represents 60% of the 
value of all goods in stock. It is still good if the pharmacy does not have such a program, as it is 
the case with our pharmacy.  In this case a manual work is done and it is sufficient to keep 
detailed records of what and how is being delivered. Afterwards the delivered quantities are 
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multiplied with the purchasing price in Excel and as a result we get the same table.  
It can be seen that usually about 15-20 % of the products constitute 80 % of the total value of 
stocks and the others 20 - 30 % represent 90 % of the total value. 
 
Results and discussion: ABC analysis is consist of three groups: A, B and C where certain 
product belongs. In which group a product will be classified depends on our analysis and does 
not mean that if a product has been classified in one group, should stay there forever because 
drug prices are constantly changing and with new research and development new drugs are 
becoming more important and old ones become less important. 'Relevance' as already mentioned 
is other characteristic of the products. Relevance not relate to the economic aspect, but the 
practical importance of the drug to patients. To simplify things, all products in the table will be 
classified as having the same importance, which is normal (No). Clearly, if we know which are 
the products that belong to the first two groups (A and B), we can concentrate on fewer products 
and be sure that we control 90 % of the costs. It should be noted that this classification is purely 
financial and does not take account of the fact that some products, although negligible in 
economic terms and therefore classified as C, are vital to the pharmacy. So, the results of the 
ABC analysis automatically reject products from Group C as unimportant. From the ABC 
analysis of data we can conclude that the Clinical Hospital - Stip is no exception in terms of 
Pareto's law. To avoid the catastrophic consequences of staying without these inexpensive but 
critical products , the ABC analysis can be corrected by dividing the products in stock not only 
by price , but also by objective importance: vital (Vi) , important (Im) and normal (No). By 
combining this division with the one given with the ABC analysis, we get the 3 × 3 matrix as 
shown in Table 1. 
 
А В С  
АVi ВVi СVi 
Vi = products vital to the pharmacy (no remaining stock is 
disastrously) 
  АIm ВIm СIm 
Im = important products (should be avoided to stay 
without supplies) 
АNo ВNo СNo 
No= normal products (can tolerate temporary lack of 
inventory) 
 
This way ABC analysis is becoming even more important because it takes into account the 
importance of the product and allows you to 'observe' the products with low price. The lack of 
these products would cause more damage than the costs of storing large amounts of inventory. 
 
Table 2. Presentation of ABC analysis in clinical pharmacy, Clinical Hospital Stip 
Group Number of products Value (denars) Percentage 
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Group А 97 (12%) 61.220.000 80% 
Group В 94 (11%) 7.250.000 9,5% 
Group С 627 ( 77%) 7.880.000 10,5% 
Total 818 76.350.000 100% 
    
 
Table 2 presents a real example of a warehouse at the pharmacy. We can note that about 800 
different products in 2012 at the Hospital pharmacy - Stip , total value 76.35 million denars, less 
than 100 items (Group A ) worth 61,220,000.00 million denars (or 80 % of the total value) and 
approximately 20 % of all articles (Group B + group C) or 700 items, worth more than 90 % of 
the total value (about 15.130.000, 00 den).  
 
Conclusion: Research shows that Pareto's law is confirmed in the warehouse of the Hospital 
pharmacy - Stip. Conclusion is that the greatest savings in the work of a hospital pharmacy (and 
every other one) can be achieved if we focus on products from Group A, because they are most 
expensive, but with normal importance.  
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Introduction: Variety of measures are introduces to control the growth of prices focusing either 
on demand or supply side of the utilization. Within supply side measures fall the price 
regulation, price freezing, positive or negative medicines lists, external and internal price 
comparison etc. External price comparison is performed at international level by comparing the 
prices in a selected basket of countries. Current study analyses the results of IRP in Bulgaria 
after the increase of the number of countries included in the the referent basket. 
 
Materials and methods: It is a prospective observational comparative study of the changes in 
prices in a selected target oncology therapy during 2008 – 2013. On a yearly basis was collected 
officially published information about the prices of the selected medicines. In total 12 INN 
presented in 37 dosage forms were included in the price analysis. Those were the top leading by 
expenses INN, for target therapy, oncology products, which during the start of the observation 
were all patented products.  
 
Results and discussion: On July 12, 2012 the National Assembly approves Supplement of the 
Drug Products in the Human Medicine Act which sets forth new substantial amendments related 
to the pricing. According to the planned amendments, the Commission for Pricing and 
Reimbursement is substituted by a new body, the number of countries included in the reference 
basket increased from 13 to 17 countries, the price revision at 6 months period was introduced, 
and the necessity of positive reimbursement decision in 5 from those 17 countries was also 
imposed. The reference countries are organized in main and supplementary baskets. The main 
basket includes Greece, Romania, Portugal, Spain, Italy, France, Denmark, Finland, Estonia, 
Lithuania, Slovakia, Slovenia. The supplementary basket (Belgium, Latvia, Czech Republic, 
Poland, Hungary) is used only in cases when a product is not available in the main basket. The 
new P&R body – The National Council for Pricing and Reimbursement of Medicinal Products 
was established on 01/05/2013. The Council is composed of well known experts in the area with 
clear vision, who immediately started working based on the new rules. In the field of targeted 
therapy the prices were decreased on average by 19% - Table 1. 
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Table 1. Average price decrease by INN 
INN 2009 2010 2011 2012 2013 2014 
Capecitabine -2.9% -7.0% -4.1% -13.0% -1.1% 
-   
28.1% 
Dasatinib -3.0% -2.3% -1.4% -0.2% 0.9% -1.8% 
Erlotinib 
-
11.0% 
-0.2% -5.7% -5.6% -4.9% -2.3% 
Everolimus 
 
-1.0% 0.4% -2.5% -6.7% -3.6% 
Imatinib -5.6% 0.2% -0.1% -2.8% -2.9% -1.6% 
Lapatinib 
  
-0.6% -4.5% -2.5% -0.9% 
Nilotinib 
  
-3.4% -17.0% 
-
11.6% 
-3.1% 
Pozopanib 
   
-2.9% -3.9% -0.3% 
Sevelamer 
-
12.5% 
-
15.2% 
1.8% -2.7% -5.9% -0.3% 
Sorafenib -5.2% 0.8% 0.6% -4.0% -2.5% -2.4% 
Sunitinib -3.5% -1.0% -4.9% -10.4% 9.9% -0.3% 
Topotecan 
  
-4.3% -2.6% -3.6% -1.9% 
 
The consecutive yearly decrease is shown on the Figure 1 – 3. It is evident that the decrease is 
higher for the high prices INN and indications.  
 
 
- лв. 
100.00 лв. 
200.00 лв. 
300.00 лв. 
400.00 лв. 
500.00 лв. 
600.00 лв. 
700.00 лв. 
800.00 лв. 
900.00 лв. 
PTH PTH PTH PTH PTH PTH
2009 2010 2011 2012 2013 2014
capecitabine FILM C.TABS 150 MG 60 everolimus TABS .25 MG 60
sevelamer  FILM C.TABS 800 MG 180 everolimus TABS .5 MG 60
capecitabine FILM C.TABS 500 MG 120 everolimus TABS .75 MG 60
topotecan CAPS 1 MG 10
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Figure 1. Price decrease in the group of low priced INN 
 
Figure 2. Price decrease in the group of medium priced INN 
 
Figure 3. Price decrease in the group of high priced INN 
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2009 2010 2011 2012 2013 2014
imatinib CAPS 150 MG 28 pazopanib FILM C.TABS 200 MG 30
imatinib CAPS 200 MG 28 sunitinib CAPS 12.5 MG 30
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6,500.00 лв. 
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PTH PTH PTH PTH PTH PTH
2009 2010 2011 2012 2013 2014
erlotinib FILM C.TABS 100 MG 30 erlotinib FILM C.TABS 150 MG 30
lapatinib FILM C.TABS 250 MG 140 sunitinib CAPS 25 MG 30
imatinib FILM C.TABS 100 MG 120 afinitor TABS 5 MG 30
pazopanib FILM C.TABS 400 MG 60 everolimus TABS 10 MG 30
sorafenib FILM C.TABS 200 MG 112 dasatinib FILM C.TABS 50 MG 60
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For some of the INN an essentially similar alternatives were autorised during the observed 
period that also contribute to the overall positive process. 
 
Conclusion: In general the increase in the reference basket countries, frequent price revision and 
creation of the National Council for Pricing and Reimbursement let to the significant decrease in 
the prices of target oncology therapy and create savings for the National health insurance fund 
for proximately than 5mln BGN in 2013. 
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EVALUATION OF COST-EFFECTIVENESS OF COCLEAR IMPLANT USE IN 
ALBANIA 
 
M. Rama MSc, A. Kaleci PhD 
 
Pharmacist at “Mother Thereza” Hospital Centre, Tirana 
 
Background: It is estimated that each year in Albania, about 70 children born with profound 
hearing loss. If detected and diagnosed early (before age 4-5 years) and treated with cochlear 
implant, these children are likely to recover the loss of hearing in a certain extent and to develop 
gradually the speech being integrated in life and society. If detected later or left untreated after 
the age of 5 years old, they lost the opportunity to fully develop their speech and so to 
communicate normally through language.  
The purpose of this study is to compare these two alternatives by combining the costs and 
respective benefits or outcomes through a pharmacoeconomic evaluation. This assessment 
provides theoretical data on the problem of profound hearing loss mainly at children, long-term 
consequences of this condition in their life mainly in developing linguistic, cognitive (cognitive), 
emotional, and social benefits and highlights the impact of cochlear implant in the lives of these 
individuals.  
Methodology: As for those individuals, their quality of life is compromised by their defect, we 
used a cost-utility analysis. The assessment is done from the perspective of the payer and the 
society. Because in our country there are no studies assessing the quality of life of children with 
profound hearing loss and the number of people (mostly children) who have undergone a 
cochlear implant to overcome their disability is small (˂ 15 individuals ), it is impossible to 
extract  significant result on benefits (utilities) that  implant brought into their quality of life. In 
this case, we had extrapolated the utilities from reliable studies on literature. The study by Barton 
and colleagues in UK is considered to have given relevant  assessing  on the weight of the utility 
of children with profound hearing loss before and after cochlear implant. From this study the 
utility is estimated at 0.421 HUI (Health-Utility Index) for the first alternative (before implant) 
and 0.653 for the second alternative (after implant), with an addition of 0.232 in the HUI. 
Assuming that the cochlear implant or the state of profound hearing loss do not affect the life 
years of these individuals, for further evaluations will we took the average life expectancy in 
Albania that of 72 years (reported officialy). After assessment of costs and calculation of QALYs 
for each alternative we concluded.  
Conclusions: Cochlear implant improves hearing perception and help the development of  
speech at young children with profound hearing loss under the age of 4-5 years. The benefits are 
as better as younger is the child. Cochlear implant improves the quality of life, outcomes in 
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terms of academic education and integration into society. Cochlear implant is more cost-effective 
from both perspectives considered by our the study (Payer and Society) compared with no 
implant. According to payer (State) perspective, by the application of alternative II (cochlear 
implant), there  will be saved 73,243 euros over the life of an individual with profound hearing 
loss. According to the society perspective, by the application of alternative II (cochlear implant), 
there will be saved 287,443 euros over the life of the individual with profound hearing loss. 
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Introduction: The reference pricing system in the Republic of Macedonia was implemented in 
2008. In some European countries this system of regulation of medication prices dates back to 
late eighties and early nineties. This system, more than just a mere form of medication price 
regulation, is a governmental policy of these countries in order to reduce the expenses on 
reimbursed medications. This system enables involved parties to determine an acceptable price 
level for “equivalent” medications with huge difference in price (set by the producers). The 
reference price of a medical product implies the maximal amount, which is reimbursed by the 
Healthcare Insurance Fund. If the price of a medical product is higher than the reference price, 
then the patient pays only the difference between the price of a medical and the reference price 
or h/she gets a comparable therapeutic product (without additional charges). By limiting the 
prices for the producers as well as motivating the prescription of generic medications through the 
above-mentioned system, the level of expenses for reimbursed medications is reduced, whereas 
the patients are offered cheaper medication prices. Despite the debates and polemics on the 
consequences of this system, the RPS is currently applied in the majority of EU countries.  This 
article will focus on the differences that exist in the organization of the RPS in some EU member 
countries and we will also analyze the “Methodology of formulating the prices of medications” 
in Macedonia and the consequences that derive from this system.  
 
Results and discussion: The Reference Pricing System is a system of controlling and stabilizing 
the prices of reimbursed medications. In Europe, this system was adopted in countries with high 
medication prices and then widely spread in many other European countries. The table below 
shows countries that have implemented the RPS and those which have not done so yet.  
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Table 1. Some European countries that have implemented the RPS 
Imp. Year       Countries with RPS Countries without RPS 
Austria, Norway, Sweden 
1989           Germany  
1991           Netherland 
1993           Denmark 
2000           Spain 
2003           France, Portugal, Italy, Hungary 
The difference in defining drug classes – is one of the most frequently discussed matter. The 
criterion for the group of medications that are considered as “interchangeable” varies from one 
country to another.  
Three types of medication classification have been identified:  
 Type I – grouping of bio-equivalent medications (ATC-5) 
 Type II - grouping of  chemically different but pharmacologically identical medications 
(ATC-4) 
 Type III - grouping of  pharmacologically different but therapeutically identical 
medications (ATC-3) 
 
Table 2. Medication grouping in different countries 
County  RPS Level  ATC   
Belgium  Level I   ATC 5            
Germany  Level I, II, III  ATC 5, ATC 4, ATC 3 
Netherlands Level II   ATC 4 
Hungary  Level I, II  ATC 5, ATC 4 
Italy  Level I, II, III  ATC 4, ATC 3 
Spain  Level I   ATC 5 
France  Level I   ATC 5 
Denmark  Level I   ATC 5 
Portugal  Level I   ATC 5 
Bulgaria  Level I, II  ATC 5, ATC 4 
Slovenia  Level I   ATC 5 
 
Different methods of calculating the referent price 
 Based on the lowest priced medications: Denmark, Italy, Poland, Slovenia, France, 
Hungary, Turkey 
 Based on the percentage of original drug: Belgium  
 Based on the econometric model: Germany 
 Based on the average price of medications: Croatia, Hungary 
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Referent Pricing System in Macedonia 
RPS was implemented in Macedonia in 2008. The Macedonian government adopted the book of 
rules on “The methodology of establishing medication prices”. Based on this methodology, the 
wholesale and retail prices of medications are established in accordance with medication prices 
in referent countries, such as UK, Serbia, Slovenia, Bulgaria, France, Croatia, Germany, Turkey, 
Russia and Greece. 
 
Conclusion: RPS has been adopted as a mechanism by governments to reduce the cost of 
expenses in the public healthcare system. By setting a limit price, competition among producers 
is fostered. The establishment of a reference value also makes the patients more aware of the 
medication prices. The determination of prices by using this system influences the compilation 
of positive lists whose main objective should be cost-saving. However, even though this system 
has been implemented in almost all European countries, there are still no sufficient analyses of 
the achieved results and outcomes.  
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Introduction: Current guidelines and business processes in physical therapy in Croatia are not 
aligned with EU guidelines and practices. As it is now, it is possible to incur significant 
unwanted costs due to very high unrestrictive number of procedures included for only one 
referral. Due to strict division of business processes and roles between doctors and physical 
therapists, which did not change for decades, many unnecessary examinations are performed. 
Moreover, there is a great opportunity for increasing the managing role of physical therapists to 
release the burden of doctors and provide better care.  
 
Results and discussion: EU and especially Slovenian practice demonstrates that giving more 
active role to physical therapists gives much better clinical results and saves significant costs. 
According to WCPT1, physical therapists should be also the first contact, able to assess and treat 
patients/clients without referral from a medical practitioner or other third party. In this study we 
have tried to estimate clinical, practical and economic benefits of this new model of physical 
therapy in Croatia. 
 
Conclusion: Besides the adapted clinical guideline, new model for physical therapy tariffs based 
on time frame and not only procedures should bring significant savings and release resources for 
closing budgets in physical therapy. Releasing the burden from doctors, and giving more patient 
management roles to physical therapists leads to optimization and rationalization of costs. New 
tariff and costing schemes enable better control over the process and budgets in physical therapy. 
 
References 
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self-referral to physical therapy. London, UK: WCPT; 2011.  (Access date 22nd September 
2011) 
 
 
 
FIRST MACEDONIAN AND FOURTH ADRIATIC CONGRESS ON 
PHARMACOECONOMICS AND OUTCOMES RESEARCH 
 
140 
 
P23 
 
POSSIBLE BENEFITS OF CYP2D6*4 PHARMACOGENETIC TESTING IN BREAST 
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Backround: Breast cancer is a costly illness which is responsible for 14% of cancer deaths 
among women. The financial costs of cancer are high for both the person with cancer and for 
society as a whole. Treatment options for this disease include radiation, lumpectomy, 
mastectomy, chemotherapy, or a combination of these options. Chemotherapy for breast cancer 
includes traditional chemotherapy, hormonal therapy, and targeted therapy. Tamoxifen is a 
widely prescribed hormonal therapy drug for the treatment of all stages of estrogen receptor 
(ER)-positive breast cancer and is also widely used for breast cancer prevention in high-risk 
women. The cytochrome P450 2D6 (CYP2D6) genotype is one of the determinants of the plasma 
concentration of 4-hydroxy-N-desmethyltamoxifen (endoxifen), an active metabolite generated 
from tamoxifen with CYP2D6, and is one of the strongest predictors of tamoxifen response in 
breast cancer patients. Variants in the CYP2D6 gene can cause patients to be either intermediate 
or poor metabolizers, thereby rendering tamoxifen treatment less effective. The CYP2D6 gene 
has multiple allelic variants, some of which, including the *4 allele, result in the loss ofCYP2D6 
enzyme function.  
 
Objectives: The objective of our study was to determinate whether or not testing for cytochrome 
P450 2D6 (CYP2D6) polymorphisms in women with early hormone receptor positive breast 
cancer leads to improvement in outcomes, is useful for health decision-making and is a cost-
effective use of health-care resources. 
 
Methods: A total of 110 patients with breast cancer from Kosovo, who had been taking 20 
mg/day of tamoxifen (TAM patients) for at least 4 weeks as adjuvant therapy (patients who were 
co-prescribed CYP inhibitors were excluded) were included in this study. Genomic DNA was 
extracted from whole blood, using a QIAGEN DNA extraction kit and the procedure 
recommended by the manufacturer (QIAGEN AS, Oslo, Norway). The presence of the 
CYP2D6*4 polymorphism CYP2D6*4 (1846G > A; rs3892097), was analyzed by the allelic 
discrimination TaqMan assay (MxPro 3005P, Strategene, La Jolla, CA) according to the 
manufacturer’s instructions (Applied Biosystems, Foster City, CA). The study was approved by 
Ethics Committee of University Clinical Center of Pristina.  A review of economic evaluations 
and models of CYP2D6 testing for patients treated with TAM was carried out. Official data 
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about annual number of patients with BC, cost for treatment and utilization of Tamoxifen were 
obtained from official institutions in Kosovo. Cost of pharmacogenetic CYP2D6 testing was 
calculated according to the standard protocol for this analyses and the price of reagents, 
laboratory equipment and human resources in Center for Biomolecular Pharmaceutical Analyses 
(CBPA), Faculty of Pharmacy, Ss Cyril and Methodius – Skopje, R.Macedonia. 
 
Results: According to the official data from Oncology Institute in Kosovo, there were 250 new 
breast cancer cases in 2013in Kosovo. The consumption of Tamoxifen tablets procured by MoH 
through tenders  in 2011 was 30720 tablets with unit price 0,07 eur per tablet, 33160 tablets in 
2012 with unit price of 0.097 eur per tablet and 32000 tablets in 2013 with unit price of 0.097 eur 
per 20mg tablet.The total amount that Republic of Kosovo spent as a direct cost for Tamoxifen 
therapy in 2013 was 3104 euros. The genotypic frequencies of the CYP2D6*4 polymorphism in 
all patients wereGG (63,8%)GA(28,9%), and AA(7,3%). The distribution of all genotype 
frequencies did not deviate significantly from Hardy–Weinberg expectations.  The CYP2D6 
mutant allel in breast cancer patient from Kosovo has similar distribution (7,33%)  as determined 
in other European populations. In our study theTAM patients homozygous for 
theCYP2D6*4allele have a higher risk of disease recurrence (3 out of 8 patients with AA 
genotype and 9 out of 67 patients with GG genotype) and they were associated withthe 
occurrenceof breast cancerin theearly age (39 years for patients with AA genotype in 
comparasion with 50,6 years in GG patients for CYP2D6*4). The total cost for pharmacogenetic 
CYP2D6 testing in Center for Biomolecular Pharmaceutical Analyses (CBPA), Faculty of 
Pharmacy, Ss Cyril and Methodius – Skopje, R.Macedonia is 35eur per patient. We still have 
controversial cost-effective information about pharmacogenetic CYP2D6 testing in patients with 
breast cancer who are on Tamoxifen therapy, but should be viewed as an investment in 
individualized patient therapy for the prevention of life-threatening recurrences. 
 
Conslusion: The CYP2D6*4 polymorphism plays an important role in breast cancer etiology as 
well as in determining the hormonal therapy where tamoxifen is used. CYP2D6 genotype testing 
led to changes in therapy among poor metabolizers, even in the absence of definitive data that an 
alternative medicine improved outcomes. More clinical research is needed before we can 
recommend routine CYP2D6*4 testing and we can rationally use this test in to daily practice. 
Physicians should be prepared to share with patients information about availability and clinical-
effectivness of this testing. 
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Introduction: Thromboembolism is the main cause of maternal mortality in developed 
countries. Venous thromboembolism (VTE) remains one of the most important cause of death 
during pregnancy. The risk is increased in women older than 35 years, those with previous VTE, 
operative delivery and underlying thrombophilia. Recent studies have indicated that certain low 
molecular weight heparine (LMWH) given subcutaneously may replace continuous intravenous 
unfractionated heparine for the treatment of venous thromboembolism. LMWH have a 
predictably high absorption rate when given subcutaneously and they do not require laboratory 
monitoring. These characteristics of LMWH raise the possibility of treating uncomplicated 
patients with deep venous thrombosis in the outpatient setting. Our study represents a 
retrospective study that was conducted at Clinical Hospital in Tetovo, Department of 
Gynecology and Obstetrics. The study was undertaken during January 1st – December 31st 2012. 
During that year, it was noticed an increase of LMWH usage for the diagnosis hyper thrombotic 
condition. The objective of this study, based on these dates, is to show the cost differences 
between inpatient and outpatient treatment. 
 
Results and discussion: During the period January 1st – December 31st 2012, were registered 
4636 patients. 2324 (50,19%) of them delivered, 534 (11,52%) were patients with other 
diagnosis, 331 (7,14%) had miscarriage. 1447 (31,21%) of them were pregnant women, from 
that number, to 298 (20,59%) of them was prescribed LMWH. 
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Figure 1. Types of diagnosis among pregnant women 
 
From 298 pregnant women who appeared as outpatients, to 119 (39.93%) of them 
transfusiologyst proscribed a therapy for the diagnosis hyper thrombotic condition. 67 (22.48%) 
had nonpatologycal pregnancy, but high levels of Dimers, 48 (16.11%) of them were with risked 
pregnancy and 12 (4.03%) of them had risked pregnancy associated with hyper thrombotic 
condition. The other 52 (17.45%) were with different diagnoses: pregnancy after IVF, pregnancy 
associated with diabetes, pregnancy after miscarriage and other. 
 
 
Figure 2. Ordinal number of pregnancy 
 
For 195 (65.44%) women, this was their first pregnancy, 55 (18.46%) declared that this is their 
second pregnancy, and for 48 (16.10%) women, this was third, fourth or fifth pregnancy (3+). At 
the department of Gynecology and obstetrics, there are used five types of anticoagulants 
recommended by the transfusiologist. The most used anticoagulant was Clexane 2000 unites – 
2188 ampules (38,12%), the detailed explanation is given into the Table 1. HFIM pays to the 
hospital an amount of 130,00 MKD for each ampule application, it also pays 390,00 MKD for 
the entire period of hospitalization. 
 
Table 1. Anticoagulants,  number of ampules and the total cost 
Anticoagulants 
Ampules Total cost 
of ampules 
(MKD) 
No. % 
119
67
52
48
12
0 30 60 90 120
Pregnancy with…
Nonpathologic…
Other forms (> 10…
Risked pregnancy
Risked pregnancy…
195
55
48
0 50 100 150 200
First pregnancy
Second pregnancy
Third + pregnancy
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Clexane 2000 2.118 38,12 262.608,00 
Clexane 4000 1.021 17,79 211.632,00 
Fraxiparine 0.2 32 0,56 3.584,00 
Fraxiparine 0.3 1.402 24,43 156.082,00 
Fraxiparine 0.4 1.097 19,11 170.539,00 
Total Cost  
(Ampules + Application + Hospitalization) = 
1.354.948,00 MKD 
 
Conclusion: The change in the manner of prescribing different types of LMWH, will result with 
large cost savings for the healthcare system with no apparent changes in effectiveness. In that 
case, HFIM will not have to pay 390 MKD for hospitalization and 130 MKD for each given 
ampule.   
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ABSTRACT 
 
Backround: Use of parenteral antibiotic therapy is investigated in the ambulatory patients, 
hospitalized ones and patients on ambulatory hemodialysis at the PHI Institute of Nephrology – 
Struga within the period of 2007 – 2012. 
 
Objective: The aim of our work is an assessment of the use of antibiotics depending on the 
patient’s needs.  
 
Materials: The data analysis of use of antibiotics by hospital’s departments at PHI Institute of 
Nephrology – Struga for period of five years. 
 
Results: Hospital’s budget spent for antibiotics in 2007 was 395.689 denars (6.434 EURO); in 
2008 - 504.762 denars (8.207 EURO); in 2009 – 1.305.350 denars (21.193 EURO); in 2010 – 
1.142.060 denars (18.570 EURO); in 2011 – 587.382 denars (9.550 EURO); and in 2012 -
981.435 denars (15.958 EURO). 
 
Conclusion: Highest amount of the hospital budget has been spent for cephalosporins, the most 
used antibiotic as well. 
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Introduction: Aim of the study is to follow up the last years presented situation with organ 
transplantation and immunosuppressant therapy in Macedonia. Immunosuppressant therapy is 
essential for patients after transplantation, in order to suppress immune response, to prevent 
rejection of grafts or transplants. Organ transplantation has increased in last five years, with last 
years cadaveric transplantation, as last stage of transplantation protocol project. Kidney, liver 
and bone marrow are tree organs that are actively transplanted in Macedonia. In 17 years, more 
than 200 patients received kidney, mostly from live organ donor, till 2013 when first cadaveric 
organ transplantation was conducted. All transplanted patients started initially with 
immunosuppressive therapy, and take lifelong doses. Bone marrow transplantation is active for 
14 years and total 270 patients are transplanted, annually approximately 20 – 25. One third of all 
are allogenic (other donor) transplantations, which by the protocol get immunosuppressant 
therapies, mostly cyclosporine and mycophenolate mofetil, at least for the first six months. Liver 
transplantation started 2011 one child is transplanted and started with tacrolimus. Twelve 
immunosuppressant products are registered in Macedonia of which two cyclosporine, two 
antithymocyte immunoglobulin, four mycophenolate mofetil, tacrolimus, daclizumab, 
basiliximab and everolimus, of which six are not marketed at all. Five generics are on 
reimbursement list of HIF, but only three of them are marketed. Data for spending for 
immunosuppressant’s are obtained from Health Insurance Fund (HIF). 
 
Results and discussion: Results for cost for immunosuppressive therapy for last five years are 
shown in table 1, according to the Health insurance fund annual reports for the last five years. In 
table is shown percentages from total budget of HIF in Macedonia that are spend for 
immunosuppressive therapy, but also you could see variety (VAR%) in percentages of spending 
for immunosuppressive, from total budget. 
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Table 1. Five year analysis of HIF spending for immunosuppressive therapy 
Year Cost for 
immunosuppressive 
therapy (Eur) 
Percentage 
of total 
budget of 
HIF (%) 
VAR % 
of total 
budget 
versus 
previous 
year 
2009 593.000 1.15 - 
2010 522.000 0.86 - 26 % 
2011 590.000 0.99 15 % 
2012 472.000 1.45 46 % 
2013 511.000 1.49 3 % 
 
Although total budget of health insurance fund increased from 2012 to 2013 for 5.5%, increase 
of spending for immunosuppressive therapy in 2013 increased for 8% according to 2012.  
 
Picture 1. Total bidget for medicines of Health insurance Fund in Macedonia 2012 vs 2013 
 
Picture 2. Spendings for immunosupresive therapy from Health insurance Fund 2012 vs 2013 
 
Picture 3. Variation of packs of immunosupresive therapy 2012 vs 2013 
Total Budget of HIF
2012
2013
Spendings for 
imunosupressive therapy
2012
2013
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Variation of packs of immunosuppressive therapy shoved that 15% more immunosuppressive 
were spend in 2013 vs 2013, nevertheless that total budget spend was only 8% more in 2013 vs 
2012. This shoved that continuous price reduction of medicines in last few years in Macedonia, 
resulted in more pack spend for fewer budgets from Health Insurance Fund. Positive 
transplantation campaigns in all fields in Macedonian Health care system was followed by 
spending for immunosuppressive therapy. 
 
Conclusion: In Macedonia there is trend in continuous price reduction of the medicines, at least 
twice a year. New investments and opportunities for transplantation of organs bring more 
transplanted patients annually, but less spending from HIF for immunosuppressive therapy. 
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Introduction: Hyperphosphatemia is a very serious condition which impacts increased mortality 
risk in patients who are undergoing chronic dialysis. Due to related secondary decrease of serum 
calcium as well as reactive elevation of parathyroid hormone, there is high risk of renal 
osteodistrophy. Furthermore, uremic artheriolopathy and cardiovascular calcification are 
developed which increases cardiac conditions in terminal renal failure. Therapy for 
hyperphosphatemia is performed with nutritional restrictions and dialysis, as well as with 
phosphate binders based. A cost minimization analysis was performed to assess costs and 
outcomes for calcium based binders and calcium and magnesium based binders (calcium 
acetate/magnesium subcarbonate, calcium carbonate and sevelamer).  
 
Results and discussion: In phosphate binders selection is determined by price. Calcium 
acetate/magnesium subcarbonate has comparable efficacy toward other non calcium phosphate 
binders and superior to calcium phosphate binders. Superiority toward calcium based phosphate 
binders lays in lower risk of hypercalcaemia, potential delay of calcification due to magnesium 
and in regulation of parathyroid hormone. Recent Cochrane analysis1 demonstrated that agents 
based on calcium should be used in first line, since they are cheaper better tolerated and of equal 
efficacy as sevelamers and lantane carbonates. 
 
Conclusion: No difference in strength, side effects, morbidity or mortality among phosphate 
binders exist, however difference in costs is present and significant. This analysis has 
demonstrated that calcium acetate/magnesium subcarbonate is dominant bringing high savings to 
health insurance due to its low cost and comparable efficacy.  
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Introduction: Allocating hearing aids in children population depends on various factors: age, 
degree and type of hearing impairment, social environment and child and family behavior. In 
Croatia, mandatory screening for newborns enables identifying children with potential hearing 
impairment and through monitoring these children may have prevented more severe hearing 
disorders. Features of hearing devices for children differ significantly than for adults. Currently 
no hearing aid adapted for children is reimbursed by Croatian health insurance. We have used a 
budget impact model to estimate the impact of reimbursing a new device specifically 
manufactured for children, and assessed outcomes and costs related to included diagnostics and 
adaptation in our model. 
 
Results and discussion: New hearing devices manufactured for children are adapted for 
anatomy of child`s ear, prevent microphonia, have protected and tamperproof and waterproof 
case, have extended frequency range and have premanufactured and adapted input audio levels. 
These and other characteristics prevent from device damage, unintentional changing of hearing 
levels, allergies and hearing damaging. Such devices also bring higher patient (child) compliance 
and bring better results in language and hearing acquisition. Also, diagnostics and adaptation for 
the hearing device make huge part of future success with the device. 
 
Conclusion: Reimbursing hearing aids brings savings in a model with longer time frame than 
proposed three years. Prevention of serious hearing damages in later age due to late allocation of 
hearing device or inappropriate device for children is evident in at least ten year horizon. In a 
context of budget impact climate, due to tightened health care budgets, alternative models should 
be considered such as cost effectiveness models. 
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Introduction: Most of health care spending in Europe is financed by public budgets. However, 
the increased health care demands, aging population and global economic recession trends can 
impair the access to health services and control of health care expenditure. Historically, the 
recession has had negative impact on public health as a result of a strong correlation between the 
weak economic situation, decreased utilization of health care services and worsened health 
indicators. In such circumstances, health care (including pharmaceutical) costs, are rationalized 
both at patient and public sector level. The measures to control public drug spending may 
include regulations on medicines prescribing and use and pharmaceutical pricing policies. 
Financial regulatory measures include the methodology of reference drug pricing, competitive 
tenders, reduction of drug prices and promotion of generic prescribing and substitution. 
Governments are usually prepared to pay for new innovative medicines, but recommend cheaper 
generic equivalents for medicines with expired patent protection.  
 
Results and discussion: The World Health Organization has recently analyzed the effects of the 
financial crisis on global pharmaceutical prices, expenditure and use during 2007-2009. 
Interestingly, the use of medicines, as well as their prices and spending, have increased in all 
WHO regions, except in Europe, and particularly in the Baltic countries. (Graph 1, 2).  However, 
branded and patent protected medicines have still been used more than generic medicines during 
this period. Another study focused on pharmaceutical legislation implemented in 8 European 
countries during 2008 – 2011. Economically more stable countries (Austria, Estonia, Finland) 
have implemented fewer regulatory changes than less stable ones (Greece, Ireland, Spain, 
Slovakia, Portugal). Most of the strategies aimed to reduce public expenditure on medicines by 
increasing private spending, changing mark-ups and reducing medicines prices. Only few 
strategies have been based on generic prescribing and substitution (positive list, generic 
prescribing and changed mark-ups in Greece 2012). Overall, the use of medicines in Europe 
have not decreased during current crisis, except for Greece and Portugal in regards to treatment 
of chronic diseases (ACE inhibitors, antidepressants).  
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Graph 1: Use of medicines (globally and WHO regions): 2007-2009 
 
WHO regions: AFR - African region, AMR - American region, EMR - Eastern Mediterranean 
and Arabic region, EUR - European region, SEAR - South Eastern region, WPR - Western 
Pacific region 
 
Graph 2: Use of medicines in Europe, Poland, Romania and Baltic countries: 2007-2009 
 
 
Conclusions: During the economic recession, many regulatory measures have been designed to 
shift the financial burden from public budgets to patients’ private spending. As a consequence, 
increased drug co-payments could reduce the use of medicines in times of financial difficulties 
and unemployment. On the other hand, the reduction of drug prices could have detrimental 
effects on access to medicines if pharmaceutical companies decide to withdraw their medicines 
from positive lists.  It is necessary to follow up the possible effects of reduced access and use of 
medicines on population health status.  
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Introduction: There is considerable debate concerning the place of generic (from a brand to 
generic product) and therapeutic substitution (switching to a cheaper product usually within the 
drug class, eg. statins, proton pump inhibitors, drugs that affect the rennin-angiotensin system). 
Generic substitution is promoted by the Croatian Health Insurance Fund in Croatia in the 
primary health care setting, and recently in the secondary healthcare setting by establishment of 
centralized drug procurement system. It is estimated that generics constitute 50% of overall drug 
consumption in Croatia. Therapeutic substitution is more contentious as direct evidence to 
support equivalence is lacking. However, the price differentials makes it an attractive application 
of cost-minimization analysis for the more efficient use of health resources.  
 
Results and discussion: Here we explore the existing open questions taking into consideration 
the clinical appropriateness and safety of generic and therapeutic switching, from an individual 
patent perspective and health service perspective. Although substitution may affect individual 
patients, it might be a price worth paying given the opportunity cost associated with the use of 
medicines that are clinically no better than cheaper alternatives. However, tensions are created 
by the promotion of the concept of patients choice at the same time. We review clinical areas or 
drug types where brand prescribing may be considered preferable because of the possibility of 
therapeutic inequivalence or potential for confusion (eg. medicines with a narrow therapeutic 
window where there is evidence regarding the risk of adverse patient reaction or inadequate 
efficacy, vaccines, biosimilars).  
 
Conclusion: Generic substitution is almost universally accepted as desirable and cost reducing. 
Therapeutic substitution, although not as widely accepted, allows also considerable cost savings 
to be made. The trade-of is patient choice vs. rational fund spending. Arguably, for any publicly 
funded healthcare system, the latter has to be the priority.  
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Introduction: The project scope is implementation of SCM in planning processes, supporting 
the production planning and detailed scheduling as well as the network planning across the 
company’s supply to optimally match supply and demand. At the start of the project, the most 
important key aspects of the company without implementation of SCM activities (named To-day 
situation) are: Four SAP R/3 systems, one Business planning and control system and one R/2 
system; no central supply chain network planning was available; production planning and 
detailed scheduling of the manufacturing processes were performed in various stand-alone 
systems interfaced with local ERP systems; no central statistical forecasting system; key-
performance indicators (KPI) measurements were not consistently defined and the complete 
business processes were rather complex, without uniquely defined responsibilities for core 
planning tasks like master planning and detailed scheduling. Evaluation of created To-be 
situation is made after one year of implementation of SCM activities on the KPI’s: planning, 
resource’s exploitation, production, distribution and customer’s satisfaction with the same 
percent of contribution. 
 
Results and discussion: Evaluation of To-day and To-be situation is made on following KPI’s: 
Planning (contribution of 35% in final score), Resource’s exploitation (contribution of 15% in 
final score), Production (contribution of 30% in final score), Distribution (contribution of 10% in 
final score) and Customer’s satisfaction (contribution of 10% in final score). The planning 
processes in To-be situation are mapped to the following ERP and APS modules: Demand 
planning SAP APO DP, Master planning SAP APO SNP, Detailed scheduling AP APO PP/DS, 
Materials requirements planning SAP R/3 MRP, Production order management SAP R/3 PP-PI, 
Inventory management AP R/3 IM-WM, Procurement direct materials SAP R/3 MM, Master 
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data management SAP R/3 MM, Supply chain controlling SAP R/3CO and SAP BW. The 
production plan is generated automatically by APO PP/DS which mine: reduction of machine 
set-ups, production of sequence ordered by increasing compound concentration, production 
sequence grouped by product and ordered by increasing order quantity. In case of bulk material, 
the holding tank has to be emptied as soon as possible, requiring to group products consuming 
the same bulk material. SCM implementation in the studied pharmaceutical company resulted in 
improvement in all defined KPIs (Fig.1). The higest improvement of 0,52% is for planning 
proces. If it is known that to the planning process were given 35% of factor of importance for the 
improvement of the company, then it can be concluded that the SCM implementation have 
allowed improvement in the most important part of the functioning of the studied pharmaceutical 
company. 
 
Fig. 1. Comparative results before and one year after implementation of SCM activities 
То-Day situation To-Be situation 
KPI Score Score KPI 
Planning 0,79 1,31 Planning 
Resource’s 
exploitation 
0,34 0,45 Resource’s 
exploitation 
Production 0,66 1,02 Production 
Distribution 0,25 0,3 Distribution 
Customer’s 
satisfaction 
0,3 0,35 Customer’s 
satisfaction 
Final score 2,34 3,43 Final score 
 
The results shown that the parameter customer’s satisfaction is with smallest improvement. That 
is owed to two factors, namely: 
1.The presented data refer to the period in analysis of only one year ( in all a relevant literature to 
evaluate the activities of SCM is said that the end score with a representative meaning can be 
obtained by been spent two years from the date of implementation of the SCM ); 
2.Clients like a end-users will need the longest period that is noted for improving the quality in 
the work of certain companies. 
 
Conclusion: The visibility and problem solving capabilities of the entire organization improved 
by the use of a common data basis and a common visualization tool, allowing better and faster 
decisions. The master planning run enables the company to better foresee the future capacity 
issues and plan accordingly future investments. Collaborative demand planning with the 
customers allow for a proactive stabilization of the demand as changes in the demand by the 
customers are compared with a constrained demand from the previous master planning run and 
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exceptions are generated. By consolidating the system landscape, the IT maintenance costs were 
reduced significantly. 
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IN REPUBLIC OF MACEDONIA 
 
Zoran Sterjev, Aleksandra N. Kapedanovska, Zorica Naumovska, Ljubica Suturkova 
 
University “Ss. Cyril and Methodius”, Faculty of Pharmacy - Skopje, Republic of Macedonia 
 
Backround: Multiple sclerosis, also known as MS, is a chronic disease that attacks the central 
nervous system, i.e. the brain, spinal cord and optic nerves.Over 2.5 millions people have MS 
worlwide.and is typically diagnosed between ages 20 and 40.At present, six treatments are 
approved for patients with MS, including three interferon beta preparations, glatiramer acetate, 
mitoxantrone, and natalizumab.Glatiramer acetate is a synthetic protein that simulates myelin 
basic protein, a component of the myelin that insulates nerve fibers in the brain and spinal 
cord.This drug is given by subcutaneous injection every day for the treatment of relapsing-
remitting MS. It is also used for patients who have experienced a first clinical episode and have 
MRI findings consistent with MS 
 
Objective: To evaluate the cost effectiveness of four disease modifying treatments (interferon 
betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis 
in the Republic of Macedonia. 
 
Methods: Cost-effectiveness and cost utility model was developed for analysis of multiple 
sclerosis treatment with two years time horizon (from a Republic of Macedonia payer 
perspective).The data used in development of the decision tree analysis model for 
pharmacological multiple sclerosis treatment were obtained from relevant randomized clinical 
studies. In the analysis only direct cost were included. Benefits and performance of medical 
treatments measured as QALY were extracted from published data. The price per dose was 
estimated and cost per QALY with 12% annual discount was calculated. Cost-effectiveness was 
evaluated using threshold ofUS $ 31.500/QALY (EUR 24.040,17 /QALY) in RM. 
 
Results: The direct costs of different available pharmacological therapy included in this model 
are presented in Table 1. 
 
Table 1. Direct cost of Multiple sclerosis pharmacological therapy in R. Macedonia 
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Cost (EUR) 
1 2 3 4 
IFNbeta 1a ( 30 mcg) IFNbeta 1a ( 44 mcg) IFNbeta 1b Glatiramer acetate 
380,307.99 467,698.81 382,734.49 350,818.83 
Incremental cost ( 1vs4) 29,489.16 
Incremental cost ( 2vs4) 116,879.99 
I Incremental cost ( 3vs4) 31,915.66 
 
 
The cost effectiveness of four disease modifying treatments (interferon betas and glatiramer 
acetate) for relapsing remitting and secondary progressive multiple sclerosis in the Republic of 
Macedonia are presented in Table 2 and 3 
 
Table 2.  Average cost per patient in R.Macedonia according to our pharmacoeconomic model 
Table 3. Cost – effectiveness of Glatirameracetat in comparasion with other available  
pharmacological treatments of multiple sclerosis in Republic of Macedonia  
 
           
           
           
           
           
           
           
           
           
            
Conclusion: Glatirameracetat in monotherapy alone is a cost-effective treatment option for the 
prevention of relapses in patients diagnosed with RRMS in Republic of Mecedonia.  
 
 
 
 
 
ATC INN 
Pharmaceutical 
Form Јачина Manufacturer Package 
Referent 
price per 
unit 
Referent 
price per 
package 
Packing 
for 
days 
Montly 
treatment 
price (30 
days) 
L03AB07 Interferon beta -1a Injection 30mcg(6MIU)/0,5ml(SRJ) 
BIOGEN IDC 4 
        
  AVONEX injection 
 
30mcg(6MIU)/0,5ml (0,5ml) 10,366.67 41,466.67 28 44,428.57 
                
L03AB07 Interferon beta -1a Injection 12MIU(44mcg)/0,5ml 
MERCK 
          
  REBIF 44 injection 
 
12MIU(44mcg)/0,5ml 3 4,233.02 12,699.06 7 54,424.53 
  REBIF 44 injection 
 
12MIU(44mcg)/0,5ml 12 4,233.02 50,796.23 28 54,424.53 
L03AB08 Interferon beta -1b Injection 250mcg(8MIU)/ml 
Bayer 15 
        
  BETAFERON injection 
 
250mcg (8MIU)/ml (1,2 ml) 2,924.02 43,860.29 30 43,860.29 
L03AX13 Glatiramer acetat Injection 20mg/1ml 
TEVA 28 
   
  
  COPAXONE     1,360.71 38,100.00 28 40,821.43 
Comparasion of 
available 
pharmacological 
tretmans 
Cost per QALY 
 ( 1 vs 4) 79,700.44 
 (2 vs 4) 417,428.52 
 ( 3 vs 4) 177,309.24 
 ( 1 vs 4) 499,816.34 
 (2 vs 4) 2,850,731.39  
 ( 3 vs 4) 797,891.60  
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Background: Dysfunctional uterine bleeding (DUB) is irregular bleeding that occurs in the 
absence of recognizable pelvic pathology, general medical disease, or pregnancy. Idiopathic 
heavy menstrual bleeding clinically defined as greater than 80 mL of blood loss per menstrual 
cycle, affects 10-30% of women and has negative influence on their health and quality of life. 
 
Objectives: Our objective was to evaluate the cost-effectiveness of Levonorgestrel-releasing 
intrauterine system-LNG-IUS in comparison with combined oral contraceptives (OC) in 
treatment of heavy menstrual bleeding.  
 
Methods: Cost-effectiveness and cost utility model was developed for analysis of menorrhagia 
treatment with one year time horizon (from a Republic of Macedonia payer perspective). This 
pharmacoeconomic model is designed for estimation of the DUB and essential menorrhagia 
alternative treatment costs in population of 1000 patients.   The data used in development of the 
decision tree analysis model for pharmacological menorrhagia treatment were obtained from 
relevant randomized clinical studies. In the analysis only direct cost were included because the 
indirect costs associated with implementation of the LNG-IUS, as well as the cost of side effects 
treatment for both combined OC and LNG-IUS, are negligible. Benefits and performance of 
medical treatments measured as QALY were extracted from published data. The price per dose 
was estimated and cost per QALY with 3% annual discount was calculated. Cost-effectiveness 
was evaluated using threshold of US $ 31.500/QALY (EUR 24.040,17 /QALY) in RM.  
 
Results: A total accumulated cost per patient was 87,885 EUR for combined OC vs. 38.462 
EUR for LNG-IUC.  Literature search results didn’t confirm differences in quality of life 
between the two compared groups. Incremental cost per patient gained for LNG-IUC is 48.423.  
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Conclusion: LNG-IUS treatment has better incremental cost-effectiveness ratio in comparison to 
combined OC treatment. On the other hand it is also certified that LNG-IUS treatment delays the 
hysterectomy for the period of 5 years in almost 60% of women with menorrhagia. As LNG-IUS 
has better treatment outcome, lower ICER and is not invasive surgical intervention it should be 
considered as first line treatment for the heavy menstrual bleeding.  
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